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Abstract 
Potentially carcinogenic DNA damage that may be derived from dietary sources can 
be quantified using a number of methods. Some of the best of these methods are 
based on the use of antibodies that have high affinity and specificity for modified 
DNA bases. However, given the sometimes limited availability of antibodies there is 
a requirement for novel reagents that mimic the properties of the best antibodies. 
From a chemical perspective antibodies are `over engineered' and synthetic affinity 
reagents would recreate the optimal properties of the binding site with respect to 
selectivity and affinity. 
Phage display was used to identify amino acid residues that contribute to recognition 
of a diet derived DNA adduct 06-carboxymethyl-2'-deoxyguanosine. However, this 
information was not sufficient to synthesise a novel peptide reagent directly and it 
was decided to develop an approach whereby a library of compounds was synthesised 
which includes the characteristics expected within the binding site of an antibody. 
This library was based around cholic acid, a readily available scaffold molecule with 
suitable functionality compatible with linking amino acids and a fluorescent tag. 
A synthetic procedure based on the formation of stable oxime derivatives of cholic 
acid was optimised and a small library of pyrene-tagged trisubstituted cholic acid 
derivatives was characterised. The library was examined for its ability to bind to 
affinity columns containing immobilised 06-carboxymethylguanosine and there was 
some evidence that indicated specific binding of a subset of library molecules. 
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Chapter 1 
Introduction 
`Let us hope that this Association (American Association for Cancer 
Research) will be out of business by the year 2000! ' - James A. Miller 
March 1969 
-1- 
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1.1 Introduction 
In spite of James A. Miller's hopeful words in 1969, the American Association for 
Cancer Research is very much still in business. At their 95`h Annual Meeting, in 
2004,5,700 abstracts were submitted for presentation and about 15,000 researchers 
attended, giving an indication of how active the area of cancer research is in the 21 s` 
century. This meeting brought together oncologists, students, biologists, chemists, as 
well as cancer survivors to facilitate a cross-disciplinary exchange of ideas and 
knowledge. The more that we learn about cancer, the more questions we find that 
require answers. 
The critical difference between a normal and a cancer cell is a discrete change in 
specific genes that control proliferation and tissue homeostasis, by the activation of 
oncogenes and/or the inactivation of tumour suppressor genes. More than 100 cancer 
related genes have been identified and they are consistently found in a mutated or in a 
different form in tumoursi. The most striking is the p53 tumour suppressor gene 
which is found, mutated, in about half of all human cancer cases2. 
p53 mutations usually occur at the pre-invasive stage events of many cancers' with 
the G-C to A-T transition, caused by DNA adducts, being the most frequent change. 
DNA adducts are covalent modifications of DNA, which if not repaired can be 
converted into mutations during cellular replication, leading to initiation and 
progression of cancer tumours. 
One major source of DNA adducts are N-nitroso compounds which can come from 
exogenous or endogenous sources. Many N-nitroso compounds have been studied 
-2- 
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and their carcinogenic properties identified. N-nitroso compounds can interact with 
DNA to result in the formation of modified bases. These modifications can exert a 
detrimental effect on cell reproduction, especially when their associated repair 
mechanisms fail. A DNA base that is modified by attachment of an alkyl residue is 
called an adduct, and adducts have been associated with risk of tumour development. 
One area of major interest in cancer research is the detection of normal background 
levels of adducts so that quantitative comparisons can be made with the high levels 
associated with tumours. 
Various methods of detecting DNA adducts, have been developed based on the 
recognition properties of antibodies. These rely on the presence of intermolecular 
forces which allow for specific binding of two molecules that have a high affinity for 
each other. Mimicking this action, but between a chemically synthesised molecule 
and a biological one has formed the basis of the work of many research chemists and 
is an ever expanding field. One of the key aspects of this is the formation of chemical 
libraries, broadly analogous to antibody repertoires, which have high levels of 
diversity. This population can then be screened to reveal any members within it that 
may be suitable candidates for molecular recognition studies. 
1.2 Cancer 
The first disease causing mutation in a human gene was identified in 197 83 and as 
more genes and their products are being identified so we increase our understanding 
of the consequences of genetic mutation. The differences in mutational frequency 
among all the different human cancer types suggest that both endogenous and 
exogenous factors contribute to the etiology of cancer and have implications for 
human cancer risk assessment1. 
-3- 
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1.2.1 Statistics of Cancer Cases 
In 2000,320,000 new cases of cancer were recorded in England; the cost of cancer 
was £1 billion being spent on the NHS and £260 million on research (£25 million 
from the Government). Less than two percent of cases occur in women under 40, and 
men under 50, and there is then a steady increase in cases until a peak is reached at 
the age of 70-75 in both sexes. The most common cancer in men is prostate cancer, 
followed by cancers of the lung and the colon/rectum. In women the most common is 
breast cancer, followed by colorectal and then lung. A total of 28,300 cases of 
colorectal cancer were confirmed for both sexes in 2000. Colorectal cancer is 
therefore the most significant cancer of the gastrointestinal tract, followed by gastric 
cancer and then oesophageal cancer. Interestingly, while the incidences of gastric 
cancer are decreasing by around 20% per year, those of the oesophagus are steadily 
increasing particular with regards to male patients4. 
1.2.2 Etiology of cancer 
Carcinogenesis is a multi-step processes, which is why it has been difficult for 
researchers to be able to say definitively what causes cancer and what can be used to 
`cure' cancer. A recognised way of discussing cancer is in terms of risk, and the 
minimisation of this risks. Studies on animals have lead to a traditional view of the 
etiology of cancer development which is demonstrated in Figure 1.1. The first step is 
the `initiation' step, in which damage or modification to the cellular DNA occurs as a 
response to chemical, physical or microbial carcinogens. These may alter the ability 
of cells to respond to their microenvironment and give them a proliferative 
advantage6. The `promotion' stage may result in the survival of the initiated cell and 
its proliferation, which may be greater than that of the surrounding normal cells. The 
probability of further genetic damage is increased and further exposure to DNA- 
-4- 
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agents may result in the activation of proto-oncogenes and/or the inactivation of 
tumour suppressor genes, and these events are also passed on through the expanding 
population of cells7. This is now recognised as being the `progression' step6. 
Carcinogen exposure 
(: ýý) 
Normal cell 
resulting in genetic (Initiation) 
changes Ci) Initiated cell 
Selective clonal (Promotion) 
expansion 
0 
Q Pre-neoplastic 
O lesion 
Further genetic changes -º 
(Progression) 
Malignant tumour 
Figure 1-1. Carcinogenesis is a multi-step process which involves genetic events within key genes. 
These genetic changes result in an initiated cell, which if it survives cellular replication, passes on 
these changes to all subsequent daughter cells. This can lead to clonal expansion of pre- 
neoplastic lesions. Further events result in the activation of proto-oncogenes and/or inactivation 
of tumour suppressor genes resulting in a malignant tumour and clinical cancer. (Adapted from 
reference 6). 
1.2.3 Gastrointestinal Cancers 
The high incidences of colorectal cancer and the steady increase of oesophageal 
cancer have made gastrointestinal cancers the centre of much research and although 
the rates of gastric cancer have declined worldwide, probably due to better food 
-5- 
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preservation and storages, they still remain high in Japan, Eastern Europe and in areas 
of Latin America9. 
The stages of initiation, promotion and progression for the development of gastric 
cancer were identified in the hypothesis developed by Correa (1992) which has been 
widely accepted'°. The etiology of this disease has been identified as having a chain 
of causation, each link having factors that act upon it. These factors and their 
consequences are summarised in Figure 1.2. 
As shown in Figure 1.2, the formation of nitrosated compounds has been identified as 
an important component1° in the many steps in the development of gastric cancer. 
These N-nitroso compounds (NOC) have the ability to alkylate DNA, a process in 
which an alkyl group is transferred from the NOC to nucleophilic sites on the DNA, 
forming a DNA adduct. The presence of such adducts are considered to be a key step 
in the induction of cancer'ý1 7 . 
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Influencing factors Cell Type Consequences 
Normal 
Inflammation 
High cell replication 
Helicobacter pylori High levels of polymorphonuclear 
infection leukocytes 
Superficial 
gastritis High cell replication 
Mucosal damage 
Excess NaCl 
Inflammation 
May increase mutagenicity of 
nitrosated foods 
Atrophic gastritis 
Higher pH, anaerobic bacterial growth 
capable of reducing nitrate to nitrite 
NO, - I 
Nitrogen containing compounds r 
N-nitroso mutagens and carcinogens 
Metaplasia 
(morphological mutations) 
Luminal synthesis of Intramucosal synthesis of carcinogens 
carcinogens Enhanced in the presence of NaCl 
Enhanced in the presence of 
Neoplasia Polymorphonuclear leukocytes involved 
NaCl in chemical reactions that produce NO, 
Bacterial catalysed nitrosation which then induces mutations in cells 
Shown by high levels of 
excreted nitrosamino acids 
Carcinoma 
Figure 1-2. A summary of the etiology of gastric cancer as a multistep process. 
(Based on Reference 10. ) 
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1.2.4 Biomarkers 
Biomonitoring of disease can involve the measurement of exposure to a particular 
chemical by analysing that chemical or its metabolites in human tissue; alternatively it 
is possible to measure the biological response to the presence of the chemical. These 
responses are termed biomarkers and epidemiological studies can tell us which 
biological markers are suitable for which diseases; chemical studies give 
understanding to how the biomarkers are formed, and finally toxicological studies can 
be generated that give a quantitative relationship between biomarker levels and cancer 
induction6,12. In terms of cancer development DNA adducts are considered suitable 
biomarkers, but it must be noted that the presence of DNA adducts does not indicate 
that a person will develop cancer, only that they have been exposed to conditions that 
may place them at a higher risk of developing cancer in the future. 
For these biomarkers to be significant they need to be present at a measurable level, 
and above those of the background damage that is present in our DNA at any given 
times. A well-documented example of this strategy is the study of urinary biomarker 
aflatoxin Bi-guanine following exposure to food that has been contaminated with 
Aspergillus strains and its association with subsequent risk of liver cancer13. 
Exposure assessment can be carried out at different stages in the process that can lead 
to the development of tumours but the measurement of biomarkers, particularly those 
that result in the alkylation of DNA are of considerable importance. One group of the 
most extensively studied alkylating agents are the NOCs. 
-8- 
Chapter 1 
1.3 The Alkylation of DNA by N-Nitroso Compounds 
1.3.1 N-Nitroso compounds 
The toxic effects of N-nitroso compounds, the generic structures of which are shown 
in Figure 1.3, have long been known14. Following the work of Barnes and Magee15 in 
1956, who induced liver cancer in rats with the administration of 
nitrosodimethylamine, much work has been carried out on this class of compounds 
and this work continues today such is the importance of these carcinogens. Humans 
have been shown to be susceptible to the carcinogenic actions of NOCs on the 
grounds of the biochemical and histopathological data that is available15. Particular 
work has concentrated on NOCs as possible factors in cancers occurring in the 
gastrointestinal tract'6, research has therefore focused on human exposure to NOCs. 
R2 R1 ýO 
AN 
NO N -C` 
R1 ON HN-R2 
R1 
ýNH2 
N- Cý 
ON HN-R2 
NO C\ 
- 
QNR 
ON 
ýO 
ýN-C 
R1 OR2 
ON ýO 
ýN-Cý 
R1 R2 
( H2)n N-NO 
Figure 1-3. The generic structures of the main types of N-nitroso compounds. (From Lijinsky, 
1992, Chemistry and biology of N-nitroso compounds, p2") 
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1.3.2 Exogenous Sources of NOCs 
Humans are exposed to a number of NOCs that are exogenous in origin. Tobacco 
products contain 4-(N-methylnitrosamino)-1-(3-pyridyl)-1-butanone and N'- 
nitrosonornicotine, both potent carcinogens related to human cancers of the mouth, 
oesophagus and lungs". Several industrial processes have been identified as being 
sources of occupational exposure for workers including rubber production and leather 
tanning's . NOCs have also been found as contaminants of food, either due to the 
7 processing procedures or from packaging. The diet of the Chinese and Japanese, 
which is high in salted fish and pickled vegetables have been inferred as a correlation 
with the high incidences of oesophageal and gastric cancers found in those areas9 and 
19. Alcohol consumption in Western countries is thought to be a major contributing 
factor to the development of oesophageal cancer. Anderson et a! 20 reproduced the 
effects of low to moderate alcohol consumption in humans in a study using primates. 
They showed that the co-administration of ethanol and nitrosamine N- 
nitrosodimethylamine (NDMA) resulted in a significant increase of methyl alkylation 
at the 06 position of 2'-deoxyguanosine in the DNA of the digestive tract21. 
1.3.3 Endogenous Nitrosation 
As well as being exposed to preformed NOCs humans are exposed to NOCs that are 
formed inside the body in endogenous processes. The principal agent is the nitrite ion, 
which is primarily found in the saliva as a result of the reduction of nitrate, which is in 
turn based on dietary intake 14, and nitrite ion concentration is one of the factors 
influencing the rate of nitrosation. The optimal pH for nitrosation depends on which 
precursor is available but the resting pH of the stomach (- 1.5-2) rises after the 
ingestion of food to around pH 522, this allows the formation of intermediates 
responsible for nitrosationto 
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Helicobacterpylori infection also raises the pH levels in the stomach and when these 
are higher than pH 4 the stomach can be colonised by bacteria capable of the 
reduction of nitrate to nitrite which in turn gives rise to the possibility of an increased 
source of precursors of NOCs. Bacterially mediated nitrosation has been shown to 
inhibited by the presence of ascorbate23. This shows that nitrosation is under the 
influence of both catalysts and inhibitors. 
A standard human diet contains many components that can be nitrosated in the 
gastrointestinal tract to form NOCs and precursors include: 
i) classes of alkylamines24,25 
ii) aromatic amines26,25 
iii) guanidines25 
iv) ureas24'25 
v) bile acidsz''zg-3° 
vi) amino acids, amides and peptides24 
These precursors differ greatly in the amount consumed and rate of nitrosation, and 
their products also differ markedly in carcinogenicity25. Many NOCs decompose 
spontaneously to generate alkyl or aromatic diazonium ions. These are strong 
reactive electrophiles and as such can react with less nucleophilic centres on DNA 
such as exocyclic base oxygens, forming a DNA adduct, via SN1 mechanisms. With 
regards to the gastrointestinal tract, interest has turned to the availability of amino 
acids due to their high concentrations within the digestive tract from the proteolytic 
breakdown of proteins of a dietary source25. In humans who have an increased risk of 
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gastrointestinal tumour formation have been shown to have higher levels of NOCs in 
gastric juice and 06-methyldeoxyguanosine in their DNA31 
1.3.4 Nitrosated Glycine Derivatives 
Glycine is one of the most common amino acids present in the diet and has the 
simplest structure; it would therefore be a likely candidate as a major source of 
alkylating agents in the gastrointestinal tract following nitrosation. 
Stable N-nitrosoglycine derivatives have been shown to produce a potent alkylating 
agent, the carboxymethyldiazonium ion, in a number of studies. Theses include N- 
nitrosoglycocholic acid27 and N-(N'-acetyl-L-prolyl)-N-nitrosoglycine29 (Figure 1.4). 
Interestingly, a natural form of a nitrosated glycine, azaserine exists and was tested as 
an anticancer agent. However, it is now regarded as a carcinogen and is widely used 
to produce experimental pancreatic cancer in mammals. 
O 
N=N=CH--ý( 
CO2H 
\0---Azaserinc 
H2N 
N-(N'-acetyl-L-prolyl)-N-nitrosoglycinc 
Figure 1-4. The structures of some nitrosated glycine derivatives. 
-12- 
N-nitrosoglycocholic acid 
Chapter I 
1.3.5 Mechanism of Adduct Formation 
In confirming the importance of nitrosated glycine derivatives, it has been shown that 
key intermediates can be isolated and lead to the expected products. The proposed 
mechanism for nitrosation of glycine itself is shown in Figure 1.5, which shows that 
nitric oxide firstly combines with oxygen to form dinitrogen trioxide. This species 
can react with glycine in neutral and alkaline conditions and its hydrolysis yields the 
diazoacetate anion which is stable enough to be detected by HPLC in alkali 
conditions. Diazoacetate reacts with deoxyguanosine to give the expected products, 
in physiological conditions32. The products can lead to a characteristic p53 mutation 
spectrum found in tumours 33 
The electrophilic species formed by the NOCs are classed as being relatively hard 
acids and the theory of Pearson proposes that hard acids have a preference to react 
with hard bases, while soft acids react preferentially with soft bases. Hard acids have 
high positive charge and low polarizability, with polarizability being defined as the 
ease with which the electrons of a molecule are distorted34. Alkylating species have 
been classified as being intermediate, as have ring nitrogen and exocyclic oxygen 
atoms on DNA (see Figure 1.7)22. Therefore, although nitrogen and oxygen atoms are 
alkylated by many alkylating agents, NOCs give significant adducts on oxygen atoms. 
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Figure 1-5. The reaction pathway of the formation of 06-methyl and 06-carboxymethylguanine 
adducts, following the formation of glycine derived diazoacetate, and subsequently the 
alkyldiazonium ion32. 
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DNA alkylating intermediates have been detected following a reaction between nitric 
oxide and glycine33 and it is known that these react with DNA to form 06 - 
methyldeoxyguanosine (O6MdG) as a minor product and 
O6carboxymethyldeoxyguanosine (O6CMdG) as a major product32, structures as 
shown in Figure 1.6. With the latter being present at ten times the concentration of 
0 6MdG in experiments that have been done to simulate those that occur in the 
gastrointestinal tract35 
Hp)-N 
NN 
HO 
HO 
06-methyldeoxyguanosine 06-carboxymethyldeoxyguanosine 
Figure 1.6. The structures of DNA adducts known to form in the presence of alkylating agents. 
1.4 Repair Mechanisms and Consequences of Non 
Repair 
Before DNA damage can be regarded as mutagenic and subsequently carcinogenic, 
the damage has to be carried through cell replication and survive in the daughter 
cells36. The carcinogenic effects of alkyl adducted deoxyguanosine have a greater 
significance if they are persistent; this suggests that the DNA repair process is an 
important consideration when looking at the mutagenicity and carcinogenicity effects 
of an alkylating agent. 
Studies on Escherichia coli (E. coli) have shown that over one hundred genes are 
responsible for the production of a remarkable multitude of enzymes involved in 
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DNA repair mechanisms37. One of the main repair pathways for DNA is nucleotide 
excision repair (NER), which involves the recognition of large adducts that have 
resulted in the distortion of the helix. A length of DNA that is about 30 nucleotides 
long containing the damaged base is first excised. The excised area is then filled by 
the action of DNA polymerase I which works in concert with other proteins. The 
ends of the new section are sealed to the strand by DNA ligase38. Smaller adducts 
that do not cause helical distortions are repaired by base excision repair in which the 
N-glycosidic bond between the damaged base and the deoxyribose is cleaved by DNA 
glycosylase; the nucleotide gap is recognized by DNA polymerase ß and filled with 
assistance of other proteins, and finally ligated by the action of DNA ligase 11136. 
Overall the simplest methods of repair in these small adducts is by the direct action of 
06 -alkylguanine-DNA alkyltransferase (ATase). ATase directly removes the adduct 
and thus restores the guanine back to its original state39. ATase genes have been 
found in a great many different species including Archaea bacteria, this suggests that 
this process is of particular significance if it has survived thoughout evolution, 
especially as it is metabolically expensive. This is because ATase is not a true 
enzyme as it is not recoverable after it has exerted its action on the damaged base. The 
action is a multi-step process that involves non-specific binding to DNA, followed by 
binding to alkylated guanine which is then flipped out of the helix and finally the 
alkyl group is transferred to a cysteine residue on ATase, possibly by the mechanisms 
proposed in Figure 1.740. The fate of the protein is a conformational change that 
ultimately leads to its proteolytic degradation. The binding motif is highly conserved 
and recognized in thirty one DNA sequences coding for ATase in many species from 
Archaebacteria and Eubacteria through to eukaryotes. The crystal structure of 39 
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ATase reveals that the active site is buried deep inside the protein, which also 
contains a groove into which DNA could potentially fit. Therefore it is reasonable to 
suggest that the surrounding DNA sequence could affect the rate of alkyl transfer41 
There is evidence to show that when modified DNA is incubated with an excess of 
ATase, 06-MdG was completely repaired but the amount of 06-CMdG remained 
unchanged. This suggests that 06-CMdG is resistant to repair by ATase35 
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Figure 1-7. The mechanism of the reaction of ATase with alkylated guanine. The above reaction 
mechanism repairs many types of alkylation but reactivity decreases with increasing size of 
adduct, with the exception of O6benzylguanine 40. 
1.4.1 Consequences of Adduct Persistence 
DNA is a polymer that is made up of deoxyribonucleotide units, with each unit 
consisting of a nitrogenous base, a sugar and a phosphate group as seen in Figure 1.8. 
The specific folding pattern of DNA is dominated by base pairing, as nucleic acid 
chains will tend to fold in such a way as to maximise base pairing. The stability of the 
double helix is largely due to base stacking, as the planar aromatic rings of adjacent 
Deo xyribose-ph osphate Deoxyribose-ph osphate 
II 
N\ HzN 
vN 
11 
N\ 
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base pairs lay vertically one on top of the other; this maximises the van der Waals 
interaction between them. 
0 
1 0= P- 
0- 
OH 
NH2 
N 
NI\ 
N NH 
Adenine 
NH2 
N 
N 
H 
Cytosine 
0 
N 
HN 
HZN NNH 
Guanine 
O 
NH 
NO 
H 
Thymine 
Figure 1-8. The structure of a nucleotide building block, consisting of a base (red), a sugar (blue) 
and phosphate group (green). The B represents one of the four available bases, adenine, guanine, 
thymine or cytosine. Hydrogen bonding between complementary bases dominate the folding 
pattern of DNA, as chains tend to fold in a way that maximises base pairing. 
Guanine is usually found in its keto tautomer (Figure 1.9) and base pairs with 
cytosine. However, if the 06 position is alkylated the enol tautomer is present and this 
blocks a hydrogen bonding site and the base is more likely to base pair with thymine. 
If the cell replicates the guanine is replaced by adenine in the daughter cell, therefore 
ATase blocks the transition mutation of GC4AT which can occur if the adduct is not 
repaired35. However, as ATase is not regenerated there is a limited supply of ATase 
at any given time in the cell, and at high levels of alkylation some alkylation escapes 
this repair process. As already mentioned, the carboxymethyl adduct is resistant to 
repair by this pathway. In addition, the biological significance of adducts depend on 
where they occur. In general, adducts that occur on atoms on DNA bases that are 
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involved in base pairing are more likely to be promutagenic; they can result in 
misincorporation during DNA replication. 
NO HZN 
N 
NH N 
N NH 
NH- O 
Guanine Cytosine 
NH2 
Alkylguanine 
0 
HN 
>-NH 
Thymine 
Figure 1-9. In guanine there are three available sites for hydrogen bond formation, but if the 06 
position is alkylated one of these sites is blocked, therefore an alkylguanine bind preferentially 
with thymine. 
1.5 Methods of detecting 06-Carboxymethyl 
deoxyguanosine 
Antibodies, both monoclonal and polyclonal, have been found to be very useful for 
the detection of alkyldeoxynucleosides in small samples of hydrolysed DNA42. A 
polyclonal antiserum specific to 06-CMdG was raised by Harrison and her co- 
workers in 1997 and was prepared by injecting rabbits with an 06-CMdG-bovine 
serum albumin (BSA) conjugate. Thirteen weeks later blood was removed, serum 
isolated and the antibodies characterised 43. These antibodies have provided the basis 
of the two methods of detecting 06-CMdG. 
1.5.1 Immunoaffinity/HPLC 
An immunoaffinity/HPLC method uses the antibodies after they have been linked to a 
Protein A-Sepharose column. A DNA sample, containing the adduct, is hydrolysed 
and the resulting mixture passed through the column. The modified DNA binds 
within the column and is later eluted by treatment with aqueous IM trifluoroacetic 
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acid (TFA). When the eluate was analysed by HPLC varying amounts of 06-CMdG 
were detectable. 06-CMdG was synthesised and used as a standard which confirmed 
the presence of the nonrepairable carboxymethyl adduct in DNA that had been 
previously treated with N-nitrosoglycocholic acid. The recognition of adducted 
nucleosides over normal nucleosides was very good and from aI mg sample of DNA 
the limits of detection were shown to be 3.4 06-CMdG per l Os bases. Using this 
method other DNA adducts have been detected, again with good selectivity and these 
used both monoclonal antibodies and polyclonal antisera44. The advantage of using 
monoclonal antibodies is their continuous availability. Despite numerous efforts a 
monoclonal antibody for 06-CMdG has not been identified45 
The amount of DNA required in this assay for low levels of adducts is more than can 
usually be obtained from small biopsies; this limits the use of this assay with regards 
to the development of a clinical useful assay32 
1.5.2 Immunoslot-blot technique 
By combining the antibodies with the immunoslot-blot technique developed by Nehls 
et a! (1984)46, it has been possible to detect 06-CMdG in DNA extracted from small 
human gastric mucosa samples. The immunoslot-blot assay involves attaching 
adducted DNA to a nitrocellulose filter. This is exposed to antibodies that have been 
raised against 06-CMdG. Secondary antibodies, which have binding affinity with the 
first, are added and they bind to the primary antibody. These secondary antibodies 
possess a light generating system. Therefore the light intensity can indirectly be 
recorded as a measure of the amount of DNA and is summarized in Figure 1.10. The 
limits of detection were shown to be 15 06-CMdG per 108 bases, however a much 
smaller sample size is required, I gg of DNA21, less than for the immunoaffinity 
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HPLC method described above. This technique has also been used to measure the 
amount of malondialdehydeoxyguanosine, an adduct formed by malondialdehyde, a 
product of lipid peroxidation and prostaglandin biosynthesis, with a detection limit of 
2.5 adducts per 108 bases47. 
Detection of background levels of the DNA adduct needs to be established so that the 
contribution of a particular adduct to the overall risk of cancer can be determined. 
The immunoslot blot method uses as little as I pg of DNA, suitable for a clinical 
sized sample but the limits of detection are 15 adducts/108 nucleosides43. The HPLC 
method can detect as few as 3.7 adduct/108 but a large sample size of DNA is required 
(1 mg)48. 
It was proposed that a new method of detecting 06-CMdG could be developed, based 
on a chemically synthesised affinity reagent with the binding properties of antibodies. 
It is suggested that a non-antibody reagent will have the ability to detect, from a small 
clinical DNA sample, the adduct at very low concentrations. Damage detected above 
a predetermined background level can be considered as an indication of the potential 
that disease may occur49, in other words a quantitative measure of risk. Being a 
chemically synthesised reagent, with a known structure, it will be possible to make 
large quantities as required and also, if necessary, improve on the binding abilities by 
selective synthesis. 
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Figure 1-10. A diagrammatic representation of the immunoslot blot assay that requires a sample 
of 1 µg of DNA. The double strand of DNA that contains the adduct is sonicated and heated, this 
disrupts the binding between the strands and the single stranded DNA is fixed upon a 
nitrocellulose filter. The primary antibody is then exposed to the filter and binds in any location 
along the DNA strand that contains the adduct. A commercially available secondary antibody, 
horseradish peroxidase-conjugated goat anti-rabbit, is then exposed to the filter, this binds to the 
primary antibody and in the presence of chemiluminescent reagents a sensitive hyperfilm records 
the intensity of the light generated32. 
1.6 Molecular Recognition 
Both the detection methods mentioned above were based on the principle that an 
antibody has the properties that allow it to bind to a specific molecule, which is the 
underlying basis of the immune system. 
A key component of the immune system is recognition; of the presence of an invader 
and the ability to discriminate between self and non-self. This is achieved by the 
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unique shape of an antibody at the antigen binding sites, resulting from the complex 
three dimension structure of the protein. Theoretically an individual, over a course of 
a lifetime, may encounter 100 million differently shaped antigens and thus requires 
potentially 100 million differently shaped binding sites. Lymphocytes, as a 
population, possess this potential and each cell within the population carries many 
copies of a single binding site. 
The multipotent stem cells that give rise to the lymphocytes carry only a few hundred 
genes that contain the coded instructions to make the 100 million variations required. 
The idea that stable DNA sequences give rise to individual proteins had to be 
reconsidered to account for this paradox. Somatic recombination is the random 
allocation of a few genes, from the few hundred available, to ensure that each 
lymphocyte receives a unique gene sequence and a unique antigen receptor50. This 
method accounts for the vast diversity required by the body to protect it against the 
whole host of antigens that it may encounter. 
1.6.1 Antibody recognition 
The major function performed by an antibody is high affinity binding to an antigen37 
This is achieved by hydrophobic forces, ionic forces and van der Waals forces but not 
covalent bonds. These intermolecular forces are individually weak and are of a 
transient existence but when many interactions are being used they produce highly 
stable structures. 
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1.6.2 Intermolecular forces 
The strongest of these forces is the hydrogen bond, especially when the donor, the 
hydrogen and the acceptor are co-linear. In order to form such a bond the donor atom 
must be electronegative, therefore polarising, the D-H bond. The acceptor atom must 
also be electronegative, with at least one non-bonding pair of electrons in its outer 
shell 
S- S+ S- S- S+ S- 
D -H +A -D -H ---A 
Ionic interactions occur as a result of the attraction that occurs between a positively 
charged cation and a negatively charged anion, these interactions do not have specific 
or fixed geometry because the electrostatic field surrounding the ions is uniform in all 
directions. 
Van der Waals interactions arise from the tranisient dipoles, momentary random 
fluctuations in the distribution of the electrons in the atoms. When two non bonded 
atoms come together, the transient dipole of one atom perturbs the electron cloud of 
the other, causing a second transient dipole, these two dipoles then weakly attract 
each other. Stacking interaction can occur between aromatic amino acids and nucleic 
bases51. 
Nonpolar molecules do not possess ions and do not become hydrated. Like molecules 
aggregate together not because they have an attraction for each other but because 
water has a high affinity for itself. 
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It is the combined affects of these interactions that bring about stability when two 
molecules come together as illustrated in Figure 1.11, a hypothetical representation of 
two proteins that have an affinity for each other. 
CH2 OH O CH-CH2-CH2- 
-CH2-CH NH3 
/ 
CH2- 
O 
CH-CH3 IC 
H3 
I 
CH3 CH3 CH-C 
CH3 C H3 
CH3 CH- 
[Protein 1 
Protein 2 
CHz-C N -CHZ CHZ- 
O 
Figure 1-11. The hypothetical binding of two proteins by two ionic bonds (green), one hydrogen 
bond (red) and one combination of hydrophobic and van der Waals interactions (blue). The 
complementarity of the two surfaces and the overall force of the interactions give rise to the 
specificity of binding between any two given molecules. 
The binding of an antibody to its antigen is a simple bimolecular reversible reaction: 
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k, 
Ag + Ab Ag-Ab 
kz 
The ability to mimic this binding and to make synthetic molecules that interact with 
biological molecules has been the goal of many chemists and there has been the 
development of a new field of chemistry devoted to this area termed `Supramolecular 
Chemistry'. This field is committed to explore the `chemistry of molecular 
assemblies' (Jean-Marie Lehn), which involves studying the noncovalent binding 
between two molecules in detail. By giving this area a specific definition a whole 
host of experts have the opportunity to bring their work to the attention of each other 
through dedicated conferences and journals, although they may be from very different 
backgrounds. Supramolecular chemistry generally involves the association of a 
`host', which can be an antibody, enzyme or a synthetic cyclic compound, with a 
smaller `guest' molecule. These guests maybe small inorganic ions or larger 
biological molecules such as neurotransmitters or DNA bases52. In `supramolcular 
biochemistry', attention is turned specifically to the interactions between larger 
proteins, either antibodies or enzymes, and considers interactions with specific 
`guests' or ligand molecules. One consideration is that both types of `hosts' are 
derived from very large families of molecules, each with slightly differing properties 
that allow for unique specificity. 
1.7 Chemical Genetics 
Chemical genetics is a term that was first used in the inaugural issue of `Chemistry 
and Biology' (1994) by Stuart L. Schreiber53. Chemical genetics has also been called 
chemical genomics, chemogenomics or chemical biology; these terms are used to 
describe the study of the effects that an exogenous ligand has on proteins (gene- 
-26- 
Chapter ] 
products) in a cellular environment. Geneticists use gene mutations to perturb cellular 
function, whereas the chemist can use low molecular weight organic molecules that 
are capable of altering protein function; these alterations are reversible and 
conditional54. These experiments are usually carried out on flies with a rapid 
reproduction rate it is harder to use these types of experiments on mammals. It is with 
the development of new techniques that have allowed the usefulness of chemical 
genetics to be explored more fully and allowed there to be a systematic approach to 
screening compounds for biologically activity immediately after dosage of the 
ligand55. There are three main steps that need to be considered, the first is the 
assembly of a large collection of small organic molecules, the generation of chemical 
diversity. Unprecedented in synthetic organic chemistry is the idea of being able to 
generate large searchable assemblies of small organic molecules S6. These assemblies 
can then undergo high throughput screening that can discover if the compounds have 
any biological function. Finally methodologies are employed to reveal the 
mechanistic basis of the biological activity, for example DNA microarrays have been 
used, and in one case the entire yeast genome was screened against a particular 
compound and it was found to induce the expression of five genes, two of unknown 
53 function 
Small molecules are usually designed to a specific shape in order to carry out a 
specific purpose on a gene product and as such have been made by retrosynthetic 
analysis in which a `compound undergoes many rounds of individualized hand-crafted 
modifications' 56. At each stage there needs to be careful control of stereoselectivity 
and regioselectivity; the desired diastereoisomer needs to be produced or purified with 
the exclusion of all other products. This paradigm has served the organic chemist well 
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and led to the widespread availability of collections of highly diverse small 
molecules. However the need to create larger collections of compounds has allowed 
the chemist to employ a diverse set of blocking blocks, working to generic schemes 
that yield a multitude of related products. Chemical genetics that require such 
diversity have shown small molecules, however produced, can be used to identify 
previously unknown gene products53 and modulate the action of other gene products 
sa More recently chemical genetics have been used to find molecules that also bind 
directly to DNA57, RNA58 and even the directly inhibit specific gene expression 59 
The limits for medicinal purposes appear to be endless and the ultimate aim of the 
chemical geneticist is that it will be possible to find a small molecular partner for 
every gene product 57 
1.8 Chemical diversity 
There are many millions of small organic molecules that exist, these have been 
collated and stored in research institutions and pharmaceutical companies. The origin 
of these compounds range from tens of thousands that are derived from nature, e. g. 
from plants, bacteria, fungi and marine sponges55, compounds that have been made by 
synthetic chemists via the traditional routes over many years, and also by the 
combinatorial chemist, whose aim it is to create populations of molecular structures. 
The goal of such chemists is to continually strive to make more libraries, with greater 
populations and this area of research is still ongoing with the challenge to do so in a 
way that is high yielding and reliable. There are many ways in which this has been 
already been achieved, and combinatorial library synthesis, in its various forms, is 
now considered to be the major routes in providing diversity60. The identification of 
biologically active parent molecules has given the opportunity for libraries to be built, 
using both solid- and solution-phase synthesis, around different scaffolds, allowing 
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natural product mimicry to be established61. Whilst many libraries still employ solid 
phase synthesis the percentage of solution phase libraries had increased to 30% by 
199860. Terpenoid and steroid based libraries are better suited to solution phase 
synthesis61 
1.8.1 Peptide synthesis 
The most diverse library of compounds must be those that are used by Nature in the 
assembly of the proteins that are utilized in the biochemistry of the body. Since the 
chemical methods for assembling individual peptides was developed over thirty years 
ago improvements have been made in both the efficiency and the minimization of 
deleterious side products62. There are now three recognised methods of peptide 
synthesis: - 
Stepwise Synthesis - the attachment of a single amino acid at a time to build 
up a linear strand. The most widely used is the Solid Phase Peptide Synthesis (SPPS) 
developed by Merrifield. 
Fragment Assembly - separate strands are built and then linked together by 
either convergent synthesis of fully protected fragments, or by chemoselective 
ligation of unprotected fragments. 
Directed Assembly - individual peptide strands are allowed to associate non- 
covalently62 
A bicylic decapeptide has been used as a scaffold to introduce tetrapodal libraries in 
solution phase combinatorial synthesis, this involved the attachment of four different 
protected sites. Following a split synthesis protocol, it proved to be a relative easy 
way to produce a library 63 
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A small library, 39 members of pentapeptides, were screened and a peptide was found 
that mimicked kinase activity by selecting a specific area of a molecule for 
phosphorylation64. Oxime bridges have been used in numerous ways to attach a 
variety of substances to proteins including in vivo applications. Peptide fragments 
with N-terminal aminooxyacetyl groups have been attached to a poly aldehyde 
scaffold via oxime bridges resulting in the formation of homogeneous branched 
polypeptides with a molecular weight of almost 20 000 D, the first protein to be made 
of this size65. Synthetic receptors were isolated from a combinatorial library that had 
been synthesized by solid phase split synthesis, in which specific individual members 
bb were encoded by the attachment of chemical markers or tags 
The peptidic synthesis of a targeted sequence depends on the folding patterns within 
the peptide chain and understanding this protein folding is by no means trivial. The 
complex, and not wholly understood, folding pattern of a linear strand of amino acids 
into a three dimensional architecture which is ultimately responsible for a particular 
protein, is the main challenge for researchers making non native but biological potent 
proteins67. Computer assisted drug design programmes such as DESIGN developed 
by Wilson (1993) has aided the understanding of the spatial requirements of a protein 
mimic68. However, this problem can be somewhat by-passed by attaching the 
biologically active component on to a pre-designed backbone template or scaffold 
molecule. By the late 1990's with the improvements in methodologies there was an 
extension of solid phase peptide synthesis which allowed for the development of 
efficient access to template based protein mimics of high structural diversity69 
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1.8.2 Template-assembled synthetic protein (TASP) 
A peptidomimetic can be made via a template-assembled synthetic protein (TASP) 
method, a two-step process. The first is the chemical synthesis of a topological 
template, and the second the chemoselective ligation of amino acid side chain 
derivatives or functional groups via covalent bond formation70, for example, attaching 
peptide binding loops with terminal aminooxy groups to aromatic templates via 
oximes71. A summary of some of the possible alternatives is given in Figure 1.12. 
Pr 
Pr 
OH SH 
/NHZ HZ I H2 
Oxazolidines 
Pr 
Pr 
O SH 
H2N 
SH 
1 
Figure 1-12. A summary of the ligation methods that have been employed using the TASP 
method of producing protein mimetics, following condensation of unprotected peptide fragments 
(Pr) in aqueous solutions62'67. 
In TASP the overall peptidic molecule is not a folded linear protein but an array of 
branched peptides. However both stepwise solid and protected segment condensation 
up to the early 1990's proved to be arduous and synthetically challenging. However 
the work of Dawson and Kent successfully used the 4-Helix TASP molecule designed 
by Mutter using thioester nucleophilic ligation between the bromoacetyl 
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functionalities on the template and COSH moiety on the peptide fragment C 
terminus72 
In addition to the design of single molecules TASP also provides a route on which a 
combinatorial library can be based and these templates were first used to make 
constrained peptides, cyclodextrins and polycyclic systems73 
Chemists are continually striving to increase the diversity within their libraries, and 
attention has turned to the scaffold molecule. As this forms a part of the overall 
compound it is thought that instead of an inert template it can also be used as a source 
of diversity in its own right. 74 
1.8.3 Non-peptide libraries 
Dolle and Nelson (1999) reviewed the 321 new libraries that have been published 
since 1997, giving information on the size of the library and the reactions used to 
make them, as well as biological activity, if known. The vast majority of these 
libraries are nonpeptidic, some are acyclic, but most range from macrocyclic to 
monocyclic; there are also scaffold based libraries60. This review highlighted the area 
of combinatorial chemistry that is being researched by a great number of people from 
many areas, it also emphasises the way that the conventional boundaries between 
chemistry and biology are being broken down. 
The main problem with nonpeptidic libraries is the lack of stereocentres, which is in 
direct contrast to the complexity that is found in nature55. However, when a 
nonpeptidic library of 126 members, based on a D-xylose scaffold with ester linked 
function groups, was screened it revealed a compound that mimicked the binding 
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properties of the Arg-Gly-Asp sequence and displayed biological activity. Many 
other saccharide based libraries are now being investigated and this has led to the 
discovery of new carbohydrate based antibodies75. Carbohydrates readily lend 
themselves to combinatorial chemistry as a scaffold molecule, a conformationally 
rigid structure, with available reactive groups that can be readily functionalized, their 
versatility is described by Hirschmann in 1993 who acknowledged them as 
`privileged platforms'. Kemp's acid has three axial carboxyl groups, which has also 
been used to build diversity upon resulting in a library with, theoretically, 75,000 
members76. A whole host of molecules have been made based on the idea that 
synthetic carbohydrate receptors can be used as anti-infectives or synthetic 
antibodies" 
Peptoids (oligo-N-substituted glycines) are suited to the construction of large 
chemically diverse libraries and have been used to make libraries with, theoretically 
up to, 531 441 members78. 
1.8.4 Biological based libraries 
Aptamers are specific RNA or DNA oligonucleotides that have been selected from by 
a `systematic evolution of ligands by exponential enrichment' (SELEX) process. The 
selection process starts with single stranded DNA oligonucleotides with a central 
region containing randomised sequences. This undergoes a series of selection, with 
amplification of an anticipated binding aptamer79. Genetically encoded peptide 
libraries can also be displayed as a library of unconstrained peptides on the coat of 
bacteriophage in phage displays0, or as constrained peptides libraries in yeast that can 
be screened in vivo81. Woiwode and his colleagues have developed a way of 
-33- 
Chapter 1 
hybridizing phage display and combinatorial chemistry by using hydrazone 
attachment to link organic molecules to a primary amine on the phage protein coatx2 
1.8.5 Steroid based libraries 
Steroids have been used in a variety of ways and in 1993 they were recognized as 
structural components in molecular engineering83 and in 1997 a review of reactions 
and partial synthesis covered the extensive work that had been done on steroids". 
More recently work has covered molecular recognition 95, cage formation96 and as a 
base for protonated aminosteroids that act as anion receptors 87,89 . In addition, Gemini 
surfactants which contain a polycationic head based on cholic acid, have turned out to 
be effective anti-bacterial agents of both Gram-positive and Gram-negative bacteria 89. 
A number of crystal structures of cholic acid have been described90 and the host-guest 
interaction between cholic acid and acetonitrile has been examined in detail91. 
Chenodeoxycholic acid was first used by Wess and co-workers to link short amino 
acid chains, two-five in length, to the C3 and C5 positions, via ethers92, to construct 
mini libraries. Steroidal cores (AB-cis and AB-trans) have been used to attach 
peptidic appendages93 and 94 respectively. Cholic acid libraries will be discussed in further 
detail in section 1.1 0. 
1.8.6 Dynamic combinatorial libraries 
Dynamic combinatorial chemistry elegantly combines combinatorial chemistry with 
molecular evolution, as the library of compounds in generated by the assembly of 
building blocks via reversible bonds. Therefore the product distribution within the 
library is under thermodynamic control and influenced by the presence of a ligand. 
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The molecules that bind to the ligand become amplified in concentration. A receptor 
for N-methyl alkylammonium salts was isolated from such a library95 
1.9 Directed Molecular Imprinting 
In addition to the many ways of making libraries of compounds and then screening 
such libraries, based on dynamic combinatorial chemistry, there was proposed a way 
of manufacturing a molecule that has the binding properties built in during the 
reaction mechanism. The required molecule is a result of the ligand being present 
during synthesis allowing the molecule to be built around it 
1.9.1 Molecular Imprinting Polymers 
The idea that a host builds itself around a ligand was first proposed by Linus Pauling 
in 1940. He suggested that a specific antibody is produced as a response to being 
exposed to a particular ligand. He thought that an unfolded polypeptide interacted 
with a ligand and it was the presence of the ligand that allowed the polypeptide to be 
moulded into the shape that is required to bind to the ligand96. Although his 
hypothesis was subsequently proved to be wrong, the idea of a polymer being able to 
be imprinted with a particular shape by the presence of a ligand has lead to the 
development of molecularly imprinted polymers (MIPs). 
MIPs are formed when the monomers of the polymer are assembled in the presence of 
a ligand which acts as a template molecule. The monomers form a complex with the 
template and following polymerization form a highly cross linked polymer. The 
template is removed, leaving a cavity within the polymer that has the complementary 
shape and functional groups that facilitate selectivity and affinity. By the nature of 
their synthesis these polymers are robust and very stable; they can be used in extreme 
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conditions, including organic solvents and in basic or acidic conditions`". Due to the 
mode of action of MIP they have been called `antibody mimics. 
MIPs have been used in the generation of biomimetic sensors, in which the key 
element of efficacy is specific recognition. With a few exceptions they remain 
inferior to biological based sensors as the MIP tend to have heterogeneous binding 
sites on the resulting polymer 97. These form as a consequence of the need to push the 
equilibrium of the reaction towards the desired product by having an excess of' 
monomers, as such many sites are formed in the absence of the template and these 
sites have much lower affinity and selectivity for the required ligand9 . This 
heterogeneity is not insignificant with regards to developing this technique and its 
removal remains high on the `wish list' of researchers. Other problems that have not 
been fully explored include the complete removal of the template following MIP 
assembly and the ability to spectroscopically characterise binding sites. 
Although theoretically MIPS have come along way since the early days, and many 
research groups are working on developing these ideas further, this technique was not 
considered further in relation to this project. 
1.10 Steroids as scaffold molecules for diversity-oriented 
synthesis 
1.10.1 An Introduction to Steroids and Bile Acids 
The basic building block of steroids is acetyl CoA, which builds into a C30 structure, 
squalene containing six isoprene units. It is from this that cholesterol is derived 38 or 
smaller amounts are ingested85. First isolated from gallstones in 1784, it has been the 
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basis of the work of thirteen Nobel Prize winners38. Cholesterol provides us with 
vitamin D and its derivatives include lipophilic hormones that are able to cross the 
cell membrane to interact with receptors inside the cell37, and bile acids that form 
micelles with water-insoluble fats allowing their uptake into the bloodstream 85,86. All 
these molecules have the same basic chemical skeleton (see Figure 1.13), in which the 
carbon atoms are numbered around the rings, and each ring is lettered. The ring 
fusion between A and B is either cis or trans, all steroid hormones that have a 
hydrogen atom at C5, have trans fusion, whereas all bile acids have cis fusion38 
Converting cholesterol into bile acids, a fifteen step enzymatic process, effectively 
removes cholesterol from the body. This is achieved by either the classical (neutral) 
pathway which involved conjugation to either glycine or taurine or by the alternative 
(acidic) pathway that results in the production of chenodeoxycholic and cholic acids". 
a 
CH3 
CH3 H R 
H H 
H 
R 5a-steroid 
CH3 
5p-steroid 
Figure 1-13. The basic structure and nomenclature of steroids, the rings are lettered from left to 
right, and the numbering starts at the top of ring A. B and C, as well as C and D ring junctions 
are always in the trans configuration, but the A and B junction is possible as either cis or trans. 
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1.10.2 The Uses of Cholic Acid and its Derivatives 
The unique properties of cholic acid are due to the presence of a hydrophobic face on 
one side of the molecule and a hydrophilic face on the other (Figure 1.14). Due to 
this cholic acid has the ability to complex with aromatic moieties to form bilayered 
structures made up of repeating hydrophilic and hydrophobic layers, with channels. 
These crystal lattices are held together via hydrogen bonds, van der Waals and 
electrostatic interactions90. The hydrophobic face of cholic acid has also been used in 
the recognition of polar molecules in non-polar solvents acting via the formation of 
hydrogen bonds1°°. Cholic acid and its derivatives have been used extensively -a 
review by Tamminen in 2001 highlights the many ways in which they have been used 
as building blocks for supramolecular hosts including the development as hosts for 
acyclic appendages and combinatorial chemistry1°'. Primary amines and/or guanidine 
groups linked to a methyl cholate scaffold have been used to synthesise a potent 
sensitiser of Gram negative bacteria102 and has also been used in the chemical ligation 
of two proteins via aminooxy acetyl and ketone functionalities on the protein N- 
terminals to produce a biochemically active heterodimer103. The oxime linkage has 
also been used in the construction of a library based on 5a, 14a-androstane scaffold 
from which Na+, K+-ATPase inhibitors have been found104. 
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H 
H 
OH 
Figure 1-14. Structure of cholic acid showing the hydrophilic a-face and the hydrophobic ß-face. 
The DNA binding properties of seven new amino and/or guanidine substituted 
deoxycholic or lithocholic acid were explored, following the conversion of the a- 
hydroxyls to cc-amino groups. Hsieh and his co-workers (1995)105 tried to follow a 
scheme proposed by Davis and Orchard (1992)106, which was successful for 
conversion at the C 12 position on the ß face. This proved unsuccessful for 
conversion at both the C3 and C12 positions. Therefore they employed a slightly 
different method which included reduction of oximes105. Davis improved the C3 
conversion in 1997 by using Mitsunobu reactions with methanesulphonic acid 107, and 
by 1998, with Broderick and Williams, Davis published the first synthesis of a tris- 
deoxa-tris-aza analogue of methyl cholate108. A fifteen step synthesis, giving an 
overall yield of <8%, did allow for the possibility of selectivity at each of the 
hydroxyl sites. This technique was explored further by the same group in 1999, with 
the publication of a trifunctional methyl cholate, which was later used as a scaffold 
for combinatorial chemistry109 as each of the three hydroxyl sites were protected with 
groups that are used in standard orthogonal peptide chemistry. Li et al suggested a 
much shorter synthesis of only four steps, but this route, via a trioxime compound, 
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required more purification steps and resulted in an overall yield of <8% of the desired 
isomer 110 
As the potential of cholic acid became more apparent the idea of selecting one of the 
available sites for modification came to the attention of other groups; the selective 
one-pot esterification of the 3a hydroxyl of cholic and deoxycholic acid was 
published in 1996"'. Cholic acid can also undergo hydroxyl conversion to keto 
groups via indirect electrochemical oxidation with Pb02, platinum and carbon; 
oxidation occurs at C 12 or C7, depending on conditions, followed by C7 or C 12, 
again dependant on conditions, and then finally at C3112 . Microbial oxidation 
has also 
been explored. The selectivity of bacteria was such that two bacteria were found to 
oxidise C7, one for C7 and C3 positions, three for C7 and C12 and finally two 
bacteria that oxidised all three positions13 
1.11 The Suitability of Cholic Acid as a Scaffold 
There are key issues that need to be addressed, before a synthetic receptor, with 
antibody-like binding properties, can be made. Effective receptors generally have 
concave binding sites that are complementary in size and electrical charge distribution 
to the ligand molecule; with as many opportunities for hydrogen bonds to form as 
possible. 
Cholic acid has been proven to be a suitable scaffold for the assembly of 
combinatorial chemistry108, it has three evenly spaced hydroxyl groups that have co- 
directed functionality ready for the presentation of appendages. It also has a side chain 
carboxylic group available for derivatization that allows for the attachment to a solid 
phase109 or a fluorescent marker molecule, that is remote from the binding area. This 
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is an important consideration as the coloured or fluorescent tag should not alter the 
receptor-substrate binding' 14. The steroid nucleus is asymmetrical and the groups are 
not equivalent, which allows for selectivity. Thus, when appendages are ligated to the 
steroid a readily available pocket is formed, due to the structure of the scaffold1°°. 
Finally cholic acid is readily available at a minimal cost of £9.90 for 25 g (Aldrich 
2004) 
The positive attributes of cholic acid have already been explored with regard of the 
construction of combinatorial libraries. Li et al used cholic acid as the scaffold for a 
range of mini libraries in which short peptide chains were linked to the support via 
ethers 102. This is the approach was used previously by Still and his colleagues, who 
synthesised a library of short peptide chains attached also by ethers on two of the 
three hydroxyl sites. The synthesis of the tri amino analogue of methyl cholate really 
opened the way for the development of combinatorial libraries. The three sites were 
shown to be available for functionalisation utilizing the more stable amide bond, 
either all at one time108 or selectively'09. 
1.12 Aims of this thesis 
A key step in the etiology of cancer is the alkylation of DNA. A major mutagenic 
lesion is the alkylation at the 06 position of 2'-deoxyguanosine. This is particularly 
significant when it involves the carboxymethyl, as this lesion appears to be resistant to 
repair by the usual pathway35. Such adducts can be brought about by the action of N- 
alkyl-N-nitroso derivatives of glycine-containing peptides or related compounds and 
these modifications can be effectively recognised by antibodies. However, the 
antibodies available have been produced as rabbit sera43 and a finite amount is 
available for use. 
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Antibodies are large complex macromolecules, of which only a small part is 
necessary for the recognition and binding to a particular ligand. In principle a simpler 
peptide based reagent could be isolated from a library of compounds -a library that 
has been made in such a way as to maximize the possibility of a candidate compound 
being present. Whilst constructing such a library a number of considerations have to 
be made, for example, which method will be used to make the library? Should a 
scaffold molecule be used as a base, if so, which is the most suitable? A `tag' that 
allows for easy detection also needs to be introduced - what is the best way to do 
this? Is it possible to add enough diversity? Finally, can a candidate molecule be 
isolated from the library, identified and synthesised in sufficient quantities to be 
useful? 
Ideally, a library of compounds could be built upon a stable backbone, a scaffold 
molecule that allows the introduction of diversity in equal amounts at each of the 
specified sites, and to have a functional group remote from this diversity that is 
available for the attachment of a molecule that allows for easy analysis (Figure 1.15). 
CIMMD 
Figure 1-15. A cartoon of the ideal affinity reagent, a rigid backbone on which diversity can be 
built, with a site remote from the binding area, on which a tag can be positioned to aid 
identification. 
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The first part of this thesis is aimed at establishing which amino aids could be present 
in the antigen binding site of the antibodies known to recognize O6CMdG, those that 
may contribute to selection and affinity, and so enhance the binding potential of a 
novel reagent. Phage display was used for this purpose and an explanation given as to 
why the method does not result in a direct method for making a reagent. 
The second part is to establish a method by which diversity can be introduced to a 
suitably tagged scaffold molecule by a method that is both reliable and repeatable. 
Preparation of the suitable building blocks was then carried out and these building 
blocks were used to construct a diverse library. The diversity in the resulting mixture 
was then investigated. 
Finally the exploration of the library using affinity columns, on which 0 6CMG has 
been immobilised to the agarose matrix, was used to see if a suitable candidate 
molecule can be extracted and identified. 
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Phage Display 
`Design must have had a designer' - William Paley (1743-1805) 
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2.1 Introduction 
Antibodies are large molecules that are, as far as chemists are concerned, over- 
engineered. They contain many hundreds of amino acids, most of which contribute to 
the three dimensional structure of the protein. Many of the functions of antibody 
molecules are related to their role in the immune system. The site of interest with 
regards to designing a novel affinity reagent is the site of binding and being able to 
discern which amino acids directly contribute to selectivity and affinity to the 
carboxymethyl DNA adduct. A technique that can be used to identify these amino 
acids is phage display. 
2.2 An introduction to Phage Display 
William Paley was a theologian who stated that if a watchmaker had designed the 
components for a watch, to have a defined structure for a particular purpose, then 
living organisms, being far more intricate than a watch, must have had a benevolent 
designer. One that adapted an organism to its environment by designing features that 
it would require to survive' 15. It is thought that Darwin was intrigued by Paley's idea 
of adaptation, and that organisms have characteristics that make them able to function 
in the environment in which they live, but that these were fashioned by a different 
process. The book, The Blind Watchmaker, written by Richard Dawkins proposes that 
evolution `has no vision, no foresight' and therefore it is a process that occurs without 
a plan within given constraints 116. If a chemist can introduce the components of 
evolution into a test tube then he could become, not just a designer of molecules but a 
`blind' overseer of chemical evolution15 
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Molecules do not possess the ability to `evolve' per se but techniques such as phage 
display can be used, as the molecule in question is in fact a gene product and there is a 
direct link between the gene product and the gene' 17. Phage display can be thought of 
as analogous to natural selection, the differential survival and replication of a 
percentage of a population 19. Another key component of evolution, mutability (the 
ability to pass on mutations to offspring) is not, as yet, incorporated into the phage 
display technique but this should be possible in the future with the development of 
`sexual polymerase chain reaction', when error prone conditions are used during the 
reaction to induce mutations' ýý. 
The application of phage display begins with a phage-display library, which is a 
heterogeneous mix of phage clones. All the clones have a foreign DNA insert of 
random sequence, with the result that the make up of the insert differs in individuals. 
When expressed each phage has a differing peptide within one of their coat proteins. 
A form of chemical evolution occurs when individuals from the overall population are 
selected against a user defined criterion to give rise to a `fitter' subpopulation' 15. This 
subpopulation replicates and further selection occurs, thus there is an ever increasing 
amplification of the selected phage. It is the ultimate combination of cloning and 
combinatorial chemistry which results in the production of great molecular diversity 
that can mimic the characteristics of the immune system'19. The key to the process is 
that there is a direct link between the protein displayed on the surface of the phage 
and the gene that encodes for it, and that these are both packaged within the same 
, 
virus 
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2.3 History 
The term phage display was coined to encompass the technology that was developed 
from the pioneering work of George Smith in 1985. Smith used vectors to introduce a 
foreign DNA segment into the gene for a minor coat protein of a filamentous 
bacteriophage (phage for short). When this gene was expressed a foreign amino acid 
sequence is fused within the wild type protein. Smith cloned a restriction enzyme 
digest of plasmid DNA into the middle of the gene III. Gene III codes for pill, a 
minor protein, in the coat. The N terminus of the protein is important in the infectivity 
of bacteria and so phage replication, whereas the C terminus participates in 
morphogenesis. Smith was able to insert a gene sequence that coded for an 
endonuclease in between these two regions. When Gene III was expressed the 
resulting pill contained a foreign sequence that did not affect the function of the 
overall protein. He went on to expose an antibody to collection of cloned and wild 
type phage. Following affinity purification he showed that the cloned phage had been 
12o selected a thousand fold over the wild type phage with no insert 
Work published in 1990121 built on the foundations laid down by Smith to give us a 
technique that is more like the ones that are in use today. He and his colleagues 
randomly synthesized DNA sequences that where then incorporated into the genome 
of the phage via an expression vector and so creating a large, diverse library, in which 
the tip of the wild type pill displayed a short variable amino acid sequence. Taking 
this diverse population they exposed it to a monoclonal antibody against L-enkephalin 
and found that from the vast phage population only those that carried a certain amino 
acid sequence were selected. He showed that it was possible to home in on a 
particular combination of amino acids that give a best fit to a molecule without having 
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prior knowledge of the ligand or antibody 121. This early work was carried out on the 
Escherichia coli (E. coli) - specific bacteriophage M 13. Its success led to the 
development of systems using other phage such as those based on ?, phage' 22 and T7 
(Novagen, Darmstadt, Germany) but M 13 phage display remains dominant123 
2.4 Background 
The most common type of M 13 based phage libraries are constructed from DNA 
inserts that have been made by adding a mixture of nucleotides to a growing 
nucleotide chain, as opposed to the addition of single nucleotides. For example, 
taking the sequence XXYXXY, X is an equal mixture of A, C, G and T, with Y being 
an equal mix of G and T. Each XXY produced this way represents one of thirty two 
triplets that could code for any of the twenty amino acids 15. 
The M 13 phage is a flexible rod like organism about 1 µm long and 6 nm in diameter 
and is lysogenic, therefore undergoes its life cycle without destroying the host 
bacterium. It contains a single strand of DNA, containing 11 genes enclosed in a coat 
made up of five different proteins115 . There are about 
2700 copies of the gene 8, 
encoding for pVIII, the major capsid protein which is fifty amino acids long'24. In 
addition to pVIII, the ends of the filament are capped by the minor coat proteins. 
There are five copies each of pVII and pIX at one end, and five copies each of pill 
and pVI at the other 123, shown diagrammatically in Figure 2.1. The pill is a 406 
amino acid protein that initiates infection by attaching to bacterium that display the f 
pilus, a threadlike appendage that is used for the transmission of genetic information 
between E. coli cells 125. pill is the most suitable protein to incorporate foreign 
peptide sequences up to twelve amino acids long, larger peptides cannot be fused to 
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this site as they can compromise infectivity 121. Although the pill gene can be 
successfully modified at the C terminal the more common methods involved variation 
is displayed at the N terminal123 
Figure 2-1. A representation of a phage, showing the single stranded DNA surrounded by many 
copies of the PVIII protein, with each end tipped with copies of the proteins Pill and PVI at one 
end and PVII and PIX the other. The overall length is 1000 nm and width is 6 nm, 
approximately. 
The success of any technique that involves selection from a library depends on the 
diversity and the quality of the said library. The development of M 13 phage libraries 
has been such that they are now considered extremely diverse and reliable' 23. 
2.5 Application 
Phage display has been used in many different applications. These include 
identifying peptides that preferentially bind to double stranded 
oligodeoxyribonucleotides126, isolating peptides that bind to immunoglobulins'27, to 
identify non competitive enzyme inhibitors128 and to identify proteins with novel 
1 enzymatic activity29. These are all examples of using phage to identify a ligand that 
fits into a known binding site. However, more recently phage have been used to 
identify partial amino acid sequences that catalyse the inorganic nanostructures made 
of calcium carbonate and silica that are found in many diatoms13o 
Two important parameters of selection are stringency and yield which often have an 
inverse relationship. That is, the greater stringency (conditions likely to perturb or 
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disrupt affinity for the receptor) the lower the yield (the number of phage that survive 
the selection process). In the early rounds of selection a high yield of clones is 
important as it is from these that stringency can be improved' 15 . In general the 
molecule of interest is immobilized to a surface which is then covered with a 
suspension of free phage particles. Some phage bind to the immobilised molecule, 
while others remain free in solution. Probing a phage library against a specific 
molecule results in the selection of a sub population, effectively removing phage that 
do not have any binding qualities. This is achieved by panning or screening the entire 
population against the molecules of interest. 
2.6 Indication of phage presence 
The Ph. D. -12TH Kit (New England Biolabs) uses phage that are derived from 
M 13mp 19 and possess a region of E. coli operon lac. This operon consists of three 
genes, two of which, Z and Y are required for the metabolism of the milk sugar 
lactose, and the third which encodes for thiogalactoside transacetylase (as shown in 
Figure 2.2). The phage contains DNA that encodes the N-terminal fragment of P- 
galactosidase37 when induced by the presence of isopropyl-ß-D-thiogalactoside 
(IPTG). This is capable of intra-allelic (a) complementation with the defective host 
ß-galactosidase, resulting in a functioning enzyme13'. The natural substrate is lactose 
and results in the formation of galactose and glucose but it will also catalyse the 
hydrolysis of 5-bromo-4-chloro-3-indolyl-ßD-galactoside (Xgal) as a substrate with 
the release of a blue indicator. Figure 2.3 shows which bonds are broken to give rise 
to the release of the indicator molecule. Bacterial colonies show on IPTG/Xgal plates 
as blue spots, as shown in Figure 2.4. Wild type virus that may have infected the E. 
coli show as white plaques and can be avoided. Figure 2.4 also shows a dilution 
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series, this was done on a single plates and 10 pL of each dilution was placed in each 
square, this allowed for a rough count of which dilution range would give the most 
accurate readings on which to base the titer. 
LacZ I LacY I LacA 
Transcription 
control region rcNA 
ribosomes 
Figure 2-2. The lac operon consists of three genes: lacZ encodes ß-galactosidase (Z), lacY encodes 
lactose permease (Y), and lacA encodes thiogalactoside transacetylase (A). Transcription is 
controlled by the binding of proteins within the transcription control region, coloured yellow, 
and lacl encodes the Inc repressor. (Adapted from37 ). 
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CHZOH 
CHi0H 
OH 
O OH 
OH 
ß-D-galactose off 
ß-galactosidase 
HZOH 
O OH 
OH 
OH 
ß-D-glucose OH 
CI- OH 
OH O OH 
OH 
ß-D-galadose OH 
H 
N 
H\/\ 
Blue indicator 
cl 
Figure 2-3. In the presence of water galactosidase catalyses the hydrolysis of the 0(1-4)- 
galactoside linkage in lactose to give two products galactose and glucose. When no lactose is 
present the same enzyme can use Xgal as an alternative substrate, resulting in the release of a 
blue indicator, therefore infected bacterial colonies show up on IPTG/Xgal plates as blue spots 
Figure 2-4. A dilution range is established by placing a small amount of each dilution into each 
square of the sample plate, at high phage concentration the spot appears totally blue and as the 
dilution decrease the amount of blue decreases until discrete spots are visible. The second 
photograph is a typical plate clearly showing the blue plaques that show single colonies of E coil 
infected with the bacteriophage. 
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2.7 Method of Use 
2.7.1 Selection 
Selection of candidate phage from the library occurs via repeated panning rounds. 
The ligand is bound to a surface, in the case of polystyrene Petri dishes the ligand is 
bound via a protein. The plates used in the panning are prepared by dissolving an 
amount of the ligand that has been previously covalently bound to a protein dissolved 
in sodium bicarbonate and left with gentle swirling movement which allows the 
protein to bind over the polystyrene surface. The interfacial behaviour of proteins on 
the surface involves a complex array of interactions including electrostatic, hydrogen 
bonding, hydrophobic and van der Waals that involve not only the protein and the 
surface but also the solvent and other solutes. These result in the protein and any 
ligand molecule covalently bound to it being adsorbed on to the Petri dish surface. 
A blocking buffer is washed over the surface of the plate to fill any sites on the plate 
that have not reacted the protein and so prevent non-specific binding. The ligand is 
then exposed to the library with gentle agitation . The phage that have not bound to 
the plate are removed and the binding between the phage and the ligand is disrupted 
with glycine-HC1 and BSA which act as a general buffer for non-specific disruption 
of binding. 
2.7.2 Titering 
Titering is a method by which the number of phage present in a given volume is 
determined, usually measured as the number of plaque forming units (pfu) per µL. A 
small quantity of the phage undergoes a series of dilutions and each dilution is used to 
infect a culture of E. coli and incubated overnight. The plaques formed are 
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multiplied by the dilution factor and the pfu determined. A phage titer was carried out 
to determine the number of plaque forming units that exist within the library. A series 
of dilutions of the original library were prepared as below (shown in Table 2.1). 10 
µL of each dilution of these were added to 200 µL of bacterial culture at the mid log 
phase (OD600 0.5). Each was then added to 3 mL of agarose top at 47 °C and poured 
over prepared IPTG/Xgal plates (100 mL LB/agar containing 4 mg Xgal and 4.5 mg 
IPTG dissolved in 100 µL DMF is sufficient for 6 plates), warmed to 37 °C. These 
plates were incubated overnight. 
Sample 
number 
LB medium µL Phage µL Dilution Plaques formed 
1 49 1 of the original library 1/50 Blue plate 
2 45 5 of sample 1 1/500 Blue plate 
3 45 5 of sample 2 1/5000 Blue plate 
4 45 5 of sample 3 04 Blue plate 
5 45 5 of sample 4 1/5x10 Too many to 
count 
6 45 5 of sample 5 1 /5x l0 517 
7 45 5 of sample 6 1/5x10 48 
8 45 5 of sample 7 1/5x10 4 
9 45 5 of sample 8 1/5x 10 1 
Table 2-1. The dilutions were made and used to establish the titer of the original library. The 
number of blue colonies produced with each dilution from which the number of phage per µL 
was determined. 
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By multiplying the number of plaques by the dilution factor the pfu can be 
determined. The pfu per 1 µL of the library is approximately 2.5x 108, this compares 
to the suggested pfu of 4x l 09 from the company literature. The phage collected after 
each panning are also titered in the same way and this reveals the percentage of the 
library that has been selected. 
2.7.3 Amplification 
The phage collected from the first panning round can then be increased in number by 
amplification. When the phage infects it uses the host's metabolism to replicate. The 
phage is extracted from the bacteria and the titer is again measured to give the number 
of phage per pL which is used to calculate the amount required to input the phage in 
the second panning round. 
Subsequent pannings can take on a variety of forms, exposing the ligand to further 
rounds aim to increase the affinity of the phage to the ligand. Also it is possible to 
carry out a negative pan, that is, to expose the phage to another, structurally different, 
molecule and take the phage that show no binding affinity. This can be used to screen 
out phage that have bound to the carrier protein molecule rather than to the ligand in 
question. 
The first panning round used the O6CMG-ovalbumin conjugate (see section 3.2.2.1) 
which selected phage that showed affinity for this moiety. The second panning round 
was against ovalbumin only, this time the non-binding phage were collected. 
Therefore the phages that were used in the third panning had affinity for O6CMG- 
ovalbumin but not for ovalbumin. The final pan was against O6CMG linked to glass 
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(see section 3.2.2.3) beads, the phage amplified in this round were assumed to have a 
high affinity to O6CMG in order to have survived the successive panning rounds. 
2.8 DNA determination 
The optimum balance between stringency and yield occurs after two or three 
pannings132. When the appropriate pannings have been completed the phage are 
plated so that there are less than one hundred plaques are on one plate, this ensures 
that each plaque contains a single phage. Phage can `leak' from one plaque to another 
if they are too close together. These plaques are used to determine the DNA sequence 
of the phage and this will ultimately give the amino acid sequence that was 
incorporated into the vector in the original library. 
The DNA concentration from each plaque is determined by UV as measuring the OD 
at 260 nm as I OD260 is equivalent to 33 µg per µl of single stranded DNA. Between 
100-250 fmol of DNA template is required for the polymerase chain reaction (PCR). 
PCR can be used to amplify the short DNA sequence that contains the variation 
giving rise to the amino acid sequence so that it can be sequenced. This can be done 
manually or automatically depending on the method used in the PCR. For automated 
sequencing a -96 primer end labelled with a fluorescent dye (IRD800TM Li-Cor) was 
used to allow for detection of the sequence products. The primer is introduced to the 
DNA template along with a temperature resistant DNA polymerase and a supply of 
dideoxynucleotides and deoxynucleotides. The PCR involves heating the template to 
95°C to denature the template. The temperature is reduced to room temperature to 
allow the primer to anneal to the template, increasing the temperature to 65-70°C 
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allows the polymerase to extend from the annealed primer. This process is repeated 
as many times as considered necessary, as shown in Figure 2.5. When the reaction is 
complete a Stop/Loading buffer is added and then template is ready for sequencing. 
111 11 11 11111111111 111 ACTOACOOATOCOATTAOOTAC 
Denaturation occurs at 95°C 
TOACTOCCTOOCTAATCCATO 
1IIIIIIIIII1II1 I(^) 
I 
AC TO AC 00 ATC Co ATT AG 0 TAO 
Mmolý 
Primer anneals at 55°C 
CCATG 
IIIIIIII [111 11 1111 [111 
AC TOACOOATCCOATTAOOTAC 
AC TOCCTAO0CTAATCCATO 
1 
ACT OACGG ATCCGATTAGGTAC 
CATß 
Polymerase binds and 
begins extension at 95°C. 
Extension continues until the cycle stops or 
a dideoxynucieotide Is incorporated. 
Figure 2-5. A summary of the PCR in which the DNA is denatured, the labelled primer anneals 
to a specific sequence, at the higher temperature the polymerase extends from the primer 
incorporating nucleotides until the cycle stops or when a dideoxynucleotide is included in the 
growing chain which prevents further nucleotides being attached. The cycle is repeated 
numerous times. 
Sequencing is possible because of the introduction of dideoxynucleotides which do 
not have a hydroxyl group on the 3' and so prevents the addition of further 
deoxynucleotides (summarised in Figure 2.6). Separation of the fragments occurs via 
gel electrophoresis on an agarose or polyacrylamide gel that has been loaded with the 
DNA fragments and a current is applied. DNA is negatively charged and will migrate 
towards the positive pole however the larger pieces of DNA are held within the gel 
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matrix and are slowed down. Smaller pieces of DNA move through more quickly. 
The DNA sequence of the non coding strand is determined and using the Crick and 
Watson base pairing rule the coding strand from the phage is found. 
Single-stranded DNA 
51 
to be sequenced 31 
11 
CTGACTTCGACAA 
T 
T 1-5' DNA polymerase 
dATP 
dGTP T 
dCTP C 
dTTD 
fluorescently labeled A 
ddATP 
-T 1IIIIIII1 ddCTP 
ddTTP 
A 
3' 
Larger 
fragments 
Smaller 
fragments 
3' 
G 
A 
C 
T 
G 
A 
A 
G 
C 
T 
G 
T 
T 
5' 
5' 
C 
So the T 
sequence G 
or the A 
temp late T 
strand is 
T 
T 
-ý C 
G 
A 
C 
A 
A 
3' 
Figure 2-6. A brief explanation of how the PCR products are read in the automated sequencer. 
The complementary strand of the DNA to be sequenced is formed during the PCR as fragments 
as the extension is stopped when a ddnucleotide is incorporated into the strand. This results in 
the formation of differing lengths of DNA; these are separated on the gel whilst an electrical 
current is applied. The bands appeared in lanes in the order that they were loaded, ACGT, and 
so the sequence can be read. The corresponding sequence is determined and from this the amino 
acid sequence. 
-58- 
Chapter 2 
2.9 Results 
lt is suggested in the literature that ten blue plaques need to be sequenced to give a 
consensus between clones 133. Therefore ten plaques were taken from a suitably 
diluted plate and the DNA coding for the end of the pill protein was sequenced. The 
following amino acid sequences were found: 
plaque 
I Thr Arg Gly Leu His Leu Ser His Ser His Arg Asp 
2 Phe Ser Gly Asp His Leu Arg Glu Lys Leu Pro Ala 
3 Trp Pro Arg Tyr Thr Ser Thr His Leu Pro Ser Phe 
4 Ile Leu Ala Leu Gly Pro Ser Lys Ser Leu Thr Ala 
5 Phe Ser Tyr Glu Lys Thr Leu Lys Thr Tyr Pro lie 
6 Thr Leu Pro Thr Thr Phe Pro Arg Ala Thr Leu Thr 
7 Ala Leu Ile His Ser Leu His Ser Asn Ser Leu His 
8 Ser Ser Pro Arg Trp Phe lie Pro Asn Ser Ser Asp 
9 Leu GIn Leu lie Arg Leu Ile Ala His Pro Pro Lys 
10 Pro Gly Tyr Ser Pro Ala Thr Glu Leu Arg Tyr Ala 
Table 2-2. The amino acids identified from ten phage plaques following the three panning 
rounds. 
Although a discrete consensus sequence of amino acids was not found, there was a 
pattern in the types of amino acids present with those having basic side chains being 
more prevalent. An amino acid distribution was available in the product literature in 
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which 104 clones from the native library were sequenced. Six of these did not contain 
the insert but from the other 98 the distribution pattern was obtained as a frequency 
percentage, this is given in the table below along with the distribution pattern 
achieved from the selected ten clones. 
Amino 
acid type 
reported 
frequency % 
observed 
frequency % ratio 
Gly aliphatic 2.6 3.3 1.3 
Ala aliphatic 6 6.7 1.1 
Pro aliphatic 12.2 10.8 0.9 
Val aliphatic 3.9 0 0 
Leu aliphatic 9.3 15 1.6 
lie aliphatic 3.4 5 1.5 
Met aliphatic 2.6 0 0 
Phe aromatic 3.3 4.1 1.2 
Trp aromatic 2.2 1.6 0.7 
Tyr aromatic 3.6 4.2 1.2 
Ser 
polar 
uncharged 10 13.3 1.3 
Thr 
polar 
uncharged 11.1 10 0.9 
Cys 
polar 
uncharged 0.5 0 0 
Lys Basic 2.8 4.17 1.5 
Arg Basic 4.7 6.7 1.4 
His Basic 6.3 7.5 1.2 
Asp Acidic 2.8 2.5 0.9 
Glu Acidic 3.1 2.5 0.8 
Asn Acidic amide 2.8 1.7 0.6 
Gin Acidic amide 5.1 0.8 0.2 
Table 2-3. The distribution of amino acids found in ten phages selected following the three 
panning rounds, shown as a frequency percentage and the frequency percentage from 98 native 
phage (supplied by the manufacturer of the Ph. D. 12 library). The final column shows the ratio 
between the two. 
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2.10 Discussion 
Three amino acids, valine, methionine and cysteine are not represented at all in the 
selected clones. Although cysteine is under represented in the native library because 
its presence interferes with phage infectivity 132, the other two are present in the native 
library and appear to have been excluded. The acidic amide amino acids asparagine 
and glutamine also appear to have been excluded. Others that are underrepresented 
include glutamic acid and the aromatic tryptophan. All the basic amino acids appear 
more often in the selected clones compared to the native library with lysine and 
arginine appearing 50% and 40% more respectively. The aliphatic amino acids 
leucine and isoleucine also are over represented. 
It was expected the negatively charged amino acids might contribute to the binding of 
the purine base however, the results suggested that this is not the case, and these can 
be excluded from any library. It was also expected that positively charged amino 
acids would be included in a binding site that is complementary to the negatively 
charged carboxymethyl moiety and this appears to be borne out by the results. The 
aromatic amino acids phenylalanine and tyrosine are also slightly in excess of the 
normal representation of the library, suggesting that the planar ring-ring interactions 
are also contributing to the overall binding affinity. 
It is difficult to draw further conclusions from this work. It was hoped that a 
consensus between the clones would give a definitive pattern of amino acids on which 
a reagent could have been based. However, with hindsight it is perhaps unlikely that 
this would have been possible. Past literature shows many examples of a ligand being 
26_'28, found that fits into a preformed binding pocket, either peptidic or RNA in origin 1 
-61 - 
Chapter 2 
but there is no evidence that phage display has been used to find the binding area of a 
given ligand even though, theoretically, it should be possible. 
Attention was therefore turned to synthesising a combinatorial library of compounds 
based on the amino acids suggested in the conclusion of the phage display work. 
Making a whole host of slightly differing molecules would increase the possibility 
that a potential novel reagent could be isolated from the library. 
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Construction and characterisation of cholate- 
amino acid libraries for recognition of O6- 
carboxymethyl-2 -deoxyguanosine 
`Science is as an edged tool, with which men play like children and 
cut their own fingers'. Sir Arthur Eddington (1882-1944) 
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3.1 Introduction 
Interest in the detection of «carboxymethyl guanine in DNA of gastrointestinal cells 
has led to a need 1ra novel reagent. The reagent must fulfil certain criteria: it must 
be as good at detecting the ligand, if not better, than the pre-existing techniques; its 
results need to be reproducible and the reagent needs to be synthesised in large 
quantities. It was decided that the best method of finding such a reagent was to 
construct a library of compounds, with a putative binding site, the synthesis of which 
was directed so as to maximise the number intermolecular forces that may participate 
in the binding between the DNA adduct and the reagent. Candidate reagents would 
be identified by screening this library. With these prerequisites in mind, the first stage 
was the synthesis of the ligand molecule in a form that could readily be immobilished. 
3.2 Synthesis of immobilised 06-carboxymethylguanine 
3.2.1 Synthesis 
The synthetic scheme for preparation of immobilised 06-carboxymethyl guanine is 
shown in Scheme 3.1. The 2', 3'5' hydroxyl groups on the ribose ring of guanosine (1) 
were protected and to ensure that the more labile ester at the 2' remains protected 
throughout the synthesis134, isobutyryl protection was used. The 06 oxygen atom is 
unaffected by the protection step as it is less nucleophilic than the hydroxyl groups on 
the ribose ring, due to delocalisation of the non bonding pair of electron into the 
adjoining cyclic system. Based on previous work it was not considered necessary to 
protect the exocyclic N2-amino group' 35 especially as the removal of protection from 
the site using standard ammonia techniques, may result in substitution of the 06-alkyl 
by an amino group' 6. The protection step was completed with an overall yield of 
74%. 
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The next step involved the introduction of mesitylene sulphonyl chloride to give O6- 
[(2,4,6-trimethylphenyl)sulphonyl]-2', 3', 5'-tri-O-isobutyryl guanosine (2), this was 
readily followed by TLC as the starting material shows as a baseline spot and the 
product appears on the solvent front as it is considerably less polar. This was 
followed by the introduction of quinuclidine which displaces the mesitylene sulphonyl. 
group to give a quinuclidium salt (3). This appeared, on TLC, as a blue, fluorescent, 
baseline spot, and again it is easy to see when the reaction reached completion. 
Addition of methyl glycolate yielded the carboxymethyl methyl ester at the 06 
position. Deprotection, using sodium hydroxide, resulted in the formation of the 
carboxymethyl group and regenerated the hydroxyl groups on the ribose ring, to give 
06-carboxymethyl guanosine (O6CMG) (4). The difference between O6CMG and 
guanosine can clearly be seen by UV (Figure 3.1). 
2 
Absorbance 
0 
Wavelength nm 
Figure 3-1. The UV traces comparing guauosine, the upper trace, overlaid with the UV trace of 
O6CMG at the same concentration. 
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3.2.2 Conjugation of the ligand to matrices 
Attaching 06-carboxymethyl guanosine to a carrier molecule or matrix results in the 
formation of a moiety that closely resembles 06-carboxymethyl-2'-deoxyguanosine. 
HO 
HO 
0 
N 
HzN 
N 
Oý0 
Figure 3-2. A figure illustrating the similarities between 06-carboxymethyl-2'-deoxyguanosine 
and 06-carboxymethyl guanosine after it has been linked to a carrier matrix. 
3.2.2.1 Preparation of 06-carboxymethyl guanine bound to ovalbumin 
The diol at the 2' and 3' positions of 4 (O6CMG) are used in the conjugation to a 
carrier molecule that contains a primary amine, for example a lysine side chain 
residue. Ovalbumin is a protein that has 385 amino acids, seventeen of which are 
lysine. Therefore, theoretically, seventeen modified guanosine molecules may be 
attached to an ovalbumin protein. In reality only one molecule was linked, possibly 
due to the folded structure of the protein in which many of the lysine amino acids are 
likely to be inaccessible. 
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Erlanger and Beiser (1964) 137 developed a general method for attaching purines and 
pyrimidines to protein carriers. In the original paper the carrier in question was 
bovine serum albumin (BSA) but the method has been used for other carriers. While 
this method of coupling may not be suitable for some oxidized nucleosides138, it was 
previously used to couple 0 6CMG to both BSA and ovalbumin139 
Sodium periodate is used to oxidised the diol to yield a dialdehyde, this is followed by 
the nucleophilic addition of the primary amine. Although the intermediates have not 
yet been characterized in full, it is thought that the reaction proceeds via a Schiff 
base'39, which is stabilized by the addition of sodium cyanoborohydride to give 5. A 
proposed mechanism for this reaction is shown in Scheme 3.2. 
Following the procedure in Scheme 3.2, the resulting mixture was dialysed overnight 
against phosphate buffer saline (PBS) to remove salts and unbound nucleoside. The 
mixture was then eluted through a Sephadex G50 column with water. Sephadex G50 
is a column matrix in which the swollen beads of the matrix are large enough to allow 
small molecules to enter in to the bead140. When a mixture of varying sized molecules 
is applied to the top of the column the larger molecules are able to pass relatively 
quickly down the column between the gel particles. However, the smaller molecules 
enter the beads and as a consequence they take a longer route down the column and 
require a greater elution volume before being released from the column. Monitoring 
the UV at 210 nm the first absorbing fraction was collected and freeze dried. 
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3.2.2.2 Determination of the hapten-carrier ratio 
A standard curve (Figure 3.3) of hapten-carrier ratio was determined at 280 nm and 
the UV absorbance for the adduct-protein was 0.691 which gives an average ratio of 
1.44 adducts per protein. This is consistent with previously published results39. 1 
3 
2.5 
2 
1 .5 c ß 
y=0.1 ß93x + 0.5552 
Z R=0.9983 
a 
0.5 
0 
012 3456789 
Hapton -Carrier Ratio 
10 
Figure 3-3. A standard curve showing the relationship between the UV absorbance, A2M, and the 
number of haptens present on a carrier protein. 
3.2.2.3 Preparation of 06-carboxymethyl guanine bound to glass 
O6CMG was also linked to amino propyl glass beads that were used in phage display 
as previously discussed in section 2.6.3. The same technique was used in the 
preparation of affinity columns that were used in probing the library and is discussed 
in detail in section 4.3. 
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3.3 Synthesis and characterisation of cholate-amino acid 
libraries 
3.3.1 The development of amide bonded cholic acid derivatives 
The orginal plan was to follow the scheme shown in Scheme 3.2. The first two steps 
were taken directly from Li et al 14' and although the literature142-144 suggests that it 
would be possible to selectively address each hydroxyl site individually it was 
decided that this would not be necessary in the initial construction of a library of 
compounds. Cholic acid, 3a, 7a, I2u trihydroxy-(5ß)-cholan-24-oic acid, was supplied 
by Aldrich and converted into methyl cholate. Methylation was achieved simply with 
methanol and a catalytic amount on concentrated sulphuric acid in almost quantative 
yield to give 3a, 7a, 12a trihydroxy-(5(3)-cholan-24-oic acid methyl ester, also known 
as methyl cholate (6). The C24 ester is reduced with lithium aluminium hydride, to 
give 3a, 7a, 12a trihydroxy-(5ß)-cholan-24-o1 (7) (Scheme 3.2). The subsequent 
reactions involving trityl chloride (8,9,11 and 13) proved to be difficult to take to 
completion in a satisfactory manner and the lowest yielding step was the tritylation. It 
was decided to miss out this step and the associated LiAlH4 reduction, as Davis and 
his co-workers had made the triamino analogue without it142 
Pyridinium dichromate was found to oxidize all three hydroxyl groups on methyl 
cholate to ketones to give 3,7,12 trioxo-(5ß)-cholan-24-oic acid methyl ester (10) in 
very good yield (Scheme 3.3). In turn this was treated with hydroxylamine 
hydrochloride to give 3,7, l2 trioximo-(5ß)-cholan-24-oic acid methyl ester (12), 
again in good yield. However the reduction of the oxime groups by the addition of 
sodium borohydride and titanium chloride in 1,2-dimethoxyethane could not be 
repeated in this laboratory with success. 
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Scheme 3-3. The revised scheme for the formation of a triamino analogue of methyl cholate. 
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However, the facility by which trioximo derivatives of trioxocholate could be 
prepared suggested a more convenient route to combinatorial libraries based on cholic 
acid. This approach became the focus of subsequent work. 
3.3.2 The development of a general synthesis of oxime bonded 
cholic acid derivatives 
A commercial laboratory in the USA was located who could supply steroid 
derivatives for research purposes and 500 g of 3,7,12 trioxo-(5ß)-cholan-24-oic acid 
(15), for approximately £55, was obtained. This compound became the starting point 
of subsequent reactions. The opportunity was taken at this point to incorporate the 
marker that would aid subsequent detection. 
3,7,12 trioxo-(5ß)-cholan-24-oic acid (15) 
3.3.2.1 Incorporation of a fluorescent marker 
Fluorescence was considered to be a readily measurable and sensitive characteristic 
that would increase the detection potential of the ultimate reagent. Fluorescence 
spectra are a plot of fluorescent intensity against wavelength 145. Light absorbed by 
the molecule is of a specific wavelength with discrete photon energies, these induce 
electronic excitation and molecular vibrations which make the molecule 
thermodynamically less stable relative to its surroundings. When the energy is lost 
via a Si--*S() transition, from a high energy state to one of a low vibrational level, the 
energy is released in the form of light, fluorescence 146. Fluorophores, substances that 
are fluorescent, usually posses delocalized electrons present in conjugated double 
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bonds145 and it was decided that pyrene would be a suitable molecule to introduce 
fluorescence into the reagent. 
Initial attempts to introduce pyrene into the cholate molecule were based on the 
synthesis of pyrene methyl esters with the C24 carboxylic acid group147. Based on 
published methods, 1-pyrenyldiazomethane was prepared from 1- 
pyrenecarboxyaldehyde hydrazone and reacted with cholic acid to give the required 
ester 141,149 However this approach was abandoned due to low yields of the ester as 
well as concerns about the stability of the pyrenyl ester linkage. It was decided that a 
better approach would be to explore an amide linkage. 
The N-hydroxysuccinimide ester of cholic acid has been used in the preparation of 
bile acid-based Gemini surfactants150 and this method was followed using 15 (3,7,12 
trioxo-(5p)-cholan-24-oic acid). This product was coupled with 1- 
pyrenylmethylamine to give the pyrenyl amide of 3,7,12 trioxo-(5ß)-cholanoic acid 
(PyCA), (Figure 3.6 compound 16), by the proposed method shown in scheme 3.3 
with overall yield of >60%. This gave a robust, highly detectable, scaffold molecule 
upon which a library could be based. 
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Scheme 3-4. The scheme that was followed during the synthesis of N-(1'-pyrenylmethyl)- 3,7,12- 
trioxo-(53)-cholan-24-amide (PyCA) Compound 16. 
3.3.2.2 The incorporation of a spacer unit 
Simple modelling of the scaffold molecule, using ball and stick, showed that there 
may be considerable restriction around the putative binding pocket if amino acids 
were bound directly to amino groups formed by possible reduction of the trioxime 
intermediate. This can be seen in Figure 3.4, a WebLab ViewerTM representation. 
WebLab Viewer"m is a basic programme that allows ball and stick models to be 
viewed on a computer. Figure 3.4 is a model of the scaffold molecule (the lower 
molecule) with the pyrene appendage shown in the lower right hand corner. The 
upper molecule is that of ligand with the carboxymethyl adduct being presented to the 
`pocket' formed by amide linked glycine amino acids. 
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Figure 3-4. A WebLab ViewerT"' representation of the ligand, the upper left hand molecule, 
which has the carboxymethyl adduct close to the binding portion of the scaffold molecule (the 
lower molecule). This molecule contains three glycine amino acids that have been attached to the 
scaffold by amide bonds. 
By replacing the amide linked glycine with aminooxy acetic acid derivatives the 
oxime bond opens out the pocket (represented in Figure 3.5). Thus, by introducing 
diversity through amide bond formation with the introduced aminooxyacetyl function 
the putative binding pocket is likely to be more accommodating to 06-carboxymethyl- 
2'-deoxyguanosine (Figure 3.6). 
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Figure 3-5. A WebLab"'representation of the scaffold with three oxime linked aminooxy glycine 
derivatives. 
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Figure 3-6. A WebLab ViewerT' representation of a proposed molecule containing aminooxy 
derivative of glycine, lysine and phenylalanine. The ligand is shown in yellow for clarity. 
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3.3.3 Oxime formation 
The coupling of hydroxylamine which results in oxime formation proved to be 
unaffected by the presence of the pyrenyl group and this remained attached 
throughout the synthesis of 17 (N-(1'-pyrenylmethyl)-3,7,12 trioximo-(5(3)-cholan-24- 
amide). It was also possible to introduce methyl, carboxyl methyl and the bulkier 
benzyl groups in all three positions using their hydroxylamine derivatives. It was also 
noticeable that, based on previous experiments, the oxime formation proved to be 
facile, reliable and repeatable. 
OH 
N0H 
HO's 
N/ Ný 
17 OH 
The coupling of two mutually and uniquely reactive functional groups in an aqueous 
environment has been given the term `chemoselective ligation' and such reactions 
have been explored by both biologists and chemists in their search for selective 
chemical couplings that may occur in living organisms 151. Traditional stepwise 
syntheses are limited by by-product accumulation particularly with regards to peptide 
synthesis. Chemoselective ligation is considered to be a way of bypassing some of 
the synthetic steps and thus improve yield. Many of the chemoselective ligation 
partners have been identified, some of which were discussed in section 1.8.2. One set 
of partners were the (aminooxy)acetyl functionality and its reaction with ketones or 
aidhydes. 
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The literature shows that under very mild conditions the (aminooxy)acetyl terminal 
group reacts specifically with aldehydes and ketones to form an oxime bond 104,152- 
161 
, in a way that is rapid, highly efficient and stable162. This ligation has been used in 
a whole host of different purposes and the compounds that result from these couplings 
have been shown to have inhibitory potential of Na', K+-ATPase16;, ill vivo 
applications 160, protein dimerisation161 and template-assembled synthetic protein 
1 (TASP) design58, to name but a few. 
It is also known that oxime formation occurs in the presence of unprotected side chain 
residues'53'ýs6 guanidino, amino, hydroxyl and carboxylic'58. This is probably due to 
the physico-chemical properties of the aminooxy group, the oxygen atom affects the 
nucleophilic character of the neighbouring amino group, the a-effect1S4 
3.3.3.1 The a-effect 
The a-effect is thought to come about because the adjacent electron pair can act to 
stabilize any charge deficiencies at the transition state164, or because they raise the 
highest occupied molecular orbital (HOMO) energy that participates in bond 
formation and enhances `soft' base behaviour 165. However the a-effect is brought 
about, atoms which are directly bonded to another with unshared electron pairs tend to 
be stronger nucleophiles166, for example, hydroxylamines (NH2OH) and hydrazines 
(NH2NH2) are both more nucleophilic than ammonia'64. 
3.3.4 Oxime bond formation 
An oxime is the condensation product of hydroxylamine and an aldehyde or a ketone, 
which can be divided into two distinct stages, of addition followed by elimination 
proceeding through a tetrahedral intermediate, shown in Figure 3.7: 
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NHOH 
OI NOH 
+ NHZOH step 1RCR step 2' 
RRIRR 
(carbinolamine) 
Figure 3-5. The two step reaction that results in oxime formation, via a tetrahedral intermediate. 
There is an optimum pH at which the rate of reaction is at its maximum, at a pH 
higher or lower than this the rate falls. This is caused by changes in the rate 
determining step. At a pH lower than the optimum step 2 is rapid and step I is the 
slow rate determining step. Most of the hydroxylamine molecules have been 
converted to the conjugated +NH3OH which cannot attack the substrate. As the pH 
increases, the fraction of free hydroxylamine molecules increases and the rate of step 
I increases. 
As the pH increases beyond optimal step 2 becomes the rate determining. Although 
the rate of step 1 is still increasing it is now step 2 which determines the overall rate 
as it is the rate of this step that is decreased in increasing basic conditions. 
Following the addition of the nucleophile the carbinolamine intermediate is formed, 
dehydration of this intermediate involves nitrogen deprotonation concerted with the 
elimination of water. 
A general method of oxime formation that was repeatable and reliable was developed. 
This was based on the oxime formation that was used to connect testosterone, 
containing one cyclic ketone, to varying alkylaminooxy compounds 'ss. The method 
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involved dissolving the reactants in ethanol, with sodium acetate to buffer the 
reaction. Therefore it was decided to develop a general coupling process based on 
these reactions that will bring about the formation of an oxime bond between the 
tagged scaffold molecule and suitable compounds to introduce diversity around this 
scaffold. 
3.3.5 The scaffold molecule 
The framework of a novel reagent was fully prepared which had an inherently rigid 
backbone with an attached fluorescent marker molecule. The presence of three cyclic 
ketones allowed for the chemoselective ligation of aminooxy derivatives that formed 
the stable oxime bond at all three sites. The next consideration was the attachment of 
diversity at these sites, synthesising a library of differing compounds. 
Figure 3-6. Compound 16.1'-pyrenylmethyl-3,7,12 trioximo-(5p)cholan-24-amide (PyCA). The 
molecule that became the scaffold of the library, it has three ketone groups on a rigid backbone 
with a remote, highly fluorescent component. 
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3.4 Synthesis of library components 
When it was considered that the oxime bond would allow for slightly more flexibility 
and there was a requirement for spacers, this suggested a molecule such as: 
OR 
O 
H2N N 
\PG 
I 
-", 
y 
H0 
in which the hydroxylamine functionality would be available after the attachment of 
suitably protected amino acids. It was decided that it would be possible to make a 
range of compounds based on the above molecule that would be used to couple to the 
scaffold molecule. An advantage of this method would be that the coupling process 
would not influenced by the side chain amino acids residues as they are situated 
somewhat remotely from the coupling site. A range of (aminooxy)acetyl derivatives 
of amino acids were therefore synthesised. 
3.4.1 Synthesis of aminooxy compounds 
((1,1-dimethylethoxycarbonyl)aminooxy ethanoic acid (18, Scheme 3.5) was first 
used in the formation of O-alkyl aminooxy ethers in 2000, with alkyl halides' 67 and 
more specifically with regard to peptides152. Succinimido-(N)-((1,1- 
dimethylethoxycarbonyl)aminooxy) ethanoate (19) was prepared by the method 
previously published 168. This was then used to couple with various protected amino 
acids according to Scheme 3.4, including glycine benzyl ester, glycine methyl ester, 
phenylalanine methyl ester, lysine (FMOC) methyl ester and arginine (c-NO2) methyl 
ester. These aminooxy derivatives of amino acids were considered to be the most 
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desirable compounds to introduce diversity to the scaffold molecule because they 
covered a range of side chain structures thought to be critical for forming a binding 
site for 06'-carboxymethyl-2'-deoxyguanosine. The products were mainly white 
fluffy powders which were hygroscopic and had to be stored under vacuum. 
O-Carboxymethyl 
hydroxylamine 
KOH 
O Me011 
O 
o Water O 
( 
65% 
O NH 
O-ý 
Ö 
O 
OH 
18 
R 
// 
H2N O-PG 
0 
Et NO 
Et ACý 
NH 
O 
O 
O NH 
PG-0 R 
N-hydroxysuccinimide 
DCC 
74% 10 
0 
0 
NH 
O 
O 
OO 
N 
O 
19 
O 
NH O 
TFA 
0R O-PG 
H2N 
Scheme 3-5. The Scheme that was followed during the preparation of aminooxy compounds that 
were used to couple to the scaffold molecule. R represents the various side chain residues for the 
different amino acids. PG stands for protecting group which was either benzyl or methyl. 
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The yields of these reactions (Table 1) were modest and although some effort was 
spent trying to improve them, there was little success in doing this. The amino acids 
were freed from their salts before coupling to succinimido-(N)-((1,1- 
dimethylethoxy)carbonyl)aminooxy ethanoate (19), it was later found that this was 
not necessary and the addition of triethylamine to the coupling reaction freed the 
amine in situ, with no difference in yield between the two methods. Although small 
quantities of the required amino acid precursors were made, with other amino acids, 
serine and alanine, the yield was too low to be useful. It has been noted previously167 
that the synthesis of aminooxy compounds give unsatisfactory yields and the 
availability of aminooxy precursors are very limited, with only the simplest being 
commercially available. This seems to be a major limitation and improvement in the 
synthetic methodologies for such aminooxy compounds is a must before the full 
potential of this chemistry can be achieved. 
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Amino acid precursor Aminooxy compound Overall yield 
Glycine 
H 
20 AOA/ 
N 
o1--*, 
33% 
0 
H 
-ý 
N 
ý 
Glycine ,, oI AOA" 34% 
21 
0 
Phenylalanine 
H 
AOA,, 
N 
O/ 24% 
22 
AOA 
HN 
O 
Arginine 35% 
NH 
H N 
"ýNH 
, 23 
0 
Lysine 
H 
N 
AOA< oý 32% 
NH-Fmoc 
24 
O 
1-4 AOA = H2N-O R 
Table 3-1. A table of the aminooxy compounds that were used in the synthesis of the library, 
showing the precursor amino acid and the structure of the compound with the overall yield. 
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3.5 Synthesis of tri-substituted 1'-pyrenyl methyl-3,7,12 
trioximo-(5ß)-cholan-24-amide (PyCA) compounds 
The aminooxy glycine derivative, which was protected on at the carboxylic acid 
group by a benzyl group, was coupled to PyCA. This reaction was undertaken in the 
same manner as with the hydroxylamines, to give a tri-substituted compound. The 
aminooxy compounds were reacted in a slight excess of 3: 1 ratio to ensure that all 
three sites reacted. The reaction was followed by TLC and was considered to be 
complete when a single spot was observed on the TLC plate. The benzyl group was 
then removed by hydrogenolysis; this also removed the pyrenyl group and so another 
protecting group had to be used. The facile removal of methyl esters by sodium 
hydroxide proved that these were a suitable alternative and were subsequently used. 
However, as the aminooxy acetyl glycine benzyl ester had already been synthesised it 
was decided to incorporate this into the library as well. The benzyl group could act to 
encourage ring-ring interaction with the 06-carboxymethyl-2'-deoxyguanosine 
analogue. For each of the aminooxy compounds the tri-substituted PyCA molecule 
was made (shown in Figure 3.7) and, although the molecular ion was not detected, ion 
fragments of these compounds were clearly seen. The Sakaguchi reagent169 was used 
to confirm that the guanidine derivatives had indeed survived the coupling reaction in 
the case of arginine derivatives. Mass spectrometry was used but in many cases it 
was difficult to locate a molecular ion. However it was apparent that the oxime bond 
was susceptible to cleavage and the fragments corresponded to the loss of an `arm' on 
the scaffold with the break occurring between the N and the 0 atoms in the bond. 
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Figure 3.7. Digrams of the structure of the tri-substituted PyCA compounds made with each of 
the aminooxy derivatives of four different amino acids. Compound 25,1'-pyrenyl methyl-3,7,12 
tri(N-iminoxymethylenecarbonyl (glycine benzyl ester). Compound 26,1'-pyrenylmethyl-3,7,12 
(tri(N-iminoxymethylenecarbonyl) glycine-(5ß)-cholan-24-amide. Compound 27,1'- 
pyrenylmethyl-3,7,12 (tri(N-iminoxymethylenecarbonyl) lysine-(5p)cholan-24-amide. 
Compound 28,1'-pyrenylmethyl-3,7,12 (tri(N-iminoxymethylenecarbonyl) phenylalanine-(5ß)- 
cholan-24-amide. Compound 29,1'-pyrenylmethyl-3,7,12(tri(N-iminoxymethylenecarbonyl) 
a rg in ine}(5ß)-c ho la n-24-amide. 
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3.5.1 Pilot studies on library formation. 
3.5.1.1 PyCA Mix 1 
In order to demonstrate that structurally diverse aminooxy derivatives could react 0- 
carboxymethyl and O-benzyl (to give products represented in Figure 3.8) were reacted 
in equal molar concentrations and coupled to PyCA in the way previously discussed. 
Using 5% methanol and 0.5% diethylamine in chloroform a TLC showed that the 
starting material PyCA had an rf value of 0.63, the trisubstituted carboxyl methyl 
compound rf = 0.04, and the tri benzyl substituted compound rf = 0.79. The mixed 
reaction gave eight spots that corresponded to rf = 0.79,0.46,0.41,0.36,0.30,0.22, 
0.13 and 0.03, shown diagrammatically in Figure 3.9. This clearly shows that a range 
of compounds were formed with a mix of characteristics between the fully tri 
substituted compounds, it also indicated that there was no remaining starting material. 
--0 
R 
Oma. 
or 
--Y OH 
0 
Figure 3.8. A diagram showing the possible products from the PyCA Mix I reaction. 
-89- 
Chapter 3 
S 
" 
1234 
Solvent 
front 
Figure 3-9 A diagram to represent the TLC plate of the first pilot study to show that a mixture 
of compounds are found in the presence of different aminooxy compounds. 1 indicates the 
position of the PyCA starting material, 2 indicates the position of the tri-carboxymethyl 
substituted PyCA compound and 3 indicates the position of the tri-benzyl substituted PyCA 
compound. 4 is the range of spots produced as a result of reacting both aminooxy compounds 
with PyCA. 
The NMR of the mix show a multiplet centred around 8 ppm (pyrene), a multiplet 
centred around I ppm (steroidal core) as well as evidence for benzyl protons and 
carbons and also carbonyl carbons. Varian normal phase HPLC using Jones Apex II 
silica 5 micron column at a flow rate of I mL/min of 50/50 methanol/dichloromethane 
was used to attempt to separate the compounds in the mixture which was monitored at 
342 nm, resulting in the trace in Figure 3.10. Although peaks were present with a 
retention time of 3.5 mins and 4.6 mins, these did not coincide with the starting 
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material as on the same system PyCA had a retention time of 3.95 mins. The peaks I- 
5 were collected and sent for MS analysis. 
#A- 
5.18- 
ie. ee- 
15.89- 
2$. 98- 
Figure 3-10. RP-HPLC trace of the mixed PyCA compounds found in the reaction mixture. The 
peaks 1-5 where collected and sent for MS. 
Peak 1 showed 100% abundance of a fragment m/z 826 that coincided with: 
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+ 
of the the three sites having 
attached. 
/o/ 
Peak 2 did not yield enough sample for MS, peak 3 showed high abundance of the 
above along with 20% of the tri benzyl compound substituted, m/z 930. Peak 4 and 5 
gave the same mass fragment pattern as peak 3. Therefore there was evidence that the 
benzyl group had attached but that it was difficult to get a molecular ion in mass 
spectrometry which is consistent with previous results as the oxime bond appears 
particularly susceptible to ionization. There was no evidence in the spectra of the 
carboxyl methyl substituted compounds and it was thought that any polar compounds 
may not have eluted under these conditions, the column was reversed and washed out. 
The mass spectra of this gave the molecular ion for the compounds substituted with I 
benzyl and 2 carboxy methyl, m/z 866, and 3 carboxyl methyl, m/z 835. 
3.5.1.2 PyCA Mix 2 
It was thought that replacing carboxymethyl with a methyl would make the above 
reaction easier to follow and therefore it was repeated by replacing the 0- 
carboxymethyl hydroxylamine with 0-methyl hydroxylamine. Using the same TLC 
conditions as above five spots were seen in the reactions mixture, rf = 0.79,0.71, 
0.69,0.55 and 0.39. These compare to the starting material (rf = 0.64), tri methyl 
substituted (rf = 0.4), and tri benzyl substituted (rf = 0.8) (Figure 3.11). 
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Salvmt 
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Figure 3-11. A diagram to represent the TLC plate of the second pilot study to show that a 
mixture of compounds are found in the presence of different aminooxy compounds. 1 indicates 
the position of the PyCA starting material, 2 indicates the position of the tri-methyl substituted 
PyCA compound and 3 indicates the position of the tri-benzyl substituted PyCA compound. 4 is 
the range of spots produced as a result of reacting both aminooxy compounds with PyCA. 
It was not possible to use the previous RP-HPLC conditions as although the sample 
was soluble in methanol, when water was added a precipitate formed, and an aqueous 
sample is essential to run reverse phase HPLC. Thus a normal phase HPLC system 
was developed using 5% methanol in dichloromethane and again peaks were 
collected. 
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6 
Figure 3-12. RP-HPLC trace of the mixed PyCA compounds found in the reaction mixture. The 
peaks 1-4 were collected and sent for MS. 
Peak 1 gave the molecular ion for a di-benzyl, mono-methyl compound, as did peaks 
2 and 3, this gives three isomers of the compound and it is assumed that the methyl 
group could be positioned at each of the three available sites. Peak 4 gave the 
molecular ion for the di-methyl, mono-benzyl compound. MS spectral data of the 
mixture showed the molecular ions of the tri-benzyl, mono-benzyl di-methyl, di- 
benzyl mono-methyl compounds. 
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Peak 1 2 benzyl, I methyl + NH3 872 
Peak 2 2 benzyl, I methyl + NH3 872 
Peak 3 2 benzyl, I methyl + NH3 872 
Peak 4 1 benzyl, 2 methyl - CH2 765 
Mix I benzyl, 2 methyl +H 
2 benzyl, I methyl + NH3 
3 methyl +H 
1 benzyl, 2 methyl CH2 
780 
872 
704 
765 
Table 3-2. A table showing the compounds in which samples and their m/z ratios. 
3.6 Synthesis and analysis of the library 
Based on the above pilot studies, a larger library was made using the prepared N- 
(aminooxy acetyl) amino acid compounds in a molar excess to the three functional 
groups on the PyCA scaffold. TLC was carried out after the overnight reflux, which 
showed that there was no starting material present and a range of fluorescent spots 
between rf= 0.56 - 0.70. This was followed by the deprotection steps that removed 
the Fmoc group from the lysine side chain. Normal phase HPLC on the PyCA tri- 
arginine aminooxy compound and tri-lysine aminooxy compounds did not give a clear 
peak however the PyCA tri-glycine derivative did and this peak was present when it 
was coeluted with the library mixture. When a sample of PyCA tri-phenylalanine and 
the library mix were co-eluted there was a sharp increase in the peak sizes that had 
retention times 37.8 and 38.9. Again the column was reversed and it was found that a 
number of compounds had become stuck on the column. After base hydrolysis to 
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remove the methyl ester from the C-termini of the aminooxy compounds, TLC 
showed a baseline fluorescent spot. At pH 11 the library was soluble in water. 
Following addition of acid, pH 4, the resulting solid was spun in a centrifuge and the 
supernatant removed. After repeated re-suspension in water and centrifugation, the 
solid was dried under vacuum. 
Co-injection of standard compounds with the library revealed that there was no PyCA 
starting material in the library as PyCA had a retention time of 28.6 and this did not 
correspond to any peaks in the library. However, there was evidence that the tri- 
phenylalanine derivative was present , as were peak patterns for the tri-arginine, tri- 
gycine and tri-lysine derivatives. The HPLC trace shows that while there were many 
compounds present, the UV trace shows that they all have the characteristic profile of 
pyrene containing compounds as shown in the following Figures 13 and 14. 
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Figure 3-13. The HPLC profile of the library mix of compounds, showing that there is a wide 
variety of compounds in the library. The retention times range from 15 minutes to 50 minutes. 
When the starting material was coeluted there was no correspondence with any of the peaks in 
the shown trace. A cross section of peaks, range from early to late eluting compounds, were 
taken and a UV trace recorded, shown in Figure 3.14. 
-97- 
__ ýý 
ý- 
E 
Chapter 3 
a 
I, - 
Figure 3-14. A cross section of peaks analysed in UV. This shows that irrespective of being an 
early or late eluting compound the UV was the same and indicative of pyrene containing 
compounds. 
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Theorectically there are 35 possible mass combinations, assuming equal reactivity of 
the aminooxy compounds over the three sites, and this, of course, gives no 
information of the position of each group on the scaffold. The following table gives 
the possible mass combinations; the PyCA scaffold has a mass of 829 and is common 
to all compounds. As the aminooxy glycine benzyl ester and the aminooxy 
phenylalanine have the same mass it was impossible to use mass spectrometry to 
define which of the two is present on the scaffold molecule and any combination 
containing either of these derivatives give the same mass. 
Mass spectral analysis of the library mixture shows the molecular ion for PyCA di- 
glycine benzyl ester mono-lysine, PyCA mono-arginine mono-glycine benzyl ester 
mono-phenylalanine, PyCA tri-glycine. There were also fragments that corresponded 
to PyCa mono-glycine benzyl ester, PyCA mono-phenylalanine, PyCA mono-glycine, 
PyCA mono-arginine mono-glycine, PyCA mono-arginine mono-lysine, PyCA mono- 
glycine benzyl ester mono-arginine 
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Combination PyCA Mass 1 Mass 2 Mass 3 Total 
aaa 829 159 159 159 1306 
aab 829 159 159 149 1296 
aag 829 159 159 59 1206 
aal 829 159 159 130 1277 
aap 829 159 159 149 1296 
abb 829 159 149 149 1286 
abg 829 159 149 59 1196 
abl 829 159 149 130 1267 
abp 829 159 149 149 1286 
agg 829 159 59 59 1106 
al 829 159 59 130 1177 
agp 829 159 59 149 1196 
all 829 159 130 130 1248 
al 829 159 130 149 1267 
app 829 159 149 149 1286 
bbb 829 149 149 149 1276 
bbg 829 149 149 59 1186 
bbl 829 149 149 130 1257 
bbp 829 149 149 149 1276 
bgg 829 149 59 59 1096 
bgp 829 149 59 149 1186 
bgl 829 149 59 130 1167 
b11 829 149 130 130 1238 
bl 829 149 130 149 1257 
bpp 829 149 149 149 1276 
999 829 59 59 59 1006 
1 829 59 59 130 1077 
829 59 59 149 1096 
gIl 829 59 130 130 1148 
gIp 829 59 130 149 1167 
9pp 829 59 149 149 1186 
111 829 130 130 130 1219 
11 829 130 130 149 1238 
Ipp 829 130 149 149 1257 
ppp 829 149 149 149 1276 
Table 3-2. The possible mass combinations; PyCA is common to all the compounds and Mass I 
represents the possible aminooxy compound that could be present at one of the three keto sites of 
the scaffold, Mass 2 and Mass 3 therefore represent the other two sites that are available for 
reaction. The total mass is give in the final column along with the average mass of the library 
compounds. a= the aminooxy arginine derivative, b= aminooxy glycine benzyl ester derivative, g 
= aminooxy glycine derivative, I= aminooxy lysine derivative, p= aminooxy phenylalanine 
derivative. The average mass of a compound within the library is 1216.6. 
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3.7 Regioselective oxime formation 
The ability to select one of the three ketones over the other would definitely be a 
synthetic advantage. Previous work has shown that gentle conditions may be 
employed to give selectivity at the C3 position147, and it is believed that the C12 
position is more reactive than the C710. Therefore it was thought that it would be 
possible to control the reaction first at the C3 and then at the C 12 by using a limited 
amount of reactants and gently increasing the temperature. It is known that refluxing 
the PyCA scaffold overnight with a >3 excess of aminooxy compounds results in a 
reaction occurring at all three keto sites, so it seemed logical that by controlling the 
time, temperature and aminooxy equivalents that the sites on the scaffold can be 
manipulated individually. A simple small scale reaction was carried out in which 
PyCA and 0-benzylhydroxylamine were reacted together in the presence of 
appropriate amounts of sodium acetate and ethanol. A heating block was used to heat 
individual reaction tubes and the reaction monitored by TLC, eluant 5% methanol in 
chloroform. In conclusion it was possible to carry out the reaction in 1 hour at room 
temperature and get a single product over the three ratios, this indicates that one site, 
possibly C3, acquires the benzyl group. After 5 hours at 70°C all three sites had gone 
to completion in the three to one ratio mixture, however there was no clear evidence 
that one of the other sites was reacted before the other as after 3 hours trace spots 
were noted in the two to one and the three to one mixes which were identical. The 
two to one mix had a total four spots after 5 hours. It should be possible to investigate 
this in more detail, on a larger scale so that enough material is made to take samples 
after each hour and explore the structure of the compounds by NMR which should 
show which position is being reacted and possibly in what order. 
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Analysis of cholate-amino acid libraries for 
recognition of 06-carboxymethyl-2 - 
deoxyguanosine 
`Science.... never solves a problem without creating ten more'. 
(George Bernard Shaw 1856-1950) 
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4.1 Chromatography 
Chromatography was coined from the Greek of two words chroma, for colour, and 
graphein, to write, by a Russian botanist M. S. Tswett in 1903. He first used the 
technique for the separation of coloured plant pigments and, although he did state that 
it could also be used for the separation of colourless substances, chromatography was 
the term he used in all his papers. Since these early beginnings chromatography has 
become a universal, versatile technique, in its many guises"' 
Despite of all the variations in the application of chromatography the principle 
remains the same, separation occurs by the distribution of the components between 
two phases, one of which is stationary and a mobile phase 172. The mixture to be 
separated is dissolved in the mobile phase and passed over an adsorbent material, the 
stationary phase. Due to the differing properties of the compounds in the mixture 
they adsorb to different extents and migrate through the stationary phase at different 
rates. They are eluted and emerge as (usually) separate compounds3. 1 
In liquid chromatography the mobile phase is a liquid which passes over a liquid or, 
more usually, a solid stationary phase of a large surface area. This can be an 
absorbent surface, found in column chromatography, thin-layer chromatography 
(TLC) and high performance liquid chromatography (HPLC); a resin, used in ion 
exchange; a gel, used in size exclusion, such as that mentioned in section 3.2, and 
affinity columns. 
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In TLC the stationary phase is planar and consists of a thin layer of the stationary 
phase being spread uniformly over a flat sheet of either glass, plastic or aluminium. 
In the other techniques the stationary phase is packed in to a column. 
Affinity chromatography involves the immobilization of either a ligand or an affinity 
reagent, such as an antibody, on to a support matrix and separation relies on 
biospecific interactions, and it is this specificity that allows some molecules to be 
retained on the column, whilst unbound molecules are eluted in the mobile phase. As 
the interaction between the molecule and ligand are reversible molecules are eluted by 
changing the pH or composition of the mobile phase. A demonstration of this 
technique has already been discussed in section 1.5.1 concerning the 
immunoaffinity/HPLC detection of O6CMdG. Briefly, the total immunoglobulin/G 
fraction from the rabbit antiserum were covalently linked to a Protein-A-Sepharose 
matrix. O6CMdG was then passed down the column, the binding between the 
modified matrix and O6CMdG being so strong that 1M trifluoroacetic acid (TFA) 
was required to release the ligand from the matrix. Under these conditions the 
glycosidic bond was hydrolysed and the eluting fractions contained the alkylated base 
O6CMguanine, and it was this moiety that was detected by HPLC fluorescence 43,44 
4.2 HPLC development for the analysis of the cholic acid 
libraries 
It was thought that it would be possible to design a HPLC system that could be used 
to give a series of retention times corresponding to each of the trisubstituted 
compounds. These could then have been used to identify any trisubstituted 
compounds that appear in the library. Any intermediate peaks would be tentatively 
assigned their amino acids residues based on their retention times. To achieve this it 
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would be necessary to find a system that worked on all compounds simultaneously so 
that a comparison could be made. 
A suitable gradient was developed that used an increase of acteonitrile from 15% to 
90% over 20 minutes with water and a constant 5% 0.1 M phosphoric acid and this 
gave a clear peak for 16 (PyCA) with a retention time of 10.2 minutes. 
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Figure 4-1. The HPLC trace of PyCA 
The same system gave a peak for 26 (1'-pyrenylmethyl-3,7,12 (tri(N- 
iminoxymethylenecarbonyl) glycine)-(5ß)-cholan-24-amide) centered at 9.5 minutes. 
The peak was very broad indicative of there being very similar compounds being 
eluted over time (8.71- 10 minutes). 
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Figure 4-2. HPLC trace for 26 (1'-pyrenylmethyl-3,7,12 (tri(N-iminoxymethylenecarbonyl) 
glycine)-(5 »-cholan-24-amide). 
The trace for 28 (1'-pyrenylmethyl-3,7,12 (tri(N-iminoxymethylenecarbonyl) 
phenylalanine)-(5ß)-cholan-24-amide) was as shown below (Figure 4.3) with no 
distinct peak profile, and with 27 (1'-pyrenylmethyl-3,7,12 (tri(N- 
iminoxymethylenecarbonyl) lysine)-(5ß)-cholan-24-amide) no stable baseline could 
be established. 
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Figure 4-3. HPLC traces showing the problems in the chromatography of trisubstituted 
compounds. 
Considerable time was spent trying to modify the method set but by gaining 
resolution for one compound resulted in the loss of resolution for another. Without 
the ability to run all compounds on the same method set, HPLC could not be used 
consistently against the library. 
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4.3 Two dimensional (2D)-TLC method for the visualization 
of cholic acid libraries 
The library gave a baseline fluorescent spot using an eluant containing 5% methanol 
in chloroform, which was indicative that the protecting methyl groups had been 
removed from the carboxylic group making the compounds more polar. However the 
development of an eluant that will facilitate the migration of these acids is possible 
and attention was turned to finding such an eluant mixture. One major advantage of 
using TLC is the fact that all the compounds present in the library will be visible on 
the plate even if they have not been separated. 
The starting point was a chloroform-methanol-acetic acid-water (80: 9: 12: 2 by 
volume) mix that was used successfully to separate lipids containing free acids by 2D- 
TLC14. The principle of 2D-TLC is that the sample is first eluted in one direction 
and, after drying the plate is rotated through 90 degrees and eluted it in a second 
direction, thus separating the sample over a larger area (Figure 4.4). 
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Origin: 25 
mm 
Figure 4-4. A representation of 2D-TLC, in which the sample is spotted at the origin which is 
positioned 25 mm from both edges of the plate. The plate is run in an appropriate eluant in the 
direction of the first dimension. The plate is then dried and run again, in either the same or a 
different eluant. 
The eluant system that proved the most successful in giving the greatest spread of 
compounds was with the first dimension consisting of 94% chloroform, 6% methanol 
with a trace (50 µL in 500 mL) of TFA. This was complemented with the second 
dimension being eluted 65% chloroform, 26% ethyl acetate, 9% methanol and again a 
trace amount of TFA (100 pL in 768 mL). The preliminary work was carried out on 
plastic backed Macherey-NagelTM TLC plates, which were replaced by glass backed 
SIL G-25 plates. High performance TLC (HPTLC) plates have a smaller particle size 
which should give a tighter particle distribution; these were tried (Analtech HPTLC- 
HL silica gel 150 microns) but they did not give a significant improvement in 
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resolution. The plates of choice proved to be Merck glass backed silica gel 60 20 cm 
x 20 cm. 
Figure 4.5 shows the main problem in developing the TLC system, namely, a 
secondary line that appeared after the solvent front had moved up the plate. Figure 
4.6 shows the consequence of the presence of this line. This was thought initially to 
be due to one or more of the following phenomena: (a) a problem with the polyvinyl 
alcohol binder of the silica, (b) a result of solvents de-mixing in the vapour state or (c) 
changes in the hydration state of the silica. The latter was later proved to be 
inconsequential as added trace amounts of water to the eluting system still resulted in 
the formation of the line. The exact nature of the binder on the Merck plates is a trade 
secret and no information could be obtained from the manufacturer. However, it was 
found that this problem could be minimised by adopting the following procedure. The 
plates were first run in the first dimension system and then left overnight in a vacuum 
dessicator. After sample application and the first dimension run, plates were removed 
from the tank and allowed to dry under vacuum for 2-3 hours before commencing 
with the second dimension. 
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Figure 4-5. A Photograph of a TLC plate that has been washed in the first dimension eluting 
system showing a line across the plate. Image taken on Kodak imager. 
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Figure 4-6. A photograph of a TLC plate that was run, after sample application, in the first 
dimension and then in the second dimension. It can be seen how the line that appears across the 
plate carries the sample along and causes a distortion of the spots. The red circle indicates the 
origin. 
Samples were applied as a 10 µL spots of 5 mg mU1. A stream of N2 was used 
between each spot to thoroughly dry the spot before the next addition, this was done 
to keep the spot as tight as possible. It was found the fluorescence was visible on the 
needle tip suggesting that some of the residue was not being applied to the plate. 
Changing to a syringe with a plastic tipped needle reduced this residue. Following 
these procedures it was possible to obtain a reproducible pattern of spots on the TLC 
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plate as shown in Figure 4.7, taken on a Kodak imager in fluorescence mode. What is 
not evident from this photograph is the clarity of the spots. However, it was possible 
to capture the image of the plate as seen under UV light in the darkroom with a digital 
camera to give the images seen in Figure 4.8, the spot pattern following the first 
dimension elution, and Figure 4.9, the plate following the second dimension elution. 
Although there is a significant area of fluorescence around the origin is was not 
possible in improve the resolution in this area without losing definition elsewhere and 
the resulting plate was a compromise of these conflicting factors. 
Figure 4-7. A photograph of the TLC following the first and second dimension eluting systems, 
which gave the best spread of spot pattern that was reproducible. 
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Figure 4-8. A photograph of the first dimension showing the spot spread, taken with a digital 
camera in the darkroom under UV light. 
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Figure 4-9. A photograph of the TLC plate following both dimension elutioos showing the spot 
spread, taken with a digital camera in the darkroom under UV light. 
By simply laying an acetate sheet over a plate and marking on the position of the 
spots, a map of the pattern was made that could be then used to compare the position 
of known compounds with those within the library mixture (Figure 4.10). The library 
contained elements within it which were recognised as being the trisubstituted 
compounds. There was also a spread of compounds between these that have 
intermediate polarities. The starting material is not evident in the library. 
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Figure 4-10. A map of the position of the spots that were produced following 2D-TLC, made by 
laying a sheet of acetate over the plate and marking outline of the highly visible spots. The 
coloured circles indicate the position of a small cluster of spots that were found when differing 
compounds were eluted in the system as that used for the library. The brown and black circles in 
the upper right hand corner indicate the position of 27 (1'-pyrenylmethyl-3,7,12 (tri(N- 
iminoxymethylenecarbonyl) lysine)-(5ß)-cholan-24-amide) and 29 (1'-pyrenylmethyl-3,7,12 
(tri(N-iminoxymethylenecarbonyl) arginine)-(5ß)-cholan-24-amide), respectively. 26 (1'- 
pyrenylmethyl-3,7,12 (tri(N-iminoxymethylenecarbonyl) glyciue)-(5p)cholan-24-amide) is 
indicated by the green circle. The blue circle marks the position of 25 (1'-pyrenylmethyl-3,7,12 
(tri(N-iminorymethylenecarbonyl) glycine benzyl ester) -(5p)cholan-24-amide) and 28 (1'- 
pyrenylmethyl-3,7,12 (tri(N-iminoxymethylenecarbonyl) phenylalanine)-(5p)-cholan-24-amide) is 
shown as a red circle. Finally the orange spot is where 16 (PyCA) starting material is situated. 
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Figure 4-11. A photograph taken with a digital camera in the dark room with UV light, it shows 
the position of the PyCA spot and the relationship between the plate and the `map' in Figure 4- 
10. 
It is surprising that the lysine and arginine derivatives run higher up the plate than the 
other compounds, as these would be expected to be the most polar compounds. 
However, it is possible that these basic products could form ion pairs, either with each 
other, or more likely, with trifluoroacetic acid and these products may be less polar. 
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4.4 Affinity chromatography. 
4.4.1 Introduction 
Affinity columns have been used for many years in the purification of proteins from 
complex mixtures. In affinity chromatography separation occurs because proteins 
interact with various matrices in different ways. These matrices are designed to 
exploit the physical and chemical interactions between the proteins of interest and the 
matrix. For example, antibodies may be coupled to a suitable column matrix and then 
packed into a column. A protein solution is then applied to the column and any 
antigenic proteins in the solution adhere to the immobilised antibodies. The adherent 
proteins are then eluted by the addition of a solution that disrupts the binding between 
protein and antibody, as shown in Figure 4.12. 
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1. A column matrix is prepared with covalently linked antibodies/ligands 
2. A mix of ligands/antibodies is applied to the column, non binding molecules are 
washed out 
3. The binding molecules are retained within the matrix, due to specific interactions. 
4. A change in the eluate cause a disruption of the binding releasing the molecules 
Figure 4-12. The basic principle of affinity chromatography. Antibodies or ligands are 
immobilised on a matrix and packed into a suitable column. A mixture of ligands or antibodies 
are applied to the column: those with specific interactions are retained within the matrix; non- 
binding residues are washed through the column. The adherent antibodies or ligands are 
released from the matrix by a change in the eluant solution which disrupts the binding between 
the two and the purified ligand or antibody is released from the column. 
4.4.2 Column matrix 
Affinity chromatography utilises an affinity support which is packed into the column, 
it consists of the antibody or ligand (usually of a known molecular configuration) 
covalently attached to a matrix of a solid insoluble substance. The matrix used is 
dependent upon the ligand and the method of ligand attachment. Ligand orientation 
needs to be considered. The end of the ligand that is used to bind it to the matrix 
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needs to be remote from the end of the molecule that is required for recognition. One 
of the main objectives of affinity chromatography is reproducibility, this can be 
affected by the separation media and differences in selectivity and capacity differ 
from one manufacturer to another and even between lot variations from the same 
manufacturer. 
Agarose, a processed seaweed extract, was considered to be the most suitable matrix 
to use, it is readily available in the aminopropyl form, which was used in the linking 
of the ligand, 4 (O6CMG), in such a way as to not hinder the binding end of the 
molecule within the column. Agarose is a polysaccharide with alternating residues of 
D-galactose and 3,6-anhydro-D-galactose which provide an uncharged hydrophilic 
matrix with an abundance of primary and secondary hydroxyl groups. Secondary and 
tertiary structures form when the single fibres are twisted into multiple fibres and 
become folded into a fabric with large accessible pores. 
Agarose has a relative narrow particle size range; resulting in a more efficient column 
by reducing the number of cracks that appear. There are also minimal `fines', these 
are smaller than average particles that can restrict the column flow. Thorough 
washing of the matrix before use can remove the majority of the fines and gentle 
handling thereafter should prevent the formation of new ones. 
The matrix is supplied as a pre-swollen thick paste that was thoroughly washed in 
buffer to remove preservatives and small fines. Three types of matrices were 
prepared, two were linked with ligands, guanosine and O6carboxylmethyl guanosine 
as discussed in 3.2, and a third control column was prepared using just agarose. 
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Following extensive washing, the agarose matrices were degassed for three hours to 
prevent the formation of channels or cracks and packed into the columns. 
4.4.3 Eluant system 
The eluant used in the column chromatography was a dilute phosphate buffered saline 
(PBS), I µM phosphate buffer, 0.27 µM KCI and 13.7 pM NaCl, to which methanol 
was added to give a range of concentration from 0% to 90% methanol. High purity 
water and HPLC grade methanol were used. Increasing the methanol concentration 
changes the polarity of the solvent and increasingly disrupts the binding between any 
compounds which have shown binding to the column matrix. The column were 
eluted with increasing amounts of methanol in PBS and one cycle was 15 mL of each 
concentration starting with 0% and increasing to 90% in 10% increments. 
4.4.4. Column capacity 
Column capacity, that is, how much target was selectively bound per unit volume of 
support material, gives an indication of the amount of library that can be added to the 
column without it being overloaded and allows selection to occur. The column 
capacity also influences the efficiency of the column, for example if a column has a 
high capacity but takes a long time to go through one cycle, it is not efficient. For 
O6CMG linked agarose the column capacity was determined by hydrolysing the 
adducted guanine base from the column matrix and comparing the HPLC trace against 
a standard for O6CMG. A range of concentrations of standard from 0.5 to 100 pmol 
per 10 µL injection were used to give the following calibration curve. 
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Figure 4-13. A standard line to show the relationship between the peak area and concentration 
of standards of O6CMG. 
A known concentration of 50 nmol mL-' was eluted in this system and the peak area 
corresponded to 54 nmol mL-' in the standard. The samples from the hydrolysed 
matrix were then run and repeated runs showed that the affinity matrix contained 30.1 
+/-0.2 nmol O6CMG per mL of gel. 
4.4.5 Antibody interaction with the column matrices 
A sample of 06-CMdG antiserum from previous work43 was found to have an 
absorbance at 280 nm of 0.9 per 100 µL. 250 µL of this stock were put onto two 
columns, one had a plain agarose matrix and the other contained the O6CMG-agarose 
matrix. These were then both eluted with PBS and increasing methanol 
concentrations, starting at 10% and going up to 90%. Three UV readings of each 
sample was taken and the average given in the following results. 
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Fraction 
Number 
Methanol % Agarose column 06C MG column 
1 0 0.0190 0.0792 
2 0 0.2824 0.1935 
3 0 0.3037 0.0566 
4 0 0.3492 0.0567 
5 0 0.2628 0.1398 
6 0 0.2322 0.1352 
7 10 0.3959 0.1049 
8 10 0.1078 0.0514 
9 20 0.1433 0.0910 
10 20 0.0742 0.2484 
11 30 0.1599 0.0238 
12 30 0.1117 0.0881 
13 40 0.0549 0.0813 
14 40 0.1369 0.2761 
15 50 0.0850 0.0746 
16 50 0.0309 0.0420 
17 60 0.0939 0.1109 
18 60 0.0022 0.1148 
19 70 0.0403 0.2310 
20 70 0.0340 0.0995 
21 80 0.0562 0.0837 
22 80 0.0473 0.1109 
23 90 0.0394 0.0595 
24 90 0.0559 0.0568 
Table 4-1. A table of results showing the UV absorbance at 280 nm over the 24 different fraction 
numbers and the corresponding methanol concentrations. Results for both the agarose only 
matrix and the O6CMG-agarose matrix are shown. 
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Figure 4-14. A graph to show the amount of absorbance at 280 nm, indicative of the amount of 
antibody being eluted from both types of column. 
In the agarose only column the majority of the antibody washed out of the column in 
PBS, although some was washed out in the fraction containing 30% methanol and an 
even smaller amount at 50%. This suggests that some of the antibodies could be 
retained by another method for example size. The O6CMG column excluded small 
amount of the antibody early in the elution cycle although the majority was retained 
until higher methanol concentrations were reached. These antibodies were eluted 
later in three peaks around 20,40 and 70 %. The antiserum used was a polyclonal 
mix in which different antibodies have been selected due to their ability to bind to the 
DNA adduct, however they are not identical and as so will have differing properties, it 
is possible that the three peaks represent three differing antibodies within the mix. 
This result compares with previously published results in which the antibody was 
covalently linked to the column matrix and a mixture of DNA bases, including 
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Obcarboxymethylated guanine, was passed down the column. Results showed that 
there was disruption of binding at 70 and 80% aqueous methanol 115 
4.5 Fluorescence detection. 
4.5.1. The Fluorimeter 
Generally a fluorescence emission spectrum appears to be a mirror image of the 
absorption spectrum. A fluorimeter contains a light source, excitation and emission 
monochromators, and a detector (Figure 4.15). Light is passed from the light source 
through the excitation monochromator, this selectively passes a narrow band of the 
spectrum, focused around the excitation wavelength, to the sample. Light given off 
by the sample then passes through to the emission monochromator which again 
selects a narrow band of the spectrum, this then passes to the detector. 
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Figure 4-15. A diagram of the basic principles of the inside of a fluorimeter, containing a light 
source, monochromators and a detector, also indicates the position of the sample cuvette. 
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4.5.2 Quenching 
Fluorescence quenching refers to any process which decreases the fluorescence 
intensity of a given substance including excited state reactions, energy transfer, 
complex formation and collisional quenching. One of the best known collisional 
quenchers is molecular oxygen which quenches almost all known fluorophores. 
There is much debate of how this phenomena actually occurs but it is known that 
contact between the oxygen molecule and the fluorophore is required for 
quenching. 145 
The effect of increasing concentration of methanol on the fluorescence emission of 
the pyrene tag in the library was examined (Figure 4.16). Significant quenching of 
fluorescence was seen at methanol concentration >50%. 
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Figure 4-16. A graph showing the effect that increasing methanol concentration as a percentage 
has on the fluorescence intensity of the library. 
4.5.3 Excitation and emission 
In order to determine which wavelengths to monitor the following scans were 
conducted on different concentrations of the library, taking 3 mL of each sample, the 
scans were conducted at excitation of 342 nm and the emission spectra recorded 
between 350 and 450 nm. 
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Figure 4-17. The emission spectra of three samples of the library. Each sample was 3 ml, and the 
pink line represents 5 nmol m; ', the yellow line represents 10 nmol mL-' and the blue line 15 
nmol m; '. 
It was decided to record with an excitation wavelength of 342 nm and an emission 
wavelength of 395 nm. 
4.5.4 Background fluorescence 
Before use all the columns were copiously washed with PBS to remove storage 
solution and then each underwent one cycle of the eluant system, the effects of this on 
the intensity of the fluorescence were recorded below. 
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Figure 4-18. A graph showing the fluorescence intensity of the columns as they undergo a cycle 
of increasing methanol concentrations. Blue represents an agarose only column, red represents 
an agarose-guanosine column and green represents an agarose-O6CMG column. 
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Therefore any reading below 400,000 was regarded as background fluorescence. 
4.5.5 Columns 
A standard solution of the library was made 1.2 mg in 50 mL PBS which equals 0.02 
nmol µL-1 and 150 µL of this library standard was added to each column containing 
an unmodified agarose matrix. These columns then underwent one cycle of the eluant 
system 
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Figure 4-19. Elution of fluorescence from unmodified agarose after the addition of 150 µL of 
library solution following one cycle of eluants. Four separate runs, on three different columns 
with one duplicate. 
The above was repeated on a set of columns that were made with an agarose matrix 
that had been conjugated with guanosine. 
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Figure 4-20. Elution of fluorescence from guanosine-agarose after the addition of 150 µL of 
library solution following one cycle of eluants. Four runs were recorded, on three different 
columns with one duplicate. 
When above was carried out on the columns that contain the O6CMG containing 
agarose it could be seen that some of the compounds in the library were retained 
within the matrix. In Figure 4.21 it can be seen that there were three discrete peaks 
that were eluted after 40% methanol concentration had been introduced on to the 
column. As these peaks do not appear in either the agarose only or in the agarose- 
guanosine columns, the O6CMG-agarose column must have inherent properties that 
encourage the binding of some of the compounds within the library which are then 
eluted as the methanol increases which changes the polarity of the eluting solution 
and disrupts the intermolecular forces that retain the compound in the matrix. 
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Figure 4-21. Elution of fluorescence from three different columns with the O6CMG-agarose 
matrix following the application of 150 µL of library solution and elution with increasing 
methanol concentration. 
As compounds within the library could be showing affinity to the carboxylate ion on 
the ligand and exhibiting no other selection processes, it was decided to add 1 mM 
sodium acetate to the eluant which would effectively remove any compounds that are 
interacting solely on an ionic basis. The results are shown in Figure 4.22. 
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Figure 4-22. A graph showing the results of three separate O6CMG columns in which 150 µL of 
the library solution was added to each column and then they were eluted with an increasing 
methanol gradient. The fluorescence intensity of aliquots of the eluant were recorded. The pale 
blue line represents an average of the three. 
In the presence of sodium acetate the peaks eluted from the column had the same 
profile, with the three discrete peaks being evident. However they appear to be 
eluted at a lower concentration of methanol with the earliest peak coming off the 
column at 30-35% methanol compared to 40-45% in the columns that were run 
without sodium acetate. Therefore, it can be concluded that the presence of sodium 
acetate does not appear to affect the binding of compounds in the library to the matrix 
but it appears to have an influence in the release of these compounds from the matrix. 
In the previous column experiments 150 µL of a dilute solution of the library was 
added to each column, giving a fluorescence count of approximately 3,000,000. A 
solution of 29 (1'-pyrenylmethyl-3,7,12 (tri(N-iminoxymethylenecarbonyl)arginine)- 
(5ß)-cholan-24-amide) in PBS corresponding to 2,800,000 fluorescence units was 
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added to the three different columns, results are shown in Figure 4.23. Similarly, a 
solution of 26 (1'-pyrenylmethyl-3,7,12 (tri(N-iminoxymethylenecarbonyl)glycine)- 
(5ß)-cholan-24-amide) in PBS corresponding to 4,500,000 was also put onto the three 
different types of column, as shown in Figure 4.24. 
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Figure 4-23. A graph to show the fluorescence intensity of 29 (1'-pyrenylmethyl-3,7,12 (tri(N- 
iminoxymethylenecarbonyl)arginine)-(5p)cholan-24-amide) as it is eluted from the three 
different columns. 
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Figure 4-24. A graph to show the fluorescence of 26 (1'-pyreoylmethyl-3,7,12 (tri(N- 
iminozymethylenecarbonyl)glycine)-(50)-cholan-24-amide) as it is eluted from the three different 
types of column. 
These preliminary results were obtained from experiments carried out only once. 
However, it appears that 26 (1'-pyrenylmethyl-3,7,12 (tri(N- 
iminoxymethylenecarbonyl) glycine)-(5ß)-cholan-24-amide) was not retained on any 
of the column types. 29 (1'-Pyrenylmethyl-3,7,12 (tri(N- 
iminoxymethylenecarbonyl)arginine)-(5(3)-cholan-24-amide) did not bind to the 
agarose and the agarose-guanosine columns. Interestingly, there were two distinct 
peaks for the O6CMG-agarose column with the arginine derivative of PyCA, eluted at 
60 and 75% methanol concentrations. These results are further evidence for the 
importance of arginine moieties in the recognition of O6CMdG. 
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5.1 Discussion and Future Perspectives 
In the development of cancer in the oesophagus and the stomach alkylation of the 
DNA plays a significant role. A known mutagenic lesion is the alkylation of the 06 
position of 2'deoxyguanosine, and particular importance is given to the 
carboxymethyl adduct (O6CMdG) as this appears to be resistant to the usual 
biological repair pathways. While this particular DNA adduct can be effectively 
recognised by antibodies there are a finite amount available for use. It would 
therefore be advantageous if a novel affinity reagent could be synthesised so that an 
unlimited amount would be available from the chemical laboratory. 
As antibodies are large complex macromolecules with the site of binding being a 
consequence of the whole structure it was thought that it would be possible to identify 
amino acids contributing strongly to molecule recognition and to synthesis a library of 
compounds based on these. The phage display technique was used to this end. It was 
initially thought that the phage display would give a clearer indication of the exact 
amino acids present. From the sequences identified in phages that bound to 
immobilised 06-CMdG there was evidence that a binding pocket required 
contribution from positively charged amino acids and the presence of aromatic side 
chains 
Based on previously published work from a number of groups cholic acid was used as 
a scaffold molecule to host not only the diversity required by a library but also a 
highly fluorescent pyrene molecule to be used to detect binding. The pyrene was 
attached through an amide linkage that was not affected by subsequent reactions. 
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Diversity around the scaffold was via the reaction of acetyl amino acid derivatives 
with keto groups at the 3,7 and 12 positions. The synthesis of the amino acid 
derivatives was no means trivial and much time was spent trying to improve the 
methods and yields. However the use of the oxime chemistry binding to the scaffold 
was a straightforward procedure. By refluxing in ethanol overnight all three keto 
functional groups reacted, in a simple and reproducible reaction, in the presence of 
sodium acetate as a base. Having made a library mass spectrometry confirmed that 
the library did indeed contain the expected molecular ions and fragments. HPLC and 
then 2D-TLC methods were used to establish that a range of compounds with varying 
properties were present in the library. 
An affinity column was made in which the adducted DNA was immobilised on to the 
column matix, the preparation of this matrix was carefully considered so that the 
resulting exposed moiety had a similar structure to O6CMdG. These columns were 
tested against a previously prepared antibody and it was shown that the matrix 
coupled with O6carboxymethylguanosine did in fact retain the antibody added to the 
column and that these antibodies would elute at increasing levels of methanol. 
Affinity columns have been used previously15 in which the antibody was 
immobilised within the matrix, hydrolysed DNA passed down the column and a 
similar range of methanol percentage was used to elute off the adducted DNA. This 
result confirmed that the columns had O6carboxymethyldeoxyguanosine-like residue 
capable of retaining known binding antibodies. 
These columns were then used to probe the library of compounds that had been 
synthesised. Results showed that there are compounds within the library which bound 
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strongly to the O6carboxymethylguanosine-agarose matrix and not to the control 
agarose or guanosine-agarose columns. As the methanol concentrations increased 
three distinct peaks were detected by fluorescence and these were not due solely to the 
presence of a negative charge on the O6carboxymethylguanosine-agarose matrix as 
the result was repeatable in the presence of sodium acetate. Finally the columns were 
tested with trisubstituted compounds, the trisubstiuted glycine derivative passed 
through both controls columns and the O6carboxymethylguanosine-agarose column. 
However the trisubstituted arginine derivative was strongly retained on the 
O6carboxymethyl guanosine-agarose matrix. These preliminary results show that the 
arginine derived compound shows high affinity for the negatively charged 
carboxymethyl residue of O6CMdG. 
Ideally a single fraction from the O6carboxymethylguanosine-agarose column would 
be collected and the compounds within the peak could have been identified and from 
this individual compounds synthesised and tested for their affinity for 06 
carboxymethyl-2'-deoxyguanosine. Such an approach could involve repeating the 
O6carboxymethylguanosine-agarose column experiment but modifying the elution 
method by washing nonbinding and weakly bound compounds with copious amounts 
of 60% methanol before increasing the methanol concentration to limit the number of 
different compounds coming off the column. However it maybe more useful to do 
this on a larger column, say 5 mL, and have the option of loading more of the library 
on to the column and hopeful have enough material for mass spectrometric 
identification. This would give information on the groups present on the scaffold but 
not the position. 
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For the position of each of the three group could determined by selectively 
synthesising each of the three keto groups. It has been shown that a single position, 
possibly C3, reacts first under mild condition. The other two sites, possibly C7 and 
C12, are not as easily controlled. However this can overcome by using either 5ß- 
cholanic acid 3,7 dione, 12 hydroxy or 50-cholanic acid 3,12 dione, 7 hydroxy 
starting materials available from Steraloid Inc. and manipulating the synthesis 
accordingly. 
Finally, consideration needs to be given to the orientation of the groups with regard to 
the oxime bond, as each of these could be in either the E or Z form. The predominant 
isomer will be selected from the library by affinity for the ligand, however for future 
synthesis the correct isomer will need to characterised. There are many references to 
how X-ray crystallography has given detailed information about the structure of 
cholic acid derivatives, e. g. the configuration at C25 in 3a, 7a, 12a-trihydroxy-5ß- 
cholestan-26-oic acid was unequivocally confirmed following TLC purification, the 
growth of crystals and X-ray crystallography176. If the reagent could be induced to 
co-crystallise with the ligand moiety, again X-ray crystallography could be used to 
determine the precise structural arrangement"'. If enough of the correct compound 
can be isolated the spatial arrangement of the H and C atoms adjacent to the oxime 
could be explored by NMR. Another consideration could be to reduce to oxime to an 
amine and explore if this has any affect on the binding properties, either positively or 
negatively. 
The main objective of this project was to identify a novel affinity reagent for 
O6CMdG and although this was not accomplished much has been achieved with 
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regards to developing a novel approach. The methods laid down by this project have 
the potential to be used for other DNA adducts. If a large cholic acid based diversity 
library can be synthesised which is optimal for recognition of alkylated DNA bases, 
the affinity approaches for isolation of candidate reagents can be applied to many 
other modified DNA bases. 
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6.1 General and Instrumentation 
6.1.1 Physical Measurements 
Infra-red spectra were recorded as thin films in nujol mulls or as potassium bromide 
discs using a Perkin-Elmer 1710 infrared fourier transform spectrometer. Ultra 
violet/visible spectra were run in solvents stated on a Uvikon XL spectrophotometer 
(BioTek Instruments). Nuclear magnetic resonance spectra, in the solvents indicated, 
were recorded at 300 MHz on a Jeol JNM-Lambda 300 spectrometer, with an internal 
standard of tetramethylsilane. Elemental analyses were supplied by Medac Ltd. at 
Brunel Science Centre, Surrey. Mass spectra were obtained by Mr Graham Jeffs 
using a VG Quattro instrument in both positive and negative electrospray (ES) mode. 
All melting points were measured on a Electrothermal digital melting point apparatus. 
Thin layer chromatography was carried out on Machery-Nagel Polygram SIL 
G/UV254 plates on a plastic backing, Fluka silica gel aluminium backed plates or 
Machery-Nagel pre-coated glass backed TLC plate SIL G25, as indicated. 
6.1.2 Reagents and Reactants 
Chemicals were used as supplied unless otherwise stated and were obtained as 
follows. Guanosine, mesitylenesulphonyl chloride, 1,8-diazabicyclo [5.4.0]-undec-7- 
ene (DBU), and hydroxylamine hydrochloride from Acros. Isobutyric anhydride and 
methyl glycolate were supplied by Fluka. Dimethylaminopyridine (DMAP), 
triethylamine, quinuclidine, amino propyl glass beads, lithium aluminium hydride, 
pyridinium dichromate, N-hydroxysuccinimide, pyrenylmethylamine hydrochloride, 
methylhydroxylamine hydrochloride, carboxymethylhydroxylamine hydrochloride 
benzylhydroxylamine hydrochloride 0-carboxymethyl hydroxylamine hemi 
hydrochloride, NN-dicylohexylcarbodiimide, glycine benzyl ester, glycine methyl 
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ester, phenylalanine methyl ester, piperidine and sodium cyanoborohydride were 
purchased from Aldrich. Tetrahydrofuran, anhydrous sodium sulphate, sodium 
carbonate, di-tert-butyl dicarbonate, sodium acetate trihydrate and triethylamine were 
supplied by Fisher. Sigma supplied cholic acid and 50-cholanic acid-3,7,12, trione 
(dehydrocholic acid) was purchased from Steraloid Inc, Newport, USA. The more 
unusual amino acids N"-Nitro-arginine methyl ester hydrochloride and N-£-Fmoc- 
lysine methyl ester hydrochloride were supplied by NovaBioChemTM 
6.2 Synthesis of DNA Adduct and conjugation to carrier 
matrices 
6.2.1 2', 3', 5'-tri-O-isobutyryl guanosine (2) 
Guanosine (5g, 18.25mmol) was dried, twice, by the evaporation of toluene. This was 
then suspended in dry tetrahydrofuran (50ml), to which isobutyric anhydride (9.7 mL, 
58.2mmol) and DMAP (100mg, 0.8mmol) was added, the resultant mixture was 
stirred, at room temperature, overnight. Sodium bicarbonate was dissolved in distilled 
water and added to the reaction mixture, the mixture was maintained above pH 7.5 by 
the continuous addition of sodium bicarbonate. The mixture was stirred for two hours 
and then filtered, washed three times with distilled water and then dried under 
vacuum. The product was recrystallized by suspending in dichloromethane and 
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adding enough methanol to dissolve the compound, this was gently heated and 
agitated. The solution was then placed in the freezer with a few drops of hexane. 
After the product had crystallised, the solvent was removed by pipette and the crystals 
blown dry with nitrogen gas. 
Yield 8.5g (74%); mp 232-234 °C; ? max 248 nm; MS m/z (ES+) 494 (M + 1) ioo, 343 
(M - guanine + 1) 40; MSMS m/z (ES+) 494 (M +1) 31,343 (M -guanine + 1) ioo, 167 
(M -guanine - COCH(CH3)2 +1) 85,97 (M -guanine - (CH2O00CH(CH3))2 - 
COCH(CH3)2 +1) 68,70 (COHC(CH3)2 ) 68, 'H NMR 6 1.3 (m, 18H, (CH(CH3)2), 2.5 
(m, 3H, (CH(CH3)2), 4.45 (m, 1 H, 1'-H), 5.60 (m, 1 H, 3'-H), 5.95 (t, 1 H, 2'-H), 6.05 
(d, 1 H, 3J 5.1,1'-H), 7.75 (s, 1 H, NCH). 
6.2.2 Os-[(2,4,6-trimethylphenyl)sulphonyl]-2', 3', 5'-tri-O- 
isobutyrylguanosine 
2 (1.0 g, 2.4 mmol) was suspended in dry dichloromethane, to this 
mesitylenesulphonyl chloride (1.05 g, 4.8 mmol) and DMAP (40 mg, 0.32 mmol) was 
added. This was followed by the dropwise addition of triethylamine (1 mL, 7 mmol), 
the resulting solution was left stirring at room temperature. The reaction followed by 
TLC (2% methanol in dichloromethane) and after l hour was used in the subsequent 
reaction without purification. 
-143- 
Lnapter b 
6.2.3 06-(carboxymethyl, methyl ester)-2', 3', 5'-tri-O- 
isobutyrylguanosine 
1-ý o- 
To the reaction vessel above quinuclidine (I g, l Ommol) was added and after a further 
1'/2 hours there was full conversion to a baseline blue fluorescent spot (presumably the 
quinuclidinium salt). Methyl glycolate (I ml, l4mmol) and DBU (I ml, 6mmol) was 
added to the reaction mixture and the reaction was left stirring overnight, at room 
temperature. The resulting mixture was rotary evaporated for 3 hours, then dissolved 
in 10ml of dichloromethane and separated using flash chromatography with methanol 
and dichloromethane (98: 2 v/v). An automated 5ml fraction collection was set up and 
each fraction was run through a normal phase LC (Varian 5060 ternary gradient LC 
system). Varian 5060 Diode array detector was used with a 25cm x 4.6 mm id 
Phenomenex LUNA C18 (2) + 3cm matching guard column at 30 °C, with a 50µl 
sample loop. The product containing fractions were pooled and rotary evaporated to 
dryness to give a pale yellow solid, which was then recrystallised from MeOH and 
hexane. 
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Yield 1.05g (93%); mp 120-122 °C; ? max 248,284 nm; 
IH NMR 6 1.1 (m, 18H, 
(CH(CH3)2), 2.5 (m, 3H, (CH(CH3)2), 3.67 (s, 3H, OCH3), 4.11 (s, 2H, 
OCH2000H3), 4.45 (m, IH 1'-H), 5.69 (m, 1 H, 3'-H), 5.85 (t, I H, 2'-H), 5.96 (d, 
I H, 3J 5.1,1'-H), 7.74 (s, I H, NCH). 
6.2.4 06-(carboxymethyl)guanosine (4) 
H2N 
N00 
N\ýN OH 
HO 
HO OH 
06-(Carboxymethyl, methyl ester)-2', 3', 5'-tri-O-isobutyryl guanosine (l g, I. 78mmol) 
was dissolved in methanol and sodium hydroxide (0.02M) added until the reaction 
went to completion. HCl (0.02M) was added dropwise until the mixture was pH7 and 
the methanol removed by rotary evaporation. Preparative LC was used for separation 
the major peak of each injection was collected and pooled. Excess water was 
removed by cold finger and the product was freeze dried, to give a white solid. 
Yield 243 mg, 33%; 236 °C (lit. >250 °C43) ? max 248,282 nm; v, ax (KBr) 3300 (0-H, 
N-H str), 2880 (C-H str) 1650 (C=N str), 1620 (C=O str), 1580 (C=C str), 1250 (C-O 
str), 1065 cm-' (C-O str); MS m/z (ES+) 342 (M+1) ioo; 1H NMR 3.7 (m, 2H, 5'- 
CHZ), 4.1 (m, 1 H, 1'-H), 4.3 (m, 1 H, 3'-H), 4.7 (m, 1 H, 2'-H), 4.80 (s, 2H, 
OCHzCOOH), 6.85 (d, 1 H, 3J 6.3,1'-H), 7.95 (s, 1H NCH). 
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6.2.5 06-carboxymethylguanosine and Ovalbumin conjugate 
06-CMG (10.6 mg, 0.03 mmol) was dissolved in water (0.5 mL), to which Na104 
(21.6 mg, I mmol) was added, this was stirred at room temperature for 15 minutes. 
The reaction was stopped by the addition of 5 µl of ethylene glycol. Ovalbumin (OV) 
(10 mg) was dissolved in I mL of water and the pH adjusted to 9.5 (Na2CO3,0.02M), 
the reaction mixture was left at room temperature for 4 minutes. A fresh solution of 
NaBH3CN (30 mg in l mL of water) was prepared and 0.5 mL of this solution was 
added to the reaction mixture, along with I drop of octanol, to prevent foaming. The 
mixture was then left at 4 °C for 3 hours. The resulting mixture was dialyzed 
overnight in dialyzing tubing against phosphate buffer saline, also at 4 °C. The 
mixture was then eluted through a Sephadex G-50 column, using water, and the first 
UV-absorbing fractions were collected, pooled and concentrated by freeze drying. 
6.2.6 Determination of the adduct to protein ratio 
I mg of ovalbumin was dissolved in 1 mL phosphate buffer and the UV at 280 nm 
was recorded, to this was added a molar equivalent of 06-CMG and the UV recorded. 
This was repeated with concentrations that gave the ratios of adduct to protein of 0: 1 
to 10: 1. The resulting standard curve was used to determine the adduct to protein 
ratio of the product. 
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6.2.7 06-carboxymethylguanosine and glass bead conjugate 
0 6-CMG (10 mg, 0.028mmol) was dissolved in water as above and the same protocol 
followed except that the OV was replaced with aminopropyl glass beads (22 mg). 
After dialyzing against phosphate buffer saline, the beads were washed with water 
and stored in storage solution at 4 °C. It was not possible to measure the level of 
modification directly: the UV profile was the same for O6CMG but this was not 
quantifiable due to refraction from the glass beads. 
6.2.8 06-carboxymethylguanosine and agarose conjugate 
The supplied agarose suspension (6 mL) was transferred to a Falcon tube and allowed 
to settle, most of the solution was poured off, leaving a little on top. Coupling buffer 
(10 ml-) was added and mixed gently to prevent the formation of fines. This was 
repeated twice more and as much buffer as possible was decanted without drying out 
the agarose, which was suspended in coupling buffer (5 mL). A 06-CMG solution 
was prepared by dissolving 06_C MG (1 I mg, 0.031 mmol) in ice cold water (2 mL) 
and to this was added sodium periodate (10 mg, 0.46 mmol). The mixture was 
allowed to stir in an ice bath for 30 minutes. Following this 0.1 volume ethylene 
glycol (200 µL) was used to remove excess sodium periodate. The resulting mixture 
was used immediately to couple with the aminopropyl agarose. 
The agarose gel was suspended in coupling buffer (10 mL) and added to the 
periodate-oxidised 06-CMGuo solution. This was then allowed to stir at room 
temperature for 6 hours. Sodium cyanoborohydride (50 mg, 0.80 mmol) was 
dissolved in 2 mL of the coupling buffer, added to the mixture and left to stir for 30 
minutes. The 06-CMG-agarose was then extensively washed with coupling buffer and 
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water, and stored in 10mM Tris-CI buffer, pH 7.2 containing 0.15M NaCl and 0.02% 
sodium azide, at 4 °C. 
6.2.9 Guanosine and agarose conjugate 
The above procedure was repeated with guanosine (10 mg, 0.18 mmol) to give an 
agarose gel to which guanosine has been linked. 
6.3 Phage Display Experimental 
6.3.1 Equipment and reagents 
The incubation of bacteria was carried out in Jencons-PLS Orbital Incubator 5150, all 
UV data was collected on UV Spectronic Genesys 5, the PCR work was done on 
Techne Genofuge 16M and the DNA was sequenced in a DNA analyser (4200 LI- 
COR gene reader). 
The Ph. D. -I2T"' Phage Display Peptide Library Kit from New England Biolabs was 
used and the supplied E. coli host strain ER2738 was well suited for M13 
propagation. It is a male-specific coli phage and infectivity occurs via the f-pilus that 
ER2738 produces to allow recombination of DNA, as such it is advised that the 
inoculation occurs to colonies that have been grown on a tetracycline containing 
medium. ER2738 that contain the F factor are tetracycline resistant. Therefore the 
supplied host was streaked out on Luria-Bertani (LB) -tetracycline (tet) plates and 
incubated, resulting in the growth of ER2738 that contain the F factor that are then 
susceptible to M 13 infection. The procedure was carried out using standard LB 
media, tris buffered saline Tween -20 (TBST) and an eluting solution for non-specific 
disruption as described in `media and solutions' (Section 6.3.9). 
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6.3.2 Phage titer of library 
A phage titer was carried out to determine the number of plaque forming units that 
exist within the library. A series of dilution of the original library were prepared as 
shown in Table 2.1,10 µI of each dilution of these were added to 200 tI of bacterial 
culture at the mid log phase (OD600 0.5). Each was then added to 3 mL of agarose top 
at 47 °C and poured over prepared IPTG/Xgal plates (100 mL LB/agar containing 4 
mg Xgal and 4.5 nag IPTG dissolved in 100 µL DMF is sufficient for 6 plates), 
warmed to 37 °C. These plates were incubated overnight. By multiplying the number 
of plaques by the dilution factor the number of plaque forming units (pfu) can be 
determined. The pfu per I µL of the library is approximately 2.5x108, this compares 
to the suggested pfu of 4x 109 from the company literature. 
6.3.3 Panning and titer 
A solution of the target molecule linked to ovalbumin, 100 µl mL-l of the target in 0.1 
M NaHCO3, pH 8.6, was prepared and 1.5 ml was repeatedly swirled on to a sterile 
polystyrene Petri dish. This was incubated overnight at 4 °C with gentle agitation in a 
humidified container (a sealable plastic box lined with damp paper towels), to allow 
maximum adsorption of the molecule on to the plate. 
The coating solution was poured off the plate and it was firmly slapped down onto a 
clean paper towel to remove residual solution. The plate was filled with blocking 
buffer and left at 4 °C for 1 hour. After the hour the plate was rapidly washed six 
times with TBST. 10 µl of the original library, containing approximately 2.5x 109 
phage, was diluted in I ml of TBST, and this was pipetted onto the coated plate, and 
rocked gently at room temperature for one hour. The non-binding phage was 
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discarded by pouring off and the plate was washed ten times with TBST. The eluting 
solution for non-specific disruption of the binding interactions was used to release 
binding phage from the target molecule. These were collected and I µL was titered as 
shown in table 2.1. The titer showed that an average of 635 pfu pUl was selected, 
corresponding to a total of 730 250 phage, thus 0.029 % of the available phage were 
selected in the first panning. 
6.3.4 Amplification 
The remaining phage were amplified by the addition of the eluate to 20 ml of ER2738 
culture at the early log phase and incubated at 37 °C for 7.5 hours. After this time the 
culture was spun for 15 mins at 10,000 rpm at 4°C, twice. The upper 80 % of the 
supernatant was transferred to a fresh tube and 1 /6 volume of PEG/NaCI added and 
the phage was allowed to precipitate overnight. This was centrifuged at 10 000 rpm (4 
°C) for 10 mins and the supernatant removed, the residual supernatant was removed 
after a second brief spin. The pellet was suspended in l mL of TBS and the 
suspension spun as before for 5 mins to pellets any residual cells. The supernatant 
was transferred to a fresh microcentrifuge tube and re-precipitated with 1/6 volume of 
PEG/NaCI, on ice for 1 hour. This was spun as before for 10 minutes and the 
supernatant discarded, the pellet was suspended in 200 pL TBS with 0.02% Na N3, 
this is the amplified eluate which was titered. The resulting titer gave an average of 
1.96x1010pfu µL-1 which equates to a total phage population of3.91x10'3 
6.3.5 Subsequent pannings 
The second panning round was carried out in the same manner as the first, but the 
molecule attached to the Petri dish was ovalbumin on its own, the phage that did not 
bind were collected and titered as well as the binding phage. This would allow phage 
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that showed affinity to the binding protein to be removed from the population. 
Taking 10 µL of the amplified phage from the first, representing 1.96x 1011 phage 
were exposed to the plate. The titer showed that 1.81 x 101 1 phage (92.6%) had bound 
to the protein and 1.46x1010 phage (7.4%) were unbound and showed little affinity for 
the protein. Amplification, as before, resulted in 2.1 x101 phage which were used in 
the final panning. 
The final panning round was carried out by linking the ligand to glass beads and 
exposing the phage population selected so far to these in solution, all other criteria 
were the same. 9.8x1010phage were exposed to the beads and 1.05x10'0 were 
collected after being released. 
6.3.6 DNA purification 
After the final panning approximately 0.00004% of the original library survived, 
corresponding to about 1000 different phage. Ten different blue plaques were 
characterized; this was done by diluting an ER2738 overnight culture to 1: 100 LB, I 
mL was dispensed into culture tubes and a blue plaque added to each. These were 
incubated with vigorous shaking for five hours. After centrifugation for 30 seconds at 
4 °C the supernatant was removed and re-spun, the upper 80% was transferred to a 
fresh tube. 500 µL of this was taken and 200 µL PEG/NaCI was added. After being 
left to stand at room temperature for 10 minutes the solution was spun for 12 minutes 
at 4 °C and 12 000 rpm. The supernatant was discarded and the remaining pellet 
suspended in 100 pL iodine buffer and 250 µL ethanol. A short incubation of 10 
minutes preferentially precipitates the single-stranded phage DNA leaving most of the 
phage protein in solution. Further centrifugation as before left a DNA pellet, this was 
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washed twice with 70% ethanol and dried. The remaining pellet was finally 
resuspended in 30 gL TE buffer and the DNA concentration measured via absorbance 
at OD260. 
6.3.7 PCR amplification 
From these concentrations it was determined that the maximum amount of DNA 
template was required for the PCR reaction. A suitable primer was obtained from 
MWG Oligo Synthesis with a 50% GC content and a -96 primer end labelled with the 
fluorescent dye IRD 800. A SequiTherm EXCEL TM 11 DNA Sequencing Kit-LC was 
obtained from Epicentre® and a premix was made containing 1µL IR-labelled 
primer, 7.5 µL DNA template, 7.2 pL sequencing buffer and I µL DNA polymerase. 
For each template four microfuge tubes were labelled A, C, G and T and to each the 
corresponding SequiTherm EXCELTM II-LC termination mix (2 µL) was added along 
with 4 pL of the premix. These were then placed in the thermal cycler and allowed to 
undergo the following steps: - 
Step 1 95 °C for 5 minutes 
Step 2 95 °C for 10 seconds 
Step 3 55 °C for 15 seconds 
Step 4 70 °C for 30 seconds 
Steps 2-4 were repeated for a total of 30 cycles. 
6.3.8 DNA sequencing 
The gel was prepared as follows, urea (28 g) was dissolved in water (28 mL), tris 
borate ethylenediaminetetraacetic acid (TBE) (5 mL), formamide (4 mL) and 
acrylamide (7.5 mL) were added and the mixture allowed to stir. When ready to pour 
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the gel, ammonium persulphate (APS) (350 µL) and tetramethylethylenediamine 
(TEMED) (75 µL) was swirled into the solution. The gel was then poured and 
allowed to set. The plates were then pre heated to 37 °C, the samples added and 
allowed to run overnight. 
6.3.9 Media and solutions used with phage display 
LB Medium /litre: 10 g Bacto-Tryptone, 5g Yeast and 5g NaCl, autoclave and store 
at room temperature. 
LB plates: add agar to LB medium (15 mL per L) autoclave and pour. Store plates at 
4 °C in the dark. 
Isopropyl-ß-D-thiogalatoside (IPTG) 5-bromo-4-chloro-3-indolyl-3D-gaalactoside 
(Xga] Mix: 1.25 g IPTG and Ig Xgal dissolved in dimethyl formamide (25 mL). 
Store at -20 °C in the dark. 
LB/IPTG/Xgal plates: 10 g Bacto-Tryptone, 5g yeast extract, 5g NaCl, 1g 
MgCI2. H20 and 7g agarose. Autoclave the solution and cool to less than 70 °C add I 
mL IPTG/Xgal and put into 50m1 aliquots. Store solid at room temperature, melt in 
microwave when needed. 
Tetracycline Stock: Tetracycline (20 mg/mL in EtOH). Store at -20 °C in the dark. 
Vortex before use. 
LB-Tet Plates: add agar to LB medium (15 mL per L) autoclave and cool to < 70 °C, 
add I ml of tetracycline stock and pour. Store plates at 4 °C in the dark and do not 
use if plates are black or brown. 
Blocking Buffer: 0.1 M NaHCO3 (pH 8.6), 5 mglmL BSA and 0.02% NaN3. Filter 
sterilize and store at 4 °C. 
-153- 
Chapter 6 
Tris-buffered saline (TBS): 50 mM Tris-HCI (ph7.5) and 150 mM NaCl. Autoclave, 
store at room temperature 
Tris-buffered saline Tween 20 (TBST) first round: TBS and 0.1% (v/v) Tween-20 
TBST subsequent rounds: TBS and 0.5% (v/v) Tween-20 
Eluting Solution: 0.2 M Glycine-HCI (pH 2.2) and I mg/mL BSA 
Polyethylene glycol (PEG)/NaCI: 20% (w/v) polyethylene glycol-8000 and 2.5M 
NaCl. Autoclave and store at room temperature. 
6.4 Synthesis of cholic acid derivatives 
6.4.1 3a, 7a, 12a-trihydroxy-(5ß)-cholan-24-oic acid methyl ester (6) 
H 
3a, 7a, 12a-trihydroxy-(5ß)-cholan-24-oic acid (20.12 g, 49.24 mmol) was dissolved 
in methanol (200 ml-) and a catalytic amount on concentrated sulphuric acid (0.5 ml-) 
was added. The mixture was refluxed for 3.5 hours, after which the methanol was 
removed under vacuum. The solid was dissolved in chloroform and repeatedly 
washed with sodium bicarbonate and water. The solution was then dried with 
magnesium sulphate and the chloroform removed by rotary evaporation. 
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Yield 20.71g (99.7%); nip 154-7 °C (lit 155-156'78); v, naX (KBr) 1750 (ester C=O), 
1350 cm-' (secondary alcohol); MS fn/z (ES+) 423 (M+1) io, 440 (M+NH4 100; 'H 
NMR 0.6 (s, 3H, C2' H3), 0.8 (s, 3H, C'H or 19H3)9 0.9 (d, 3H, C's or 19H3), 1.4 (m, 27H, 
steroid), 3.4 (m, 3H, C3H, C7H, C'2H), 3.7 (s, 3H, OCH3); 13C NMR 6 13 (C's), 17 
(C'9), 23 (C23), 24-51 (C, steroid), 70 (C3), 73 (C7), 74 (C'2), 170 (C24). 
6.4.2 3a, 7a, 12a-trihydroxy-(5ß)-cholan-24-oI (7) 
Using dry THF, suspend 6 (3a, 7a, 12a-trihydroxy-(5ß)-cholan-24-oic acid methyl 
ester) (30.67 g, 67.45 mmol) in a1L round bottom flask, add LiAIH4 (4.13 g, 109 
mmol) and reflux for 48 hours. Saturated Na2SO4 (100 mL) was introduced slowly 
and the resulting mixture filtered. The insoluble precipitate was washed with a 
mixture of hot THE and MeOH. The solvents were evaporated of the resulting white 
solid was re-dissolved in hot methanol and allowed to crystallise in the freezer. 
Yield 14.69 g (51%); mp 233-235 °C (lit. value 236.5-238 °C141); TLC 
dichloromethane and methanol (5: 1 v/v) rf = 0.65; 'H NMR 0.2 (s, 3H, C21H3), 0.4 (s, 
3H, c18 or 19H3), 0.5 (d, 3H, CI8 or 19H3), 1.1 (m, 25H, steroid), 3.0 (s, 3H, OCH3), 3.3 
(t, 2H, C24H2), 3.5 (m, 3H, C3 H, C7 H, C'2H); 13C NMR 6 12 (C'8), 17 (C19), 22 (C23), 
22-46 (C, steroid), 61 (C24), 66 (C3), 70 (C7), 71 (C'2), 170 (C24). 
-155- 
Chapter 6 
6.4.3 3,7,12 trioxo-(5ß)-cholan-24-oic acid methyl ester (10) 
6 (3a, 7a, I2(x-trihydroxy-(5ß)-cholan-24-oic acid methyl ester) (500 mg, 1.2 mmol) 
was suspended in dry CH2CI2 (18 mL) with 4A sieves, to which pyridinium 
dichromate (1.8 g, 677 mmol)was added and left stirring at room temperature. After 
20 hours the solvent was removed under vacuum and redissolved in ethyl acetate and 
hexane (1: 2) and passed through a silicon column using the same solvent mix as 
eluant. The product containing fractions were pooled and again the solvent was 
removed under vacuum to yield a white powder. 
Yield 200 mg (40%); mp 238-240 °C; v,,, ax 1720 (cyclic ketone), 1750 (ester C=O), 
1200 cm-1 (ester C-O); MS m/z (ES+) 417 (M-methyl ester) ioo; 1H NMR 0.8 (d, 3H, 
C21 H3)9 0.9 (s, 3H, c18or 19H3), 1.0 (s, 3H, c18or '9H3), 1.7 (m, 32H, steroid), 3.0 (s, 
3H, OCH3); 
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6.4.4 3,7,12 trioximo-(5ß)-cholan-24-oic acid methyl ester (12) 
OH 
10 (3,7,12 trioxo-(5p)-cholan-24-oic acid methyl ester) (110 mg, 24 mmol) was 
stirred into ethanol (10 mL) to which hydroxylamine hydrochloride (60 mg, 87 mmol) 
was added. After the addition of sodium acetate (120 mg, 146 mmol), the mixture 
stirred at room temperature for 1 hour followed by 12 hours of reflux. The solvent 
was removed and dissolved in HCl (0.1 M), NaCO4 (0.1 M) was added and the solids 
filtered and washed with water. This was then extracted thrice with chloroform and 
the solvent removed under vacuum. 
Yield 100mg (83%); mp 236 °C; v,, 3500 (oxime), 1750 (ester C=O), 1660 (oxime), 
1250 cm-' (ester C-O); MS m/z (ES+) 461 (M) ioo; 'H NMR 1.3 (s, 3H, C21H3)9 1.7 
(m, 30H, steroid), 4.0 (s, 3H, OCH3); 
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6.4.5 Succinimido-(N)-3,7,12 trioxo-(5ß)-cholan-24-oate 
o o° 
p-N 
O 
OO 
H 
To a solution of 15 (3,7,12 trioxo-(5ß)-cholan-24-oic acid acid) (6.02 g, 15 mmol) in 
dry THE (100 mL), add N-hydroxysuccinimide (1.80 g, 15.45 mmol, 1.03 eq. ). After 
5 minutes, a solution of DCC (3.2g 15.45 mmol 1.03 eq. ) in THE (20 mL) was added. 
The reaction mixture was stirred at room temperature for 28 hours. The dicyclohexyl 
urea formed was filtered and washed with ethyl acetate. The solvent was removed and 
the residue was dissolved in ethyl acetate, filtered and concentrated to dryness. The 
resulting oil was dissolved in a small amount of CHC13 and Et20 was added to induce 
crystallisation. The solid was filtered off and dried to give the product. 
Yield 5.4 g (72%); mp 236 °C; v, (nujol) 1784 (ester C=O), 1739 (ester C=O/cyclic 
ketone), 1708 (cyclic ketone), 1377 (cyclic ketone), 1206 (ester C-O), 1069 cm-I (C- 
N); MS m/z (ES+) 517 (M+NH4+) ioo; TLC dichloromethane and methanol (95: 5 v/v) 
rf = 0.36 +/- 0.05; elemental analysis, theoretical C 67.32% H 7.46% N 2.80%, found 
C 66.82% H 7.29% N 3.13%; 'H NMR 0.9 (d, 3H, C21H3), 1.9 (m, 30H, steroid), 2.8 
(m, 4H, succinimide), 4.1 (q, 1H, succinimide); 13C NMR 6 11 (C'8), 19 (C19), 22 
(C23), 24-56 (C, steroid), 168 (C24), 169 (succinimide), 208 (C3), 209 (C7), 212 (C'2). 
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6.4.6 1'-pyrenyl methyl-3a, 7a, I2a trioxo-(5ß)-cholan-24-amide (16) 
o 
0 
HN 
H 
Succinimido-(N)-3,7,12 trioxo-(5(3)-cholan-24-oate (1 g, 2 mmol) was dissolved in 25 
mL DCM, to which triethylarnine (0.2 g, 2 mmol) and pyrenylmethlyamine (0.5 g, 2 
mmol) was added and allowed to stir at room temperature overnight. The reaction 
mixture was filtered and washed with HCI (0.1 M), then NaOH (0.1 M) and twice 
with water. Finally the solvent was dried with sodium sulphate and removed under 
vacuum. Recrystallization was from CHC13 with a small amount of Et20. 
Yield 1.06 g (85%); mp 207 °C; Xmax 242,276,326,342 nm; MS m/z (ES+) 616 
(M+1) 55,1232 (2M+2) go; accurate mass, calculated 616.3421, measured 616.3427; 
TLC dichloromethane and methanol (95: 5 v/v) rf = 0.32; 1H NMR 0.6 (d, 3H, C21 H3)9 
0.7 (s, 3H, C18 or 19H3)11.1 (s, 3H, Cog or 19H3), 1.6 (m, 21 H. steroid), 2.3 (m, 3H, 
steroid) 5.0 (m, 2H, NHCH2), 8.0 (m, 9H, pyrene); '3C NMR 6 11 (C18), 18 (C'9), 21 
(C23), 24-56 (C, steroid), 123-131 (C, aromatic), 172 (C24), 208 (C3), 209 (C) , 212 
(C 12). 
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6.4.7 1'-pyrenyl methyl-3,7,12 trioximo-(5ß)-cholan-24-amide (17) 
N 
HO 
16 (1 '-pyrenyl methyl-3,7,12 trioxo-(5ß)-cholan-24-amide) (200 mg 0.32 mmol) was 
dissolved in ethanol (20 mL) to which NaOAc (160 mg, 1.94 mmol) and 
hydroxylamine hydrochloride (81 mg, 1.17 mmol) was added. The mixture was 
stirred at room temperature for l hour and then refluxed overnight. The solvent was 
removed under vacuum, HC! (0.1 M) was added to the flask and this was washed trice 
with chloroform (20 mL each), the extract was dried with sodium sulphate, and the 
solvent removed under vacuum to give a pale yellow glass. 
Yield 200 mg, (93%); ? ax 242,276,326,342 nm; MS m/z (ES+) 661 (M+1) ioo, 
'H 
NMR 0.7 (d, 3H, C21H3), 0.9 (s, 3H, C18 '9H3), 1.4 (m, 30H, steroid), 5.1 (d, 2H, 3J 
5.1, NHCH2), 8.1 (m, 9H, pyrene); 
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6.4.8 1'-pyrenyl methyl-3,7,12 trioximomethyl-(5ß)-cholan-24-amide 
1'-pyrenyl methyl-3,7,12 trioximomethyl-(5ß)-cholan-24-amide was prepared as in 
1'-pyrenyl methyl-3,7,12 trioximo-(5ß)-cholan-24-amide, using 1'-pyrenyl methyl- 
3,7,12 trioxo-(5ß)-cholan-24-amide (200 mg 0.32 mmol), methylhydroxylamine 
hydrochloride (73 mg, mmol). 
Yield 160 mg (71 %); Amax 242,276,326,342 nm; MS m/z (ES+) 720 (M + NH3) 30, 
689 (M -0 methyl + NH3) 20,1 H NMR 1.7 (m, 33H, steroid), 4.2 (m, 9H, (CH3)3)5 
5.1 (m, 2H, NHCH2), 8.2 (m, 9H, pyrene); 
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6.4.9 1'-pyrenyl methyl-3,7,12 trioximocarboxymethyl-(5p)-cholan- 
24-amide 
0 
1'-pyrenyl methyl-3,7,12 trio ximocarboxymethyl -(5ß)-cholan-24-amide was prepared 
as in I'-pyrenyl methyl-3,7,12 trioximo-(5p)-cholan-24-amide, using I'-pyrenyl 
methyl-3,7,12 trioxo-(5ß)-cholan-24-amide (200 mg, 0.32 mmol), with 
carboxymethylhydroxylamine hydrochloride (150 mg, mmol) and sodium acetate 
(160 mg, 1.94 mmol). 
Yield 240 mg (89%); ? max 242,276,326,342 nm; MS m/z (ES+) 834 (M) wo, 760 (M- 
O-carboxymethyl) ss, 1H NMR 1.7 (m, 31H, steroid), 4.5 (m, 9H, (CH3)3), 4.9 (m, 2H, 
NHCH2), 7.9 (m, 9H, pyrene); 13C NMR 6 11 (C'8), 14 (C19), 15 (C23), 21-56 (C, 
steroid), 124-131 (C, aromatic), 70 ((NOCH2)3)9 157 (C3, C7 andC'2). 
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6.4.10 I'-pyrenyl methyl-3,7,12 trioximobenzyl-(5ß)-cholan-24-amide 
0-1 
N 
0 
0 
rrý 
ý' 
o 
N 
O 
ýN 
H 
O 
I 
II 
I'-pyrenyl methyl-3,7,12 trioximobenzyl-(5ß)-cholan-24-amide was prepared as in 
1'-pyrenyl methyl-3,7,12 trioximo-(5ß)-cholan-24-amide, using 1'-pyrenyl methyl- 
3,7,12 trioxo-(5ß)-cholan-24-amide (200 mg, 0.32 mmol), benzylhydroxylamine 
hydrochloride (195 mg, 1.17 mmol) and sodium acetate (160 mg, 1.94 mmol) 
Yield 241 mg, 80%; TLC dichloromethane and methanol (95: 5 v/v) rf = 0.7; ? max 242, 
276,326,342 nm; MS m/z (ES+) 932 (M + 1) so, 823 (M - 0-benzylmethyl) ioo; 
1H 
NMR 1.5 (m, 44H, steroid), 4.9 (m, 6H, (CH2benzyl)3), 7.2 (m, 15H, (benzyl)3), 8.0 
(m, 9H, pyrene); 13C NMR 6 12 (C'8), 14 (C19), 19 (C23), 21-53 (C, steroid), 75-77 
(C, (benzyl)3,122-128 (C, aromatic), 156 (C3, C7 and C12). 
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6.5 Synthesis of N-(aminooxy acetyl) amino acids 
6.5.1 ((1', 1'-dimethylethoxycarbonyl)aminooxy)ethanoic acid (18) 
H 
O 
iKO` vNO 
p OH 
Solution A was prepared as follows, KOH (2.24 g) was dissolved in McOH (40 mL) 
and H2O (60 mL). O-Carboxymethyl hydroxylamine hemihydrochloride (1.00 g, 7.87 
mmol) was dissolved in 15 mL of solution A and adjusted to pH 9. Di-tert-butyl 
Bicarbonate (3.43 g, 15.74 mmol) was added in one portion, the mixture was then 
stirred at room temperature for 16 hrs, maintaining pH 9 by the dropwise addition of 
solution A. The mixture was then concentrated to dryness by rotary evaporation to 
give a white solid which was dissolved in H2O (10 mL). This was cooled to 0°C and 
the dropwise addition of 6N HCl lowered the pH to 3, whilst being stirred vigorously, 
resulted in the formation of a white precipitate. This was filtered and freeze dried to 
give the desired product as a white solid. 
Yield l. lg (73%); mp 99-102 °C, mp (lit. 111-112'C' 79); MS m/z (ES+) 192 (M + H) 
3o; elemental analysis, theoretical C 43.98% H 6.85% N 7.33%, found C 43.75% H 
6.96% N 7.26%; 1H NMR 6 1.5 (s, 9H, (CH3)3), 4.0 (s, 2H, NHCH2), 4.3 (s, 2H, 
OCH2); 13C NMR 6 23 ((CH3)3)9 74 (C(CH3)3), 83 (NOc), 159 (OC=O), 172 
(COOH) 
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6.5.2 Succinimido-(N)-((1', l'-dimethylethoxycarbonyl)aminooxy) 
ethanoate (19) 
O 
OyNý 
ro 
O 
O 
A solution of N- hydroxysuccinimide (0.6 g, 5 mmol) in ethyl acetate (15 mL) was 
prepared and to it was added a solution of 18 ((1, l, dimethylethoxycarbonyl)- 
aminooxy) ethanoic acid (0.95 g, 5 mmol) and ethyl acetate (15 mL). This was 
allowed to stir at room temperature for a few minutes and a solution of N-N'- 
dicyclohexylcarbodiimide (1.03 g, 5 mmol) in ethyl acetate (1.5 mL) was added. The 
mixture was stirred overnight. Dicyclohexylurea forms as a white precipitate which is 
removed by filtration. The solvent is removed by rotary evaporation; the product is a 
white solid. 
Yield 1.2 g (85%); MS m/z (ES+) 274 (M+1) ioo; IR (KBr) 3343 (N-H), 1786 (ester 
C=O), 1737 (ester C=O/cyclic ketone), 1377 (cyclic ketone), 1208 cm-I (ester C-O); 
MS m/z (ES+) 576 (Mx2) 30,215 (M -0 tert butyl) ioo; 
'H NMR 8 1.4 (s, 9H, 
(CH3)3), 2.8 (s, 4H, succinimide), 4.7 (s, 2H, OCH2); 13C NMR 6 24 (succinimide), 28 
((CH3)3), 70 (C(CH3)3)9 83 (NOQ, 156 (OC=O), 165 (COOH), 169 (succinimide) 
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6.5.3 Glycine benzyl ester toluene-4-sulphonate 
Glycine (1 g, 13.3 mmol) was added to toluene-4-sulphonic acid (3.2 g, 16.7 mmol) in 
toluene (20 mL) and benzyl alcohol (20 mL). This was heated and kept at reflux for 3 
hours using a Dean-Stark head until it became apparent that no more water was being 
produced. The mixture was placed in an ice bath and when cool diethyl ether (100 
mL) was added to the flask which was then kept on ice for a further two hours. After 
filtration, the white solid was washed well with ether and allowed to dry. 
6.5.4 Glycine benzyl ester, 
Glycine benzyl ester toluene-4-sulphonate (1.03 g, 3. Ommol) was dissolved in 
dichloromethane (50 mL) with triethylamine (0.6 g, 6.0 mmol), this was stirred and 
left to stand for 10 minutes. The mixture was washed with water (20 ml-) and dried 
with sodium sulphate and the solvent removed to give an oil that was used 
immediately in the coupling reaction. 
6.5.5 N-(1 "-glycine benzyl ester)-((1', 1'- 
dimethylethoxycarbonyl)aminooxy) ethanamide 
OO 
/jam OO 
H Hý 
0 
Glycine benzyl ester (128 mg, 0.78 mmol), prepared as above, was dissolved in ethyl 
acetate (1 mL), this was then added to a solution of ethyl acetate (20 mL) and 19 
(succinimido-(N)-((1', 1'-dimethylethoxycarbonyl)aminooxy) ethanoate) (225 mg, 
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0.78 mmol). This solution was left to stir at room temperature and the reaction 
followed by TLC (chloroform and methanol (95: 5 v/v)). The reaction was complete 
after three hours and the solvent removed under vacuum. The semi-solid was 
dissolved in a little ethyl acetate (2-3 mL), washed twice with water and dried with 
sodium sulphate. The solvent evaporated and recystallised from warm ethyl acetate 
with the addition of diethyl ether. 
Yield 153 mg, 45%; 1H NMR 6 1.5 (s, 9H, (CH3)3), 4.2 (d, 2H, 3J=4.74 Hz, 
NHCH2), 4.4 (s, 2H, OCH2), 5.5 (s, 2H, OCH2), 7.3 (s, 5H, C6H5); 13C NMR 6 28 ( 
(CH3)3)7 52 (OCH3), 53 (NHCH), 75 (C(CH3)3), 83 (NOC), 158 (OC=O), 172 
(CH2CONH, ), 179 (CHC=O), 126 (CH2C6H5), 128 (CH2C6H5 ), 129 (CH2C6H5); 
6.5.6 N-(1"-glycine benzyl ester)aminooxy ethanamide (21) 
O 
O /O` 
H3N 
v\O 
N 
CF3CO2 
O 
Taking 21 (N-(1 "-glycine benzyl ester)-((1', 1'-dimethylethoxycarbonyl)aminooxy) 
ethanamide) (51 mg, 0.15 mmol), TFA was added dropwise until the solid had 
dissolved, this was then left for 1 hour. The acid was removed under vacuum 
overnight which found an oily residue, to which 5mL of diethyl ether was added and 
fine powder formed overnight in the freezer, this was filtered and dried 
Yield 40 mg, 75%; MS m/z (ES+) 239 (M+1) 45,477 (Mx2+1) too, 'NMR 6 4.0 (s, 
2H, OCH2, ) 4.2 (s, 2H, NHCH2O) 5.2 (m, 2H, OCH2 C6H5), 7.4 (s, 5H, C6H5), 
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6.5.7 N-(1"- glycine methyl ester)-((1', l'- 
dimethylethoxycarbonyl)aminooxy) ethanamide 
OO 
/}ý 
O//// 
\\H v \H 
X 
Glycine methyl ester (325 mg, 2.6 mmol) was suspended in DCM (25 mL) and 
triethylamine (600 mg, 6 mmol) was added. To this was added succinimido-(N)- 
((1', 1'-dimethylethoxycarbonyl)aminooxy) ethanoate (750 mg, 2.6 mmol) dissolved 
in DCM (10 mL) and the mixture was stirred at room temperature for 48 hours. This 
was then washed trice with water and dried with sodium sulphate, solvent removed 
under vacuum to give a clear glass. 
Yield 270 mg, 37%; MS m/z (ES+) 239 (M+l) 45,476 (Mx2) loo, 'NMR 8 1.4 (s, 9H, 
(CH3)3), 3.7 (s, 3H, methyl), 4.0 (s, 2H, NHCH), 4.4 (s, 2H, OCH2); 
6.5.8 N-(1 "-glycine methyl ester)aminooxy ethanamide (20) 
0 
p /o oý H3N H 
0 
CF3COz 0 
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N-(1 "-glycine methyl ester)-((1', l'-dimethylethoxycarbonyl)aminooxy) ethanamide 
(200 mg, 0.76 mmol) was treated the same as for N-(1 "-glycine benzyl ester) 
aminooxy ethanamide. 
Yield 178 mg, 89%; 6 3.6 (s, 3H, methyl), 3.8 (s, 2H, NHCH2), 4.2 (s, 2H, OCH2); 
6.5.9 Phenylalanine methyl ester 
Phenylalanine methyl ester hydrochloride (1.1 g, 5.1 mmol) was converted into the 
free base as for glycine benzyl ester and also used immediately in the following 
reaction. 
6.5.10 N-(1 "-phenylalanine methyl ester)-((1', 1'- 
dimethylethoxycarbonyl)aminooxy) ethanamide 
°\ 
/o` 
x oý 
ON \H HH 
0 
Phenylalanine methyl ester (210 mg, 1.2 mmol) was prepared the same as N-(1 "- 
glycine methyl ester)-((1', 1'-dimethylethoxycarbonyl)aminooxy) ethanamide, using 
succinimido-(N)-((1', l'-dimethylethoxycarbonyl)aminooxy) ethanoate ( 346 mg, 1.2 
mmol) 
Yield 93 mg, 25%; 'NMR 6 1.4 (s, 9H, (CH )3), 3.8 (s, 3H, methyl), 4.3 (s, 2H, 
OCH) 4.6 (s, 2H, NHCH2), 4.8 (m, IH, CH2CHNH), 7.2 (s, 5H, phenyl); 
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6.5.11 N-(1 "-phenylalanine methyl ester)aminooxy) ethanamide (22) 
0 
O 
H3N 
G CF3CO2 0 
N-(1 "-phenylalanine methyl ester)-((I', 1'-dimethylethoxycarbonyl)aminooxy) 
ethanamide (90 mg, 0.24 mmol) was treated the same as N-(1 "-glycine benzyl 
ester)aminooxy ethanamide and the product was a pale yellow oil. 
Yield 86 mg, 95%; 3.6 (s, 3H, methyl), 4.3 (s, 2H, OCH2) 4.6 (s, 2H, NHCH2), 4.8 
(m, 1H, CH2CHNH), 7.1 (s, 5H, phenyl); 
6.5.12 Lysine (Fmoc) methyl ester 
N-c-Fmoc-lysine methyl ester hydrochloride (1.1 g, 2.6 mmol) was converted into the 
free base in the same way as for glycine benzyl ester and also used immediately in the 
following reaction. 
6.5.13 N-(1 "-lysine (FMOC) methyl ester)-((1', 1'- 
dimethylethoxycarbonyl) aminooxy) ethanamide 
ao 0oa_ 
sI 
/ 
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N-c-Fmoc-lysine methyl ester (992 mg, 2.6 mmol) treated in the same way as 
phenylalanine methyl ester, using succinimido-(N)-((1', 1'- 
dimethylethoxycarbonyl)aminooxy) ethanoate ( 750 mg, 2.6 mmol). 
Yield 510 mg, 47%; 'NMR 6 1.3 (m, 2H, CH2CH2CH2), 1.4 (m, 2H, CH2CH2CH2), 
1.6 (m, 2H, CH2CH2CH2), 1.5 (s, 9H, (CH3)3), 3.6 (m, 2H, CH2CH2NH), 3.7 (s, 3H, 
methyl), 4.3 (m, IH, NHCH), 4.4 (m, IH, NHCH), 4.5 (s, 2H, OC, HH2), 4.7 (m, 2H, 
OCH2CH), 7.4 (m, 4H, Fmoc), 7.6 (m, 4H, Fmoc); 
6.5.14 N-(1"-lysine (FMOC) methyl ester)aminooxy) ethanamide (24) 
0 
HP 
CF3CO2 
N-(1 "-lycine (FMOC) methyl ester)-((1', 1'-dimethylethoxycarbonyl) aminooxy) 
ethanamide (488 mg, 1.2 mmol) was treated in the same way as was treated the same 
as N-(1 "-glycine benzyl ester)aminooxy ethanamide. The product was a very sticky 
semi solid which was dissolved in chloroform and placed under vacuum, which, when 
removed gave a pale yellow solid. 
Yield 460 mg, 69%; 'HNMR 6 1.2 (m, 2H, CH2CH2CH2), 1.4 (m, 4H, CH2CH2CH2), 
1.7 (m, 2H CH CH2CH2), 3.4 (m, 2H, CHZCtNH), 3.7 (s, 3H, methyl), 4.3 (s, 2H, 
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OCH2) 4.4 (m, I H, NHCH), 4.7 (m, 2H, OCH2CH) 7.2 (m, 4H, Fmoc), 7.8 (m, 4H, 
Fmoc), 
6.5.15 N-(1 "-arginine (NO2) methyl ester)-((1', 1'- 
dimethylethoxycarbonyl)aminooxy) ethanamide 
NH2 
ON NO2 
N Ný 
H 
N 
0 00 
NG -Nitro-arginine methyl ester hydrochloride (250 mg, 0.93 mmol) was prepared in 
the same way as for N-(1 "-glycine methyl ester)-((1', 1'-dimethylethoxycarbonyl) 
aminooxy) ethanamide, using triethylamine (2 g, 2 mmol) and succinimido-(N)- 
((1', l'-dimethylethoxycarbonyl)aminooxy) ethanoate (288mg, 1 mmol). In the clean 
up the organic layer was yellow but after concentrating and drying under vacuum a 
white powder was formed. 
Yield 202 mg, 52%; 'NMR 6 1.2 (m, 2H, CH2CH2CH2), 1.5 (m, CH2CH2CH2), 1.5 (s, 
9H, (CH3)3), 2.9 (m, 2H, CH2CH2NH), 3.7 (s, 3H, methyl), 4.3 (s, 2H, OCH2) 4.5 (d, 
I H, NHCH); 13C NMR 6 28 ((CH3)3), 30 (CHZCHZ), 41 (CH2CH2C), 46 (OCHS), 53 
(NHCH), 76 (C(CH3)3), 83 (NOC), 158 (OC=O), 170 (NCN), 171 (CH2CONH, ), 173 
(CHC=O), 
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6.5.16 N-(1 "-arginine (NG -NO2) methyl ester)aminooxy) ethanamide 
H2N 
H 
ON 
N 
H 
HZN 
\O 
/NO2 
The t-butyl protecting group was removed from N-(I "-carboxymethyl arginine 
(N02))-((1', l'-dimethylethoxycarbonyl)aminooxy) ethanamide (760 mg, 1.9 mmol) 
in the same way as in N-(1 "-carboxymethyl phenylalanine)aminooxy) ethanamide. 
Yield 580 mg, 73%; 1NMR 6 1.3 (t, 2H, CH2CH2CH2), 1.8 (m, CH2CH2CH2), 3.2 (m, 
2H, CH2CH2NH), 3.8 (s, 3H, methyl), 4.5 (s, 2H, OCH2) 4.6 (m, IH, NHCH); 13C 
NMR 6 20 (CH2CH2), 41 (CH2CH20,52 (OCHS), 53 (NHCH), 72 (OCH2CO), 161 
(CH2OC), 170 (NCN), 173 (OCO), 
6.5.17 N-(1 "-arginine methyl ester)aminooxy) ethanamide (23) 
G) NH3 
0N 
N NH 
H 
H3N 
000 
(CF3CO2)2 
The NO2 protecting group on the arginine side chain was removed by hydrogenation 
with palladium/charcoal catalyst. N-(I "-arginine (NO2) methyl ester)aminooxy) 
ethanamide trifluoroacetate salt (500 mg, 1.2 mmol) was dissolved in methanol and 
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the reaction was complete after 3 hours. The mixture was filtered and the solvent 
removed under vacuum. 
Yield 412 mg, 91%; 1H NMR 1.3 (t, 2H, CH2CH2CH2), 2.0 (m, CH2CH2CH2), 3.4 (m, 
2H, CH2CH2NH), 3.8 (s, 3H, methyl), 4.5 (s, 2H, OCH2) 4.6 (s, I H, NHCH); 13C 
NMR 6 25 (CH2CH2), 41 (CH2CH2C), 49 (OCHS), 53 (NHCH), 75 (OCH2CO), 158 
(CH2OC), 160 (NCN), 172 (OCO), 
6.6 Synthesis of tri substituted 1'-pyrenyl methyl-3,7,12 
trioxo-(50)-cholan-24-amide 
6.6.1 1'-pyrenyl methyl-3,7,12 tri(N-iminoxymethylenecarbonyl 
(glycine benzyl ester)) (25) 
oý 
8 
1'-pyrenyl methyl-3,7,12 trioxo-(5ß)-cholan-24-amide (20 mg 0.033 mmol) was 
suspended in ethanol (2 mL), N-(1 "-glycine benzyl ester)aminooxy ethanamide (40 
mg, 0.12 mmol) and sodium acetate (16 mg, 0.194 mmol) were added and the mixture 
was allowed to stir at room temperature for 1 hour. The pale yellow solution was then 
refluxed overnight. The solvent was then removed under vacuum and enough 0.1 M 
HCl added to dissolved the solid. This was extracted thrice with chloroform, which 
was then dried with sodium sulphate and the solvent removed again under vacuum. 
The resulting yellow glass was dissolved in chloroform and a few drops of diethyl 
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ether added, this was left in the freezer and the pale yellow solid was filtered off and 
dried 
Yield 22 mg, 52%; Amax 242,276,326,342 nm; MS m/z (ES-) 1274 (M-1)35, 'H 
NMR 6 0.8 (m, 22H, steroid), 1.3 (m, 6H, steroid), 4.0 and 4.6 (m, 14H, 
(OCH2CONHCH2)3 and NHCH2), 5.1 (m, 6H, CH2C6H5), 7.2 (m, 15H, C6H5), 8.0 
(m, 9H, pyrenyl). 
6.6.2 1'-pyrenylmethyl-3,7,12 (tri(N-iminoxymethylenecarbonyl) 
glycine-(5ß)-cholan-24-amide (26) 
HO OII\ 
NH 
NH 
Oi \I 0 
p HO ON 
NH 
Op 
Nj-, N N' 
u 
H 
^ 'OH 
/ 
IvnOl 
I'-pyrenylmethyl-3,7,12 (tri(N-iminoxymethylenecarbonyl) glycine-(5ß)-cholan-24- 
amide was prepared in the same way as for I'-pyrenylmethyl-3,7,12 (tri(N- 
iminoxymethylenecarbonyl) glycine benzyl ester-(5ß)-cholan-24-amide, using I'- 
pyrenyl methyl-3,7,12 trioxo-(5ß)-cholan-24-amide (167 mg, 0.27 mmol), N-(1 "- 
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glycine methyl ester) aminooxy ethanamide (250 mg, 0.9 mmol) and sodium acetate 
(220 mg, 1.62 mmol). The resulting compound gave m/z ES+ of 1049 (M+1) ioo, the 
methyl protecting groups were removed by the addition of sodium hydroxide (0.1 M, 
1 mmol) until there was full conversion to a baseline spot by TLC. 
Yield 220 mg, 78%; X, max 242,276,326,342 nm; MS m/z (ES+) 1007 (M+1) 20,874 
(M- OCH2CONHCH2COOH +1) 3o, 743 (M - 2(OCHZCONHCH2000H) +1)ioo ; 
'H 
NMR 6 1.8 (M, 33H, steroid), 4.4 and 5.0 (m, 14H, (OCH2CONHCH2)1 and NHCH2), 
8.1 (m, 9H, pyrenyl). 
6.6.3 I'-pyrenylmethyl-3,7,12 (tri(N-iminoxymethylenecarbonyl) 
phenylalanine-(5ß)-cholan-24-amide (28) 
ax 
0 
ý'"ýý 
ý\ 
N 
H 
O 
I'-pyrenylmethyl-3,7,12 (tri(N-iminoxymethylenecarbonyl) phenylalanine)-(5ß)- 
cholan-24-amide was prepared in the same way as for I'-pyrenylmethyl-3,7,12 (tri(N- 
iminoxyrn ethylenecarbonyl) glycine benzyl ester)-(5ß)-cholan-24-amide, using I'- 
pyrenyl methyl-3,7,12 trioxo-(5ß)-cholan-24-amide (100 mg, 0.16 mmol), N-(1 "- 
phenylalanine methyl ester)aminooxy) ethanamide (212 mg, 0.58 mmol) and sodium 
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acetate (131 mg, 0.96 mmol). This compound gave the following data: MS m/z (ES+) 
1318 (M+1) 30,1083 (M- OCH2CONHCHCH2C5H6000H +1) 60,947 (M- 
(OCH2CONHCHCH2C5H6000H3)2 + 1) 1oo; 'H NMR 6 1.3 (M, 33H, steroid), 3.2 
(m, 6H, CH2C6H5), 3.6 (m, 9H, (CH3)3), 3.8 and 4.8 (m, 14H, (OCH2CONHCH2)3 and 
NHCH? ), 7.1 (m, 15H, C6H5), 8.1 (m, 9H, pyrenyl), and also underwent deprotection 
by base treatment as before. 
6 
Yield 200 mg, 94%; %max 242,276,326,342 nm; MS m/z (ES-) 1275 (M-1) <io, 1054 
(M- OCH2CONHCHCH2C5H6COOH -1) 30,833 (M- 2(OCH2CONHCHCH2 
C5H6COOH) -1) 70,1H NMR 6 1.8 (M, 36H, steroid), 3.3 and 4.8 (m, 
14H, 
(OCH2CONHCH2)3 and NHCH2), 7.1 (m, 15H, C6H5), 8.1 (m, 9H, pyrenyl), 
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6.6.4 1'-pyrenylmethyl-3,7,12 (tri(N-iminoxymethylenecarbonyl) 
lysine-(5ß)-cholan-24-amide (27) 
HO O 
N 
H 
H! N 
I'-pyrenylmethyl-3,7,12 (tri(N-iminoxymethylenecarbonyl) lysine (Fmoc))-(5(3)- 
cholan-24-amide was prepared in the same way as l'-pyrenylmethyl-3,7,12 (tri(N- 
iminoxymethylenecarbonyl) phenylalanine)-(5ß)-cholan-24-amide, using 1'-pyrenyl 
methyl-3,7,12 trioxo-(5ß)-cholan-24-amide (20 mg, 0.033 mmol), N-(1 "-lysine 
(FMOC))aminooxy) ethanamide (50 mg, 0.09 mmol) and sodium acetate (73 mg, 0.54 
mmol). I'-pyrenylmethyl-3,7,12 (tri(N-iminoxymethylenecarbonyl) lysine (Fmoc))- 
(5ß)-cholan-24-amide (50 mg, 0.024 mmol) was dissolved in piperidine and DMF 
(2: 8 v/v) and stirred at room temperature for 5 minutes, this was repeated two more 
times and washed in DMF which was removed under vacuum, followed by sodium 
hydroxide to remove the methyl protecting group as before. 
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Yield 30 mg, 83%; X,.. 242,276,326,342 nm; MS m/z (ES+) 837 (M- 
(OCH2CONHCH(CH2)4NH2COOH)2 + 1) 30; 1H NMR 6 1.3 (m, 71 H, steroid), 2.6 
(m, 6H, CH2NH2), 4.8 (m, 14H, (OCH2CONHCH2)3 and NHCH2), 8.1 (m, 9H, 
pyrenyl), 
6.6.5 1'-pyrenylmoth yl-3((N-iminoxymethylenecarbonyl) arginine) 
7,12(dioxo)-(5ß)-cholan-24-amide (29) 
H 
H2N yN 
NH 
ov -or 
This was prepared in the same way as for 1'-pyrenylmethyl-3,7,12 (tri(N- 
iminoxymethylenecarbonyl) glycine benzyl ester)-(5ß)-cholan-24-amide, using 1'- 
pyrenyl methyl-3,7,12 trioxo-(5ß)-cholan-24-amide (58 mg, 0.095 mmol), N-(1 "- 
arginine)aminooxy) ethanamide (37 mg, 0.1 mmol) and sodium acetate (82 mg, 0.6 
mmol) 
Yield 61 mg, 75%; %1, max 242,276,326,342 nm; 
1H NMR 1.5 (m, 42H, steroid), 1.8 
(m, 12H, 3(CHZCHZ)), 3.5 (m, 6H, 3(NOCH2)), 4.5 (m, 3H, 3(NHCHCH2)), 5.1 (d, 
6H, 3J 5.3,3(NHCH2)), 8.1 (m, 9H, pyrenyl). 
- 179- 
Chapter 6 
6.6.6 1'-pyrenyl methyl-3,7,12 trioximo-(5ß)-cholan-24-amide tri 
substituted with a mixture of methyl and benzyl 
hydroxylamines 
I'-pyrenyl methyl-3,7,12 trioximo-(5(3)-cholan-24-amide tri substituted with a 
mixture of methyl and benzyl hydroxylamines was prepared as in I'-pyrenyl methyl- 
3,7,12 trioximo-(5p)-cholan-24-amide, using l'-pyrenyl methyl-3,7,12 trioxo-(5 j3)- 
cholan-24-amide (150 mg, 0.24 mmol), sodium actate (200mg, 1.46 mmol) 
methylhydroxylamine hydrochloride (40 mg, 0.45 mmol) benzylhydroxylamine 
hydrochloride (78 mg, 0.49 mmol) 
yield 200mg; ? max 242,276,326,342 nm; 
6.6.7 1'-pyrenyl methyl-3,7,12 trioxo-(5ß)-cholan-24-amide library 
containing all aminooxy amino acid derivatives 
1'-pyrenyl methyl-3,7,12 trioxo-(5ß)-cholan-24-amide (0.5 g, 0.81 mmol) was 
suspended in ethanol (150 mL) and left to stir at room temperature. N-(1 "-lysine 
(FMOC) methyl ester)aminooxy) ethanamide (278 mg, 0.5 mmol), N-(1 "-arginine 
methyl ester)aminooxy) ethanamide (224 mg, 0.6 mmol), N-(1 "-phenylalanine 
methyl ester)aminooxy) ethanamide (183 mg, 0.5 mmol), N-(1 "-glycine benzyl 
ester)aminooxy ethanamide (176 mg, 0.5 mmol) and N-(1 "-glycine methyl 
ester)aminooxy ethanamide (138 mg, 0.5 mmol) were all dissolved in ethanol (0.5 
mL) each and added to the 1'-pyrenyl methyl-3,7,12 trioxo-(5ß)-cholan-24-amide 
suspension. After the addition of sodium acetate (660 mg, 4.9 mmol) the mixture was 
allowed to stir at room temperature for one hour, it was then heated and left refluxing 
overnight. TLC, chloroform and methanol (95: 5 v/v), showed the conversion of all the 
starting material. The clean up was as before to give 0.91 g. The deprotection of the 
Lys side chains was carried out as before. The methyl groups protecting the carboxyl 
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functionality were removed by adding sodium hydroxide (0.1 M, 2.5 ml-) and left to 
stir overnight. The methanol was removed under vacuum and the pH reduced to 7 by 
the dropwise addition of HCl (0.1 M). The precipitate was washed thrice with water 
and centrifuged each each, with the supernatant being removed, finally the product 
was freeze dried. 
Yield 610 mg, mmol; X,,,;, x 242,276,326,342 nm; 
6.7 Sakaguchi Reagent 
Solution A: 16% Urea, 0.2% 1-naphthol in ethanol/water 1: 1 
Solution B: 500 ml- aq. NaOH, 3.3 mL bromine 
Spray solution A on the sample, dry at room temperature and spray solution B. 
Positive for arginine and other guandine derivatives appear as pink/red spots 
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